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Schematic outline of the project. A central theme in this study was the use of gene expression analysis in the 
search for susceptibility genes for Crohn’s disease (CD), and for the study of CD-related gut inflammation 
observed in spondyloarthropathy (SpA). Crohn’s disease is a complex genetic trait where both genes and 
environmental factors play a role. In Chapter 1, the current status on genetic susceptibility in CD is reviewed. A 
novel functional promoter polymorphism in the recently identified CD-susceptibility gene, CARD15, is illustrated 
in Chapter 2. We describe a method to identify new susceptibility genes by the use of transcriptome profiling in 
Chapter 3, while two new candidate genes are characterized and described in Chapters 3 and 4 respectively.  
The occurrence of silent or subclinical gut inflammation in SpA patients and its relation to CD is reviewed in 
Chapter 5. In addition, the genetic contribution of CARD15 in SpA is studied in Chapter 6. In Chapter 7, we 
compared global gene expression in intestinal biopsies of SpA and CD patients, and provided additional evidence 
that SpA is a good model to study early CD. Finally, the influence of genetic risk factors on gene expression is 
described in more detail in the Future prospects, together with an allusion on the importance of epigenetic 
mechanisms in gene expression studies. In this last section, a new approach for the identification of susceptibility 
genes, based on the transmission of gene expression within families, is suggested. 
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Section I  
The objective of this project was to use gene expression analysis for the study of genetic 
susceptibility in Crohn’s disease (CD). Crohn's disease is a painful and incapacitating chronic 
inflammatory disease of the intestine. The symptoms of CD include chronic diarrhea, abdominal 
pain, loss of appetite, and weight loss. Approximately 1-2 in 1,000 people are affected and the 
incidence is still increasing. A life-long treatment is required, and the quality of life is severely 
influenced. Currently, there is no cure and patients suffer from a high rate of recurrence.  
The cause of ongoing inflammation in the intestine of patients with CD results from a complex 
interaction of susceptibility genes and environmental factors. Chapter 1 provides an overview of 
the current status of genetic linkage data, association studies and genetic risk factors for CD. In 
2001, the first susceptibility gene for CD was cloned. This gene, called CARD15, is an 
intracellular receptor for bacterial cell-wall components, and can activate NFκB to induce an 
inflammatory response. Three single nucleotide polymorphisms (SNPs) within CARD15 have 
been independently associated with CD, and are present in approximately 40% of CD patients. 
The identification of functional consequences of these SNPs is the subject of much ongoing 
research. Because CARD15 expression is up-regulated during inflammation, we screened its 
promoter for polymorphisms. In Chapter 2, we describe a novel SNP in the 5’ untranslated 
region (5’UTR) of CARD15, located within a DNA stretch that contains a potential binding site 
for the E2F transcription factor. Interestingly, this SNP influences the induction of a reporter 
gene controlled by a part of the CARD15 promoter in response to tumor necrosis factor alpha, 
which is a crucial pro-inflammatory cytokine. Furthermore, this polymorphism is linked to the 
known CD-associated mutations. In order to characterize this link, we are currently mapping the 
haplotype structure surrounding CARD15.  
Unfortunately, the identification of new susceptibility genes for CD by classical linkage studies 
is complicated by genetic heterogeneity and incomplete penetrance of the disease. Therefore, in 
Chapter 3, we suggest an alternative approach for the identification of new candidate genes by 
the use of transcriptome analysis. This initiative was based on the idea that much of the natural 
variation in gene expression is genetically transmitted and probably accounts for susceptibility to 
common diseases such as CD. We studied genome-wide gene expression in biopsies from 
unaffected colon areas of CD patients and healthy controls, and focused on those genes that are 
differentially expressed and located near a known locus for CD. A cluster of highly related 
genes, encoding metallothioneins (MTs), was studied in more detail. These genes are located 
approximately 6 centimorgan q-telomeric from the locus containing CARD15. We provide 
evidence for MT expression as a genetic risk factor in CD, and describe a new disease-
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modifying polymorphism in the main transcriptional regulator for MTs, called the MRE-binding 
transcription factor 1 (MTF1). In addition, a review of the involvement of MT in several diseases 
is provided in Chapter 4, together with current knowledge of the regulation of human MT 
expression. 
 
Section II 
The most common extra-intestinal manifestation of CD is inflammation of the joints and the 
spine. This causes pain, swelling and stiffness of the joints and the back. Spondyloarthropathy 
(SpA) is a group of rheumatic disorders of the spine. Interestingly, a close relationship exists 
between CD and SpA clinically as well as immunologically, which is discussed in Chapter 5.  
Not only is CD prevalent among patients with SpA, silent or subclinical gut inflammation has 
been described in up to two-thirds of patients with SpA. When CARD15 was mapped as the first 
CD-associated gene, we tested the presence of the CD-associated CARD15 mutations in a cohort 
of SpA patients, as described in Chapter 6. We provided a first genetic link between CD and 
SpA: the presence of CD-associated CARD15 polymorphisms was associated with SpA patients 
with subclinical chronic gut inflammation. Lastly, in Chapter 7, we reported a gene expression 
survey of intestinal biopsies of SpA and CD patients, and showed that an altered gut 
transcriptome was found in SpA patients with subclinical chronic gut inflammation. The 
alterations were comparable to those seen in CD, confirming initial clinical observations and 
suggesting that SpA serves as a good model for early CD. 
 
To conclude, the mounting significance of studying gene expression in genetic susceptibility 
studies is outlined in the Future prospects. We describe a new approach to identify risk genes 
based on the transmission of gene expression signatures in families. 
 
-Section I- 
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Chapter 1 
 
INTRODUCTION TO THE MOLECULAR GENETICS OF CROHN’S 
DISEASE 
 
Debby Laukens 
 
Department of Molecular Biomedical Research, Ghent University and Flanders Interuniversity 
Institute for Biotechnology (VIB), Gent, Belgium 
 
INTRODUCTION 
 
Inflammatory bowel disease (IBD) is a term that refers to both Crohn’s disease (CD) and 
ulcerative colitis (UC). Generally, the diagnosis of CD or UC is made based on the location of 
inflammation and depth and kind of lesions after endoscopic (Figure 1), radiologic and 
histologic examination. Although CD most commonly affects the terminal part of the small 
intestine (ileum) and the proximal part of the large intestine (colon), it may involve any section 
of the gastrointestinal tract. All layers of the intestine may be involved, and normal healthy 
bowel can exist between patches of diseased bowel. Granulomas are commonly found. In UC on 
the other hand, inflammation is limited to the colon. Only the superficial layers (mucosa) of the 
colon are affected in a symmetric and continuous distribution, starting at the level of the rectum. 
On the other hand, there may be a spectrum of illnesses within each disorder, suggesting distinct 
underlying pathogenic mechanisms. In 10 percent of the cases where only the colon is affected, 
it is difficult to establish a definite diagnosis, hence these are classified as indeterminate colitis 
(Price 1978). However, most patients with indeterminate colitis evolve to a definite diagnosis of 
UC or CD during follow-up. Whether UC and CD are fundamentally different diseases, or part 
of one concept, remains unclear and holds conceptual and practical implications. Good 
classification practice is essential because CD and UC differ in response to therapy and 
involvement of genetic and environmental risk factors (Vermeire et al. 2000).   
Both CD and UC have a prevalence of 1-2 cases per 1,000 individuals in western countries. In 
Brussels, the mean annual incidence for CD has been estimated in 1992-1993 at 4.1 per 100,000 
inhabitants/year (Van Gossum et al. 1996).   The emergence of
  
IBD in  the developed  nations of  
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Figure 1 Colonoscopy images from healthy control, Crohn’s disease and ulcerative colitis (left to right). 
 
Western Europe and North America during the
 
past century seems indisputable (Farrokhyar et al. 
2001).
 
Part of the increase in incidence reflects developments in endoscopic and other diagnostic 
techniques. Nevertheless,
 
most epidemiologists accept that there was a considerable increase in 
CD incidence during the last century in developed countries. Western lifestyle, diet (Gibson and 
Shepherd 2005), exposure to infection (Hugot et al. 2003), and  domestic hygiene (Wells and 
Blennerhassett 2005) are most probably involved in this process. Crohn's disease may occur 
among people of all ages, but it is primarily a disease of adolescents and young adults, affecting 
mainly those between the age of 15 and 35.  
Currently, the long-term treatment of IBD is multifaceted, depending on the type of disease, and 
sites involved (Podolsky 2002). Most clinicians use a stepped approach to therapy, the so-called 
therapeutic pyramid, in which more potent agents are added to the regimen if less active drugs 
fail to achieve an adequate response. The primary treatment of symptoms with antidiarrheal 
agents itself is important. Aminosalicylates, corticosteroids and other immunomodulators are 
aimed at controlling inflammation. The use of antibiotics and probiotics is being investigated, 
especially for CD. Beneficial health effects, which might result from rebalancing of the gut flora, 
were observed after such treatment (Sartor 2003). Towards the top of the pyramid are the 
biological agents. The first biological therapy for CD, based on anti-tumor necrosis factor alpha 
(anti-TNF) has been approved by the Food and Drug Administration in 1998, and has turned out 
to be very effective (Targan et al. 1997). Up to 60% of CD patients need an operation within 10 
years of disease onset, as a result of fistulizing, perforating, stricturing and/or obstructing 
complications. 
The exact cause of IBD remains uncertain. It is clear that IBD arises from the interplay of 
environmental factors in genetically defined individuals. Today, the most accepted hypothesis 
about pathogenesis of IBD is that disease results from an abnormal host immune response to 
Introduction to the molecular genetics of Crohn’s disease 
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bacteria that are normally found in the intestine (Sartor 2003). It is hypothesized that in normal 
conditions, exposure to commensal bacteria modulates the inflammatory immune response of the 
gut to the numerous bacteria and food antigens to which it is constantly exposed (Saxelin et al. 
2005). In IBD, however, exposure to microflora triggers an inflammatory response by the cells 
lining the mucosa, leading to a chronic, destructive immune response, ultimately causing 
ulcerations and bowel injury. Indeed, an immune response to intestinal bacteria seems to be 
crucial in the pathogenesis of IBD (Sartor 2003): 1) genetically engineered rodents, such as IL10 
deficient mice, develop colitis when exposed to commensal bacteria but remain disease free 
when raised in a sterile environment (Shi and Walker 2004); 2) the negative influence of faecal 
stream in the pathogenesis of recurrent CD lesions after curative resection of the distal ileum 
(Rutgeerts et al. 1991); 3) the efficacy of probiotics and antibiotics in treatment and prevention 
of IBD; 4) loss of tolerance to commensal bacteria (Jump and Levine 2004); 5) the increased 
number of surface-adherent and intracellular bacteria in the colon and ileum of IBD patients 
(Swidsinski et al. 2002; Darfeuille-Michaud et al. 2004); 6) the association of microbial receptor 
gene variants with IBD (Hugot et al. 2001; Klein et al. 2002; Franchimont et al. 2004); and 7) 
microbial DNA is found in granulomas, the most specific histological lesion found in CD (Ryan 
et al. 2004). It is, however, unclear whether the immune system is activated as a result of an 
intrinsic defect (either a constitutive activation or the failure of down-regulatory immune 
mechanisms) and/or because of continued stimulation resulting from a defective epithelial 
mucosal barrier.  
Many researchers have invested in finding causative agents and risk factors for IBD. One of the 
leading infectious candidates is Mycobacterium avium paratuberculosis (Autschbach et al. 
2005), but also Listeria monocytogenes and Helicobacter hepaticus have been linked to IBD. 
However, so far, attempts at using specific anti-mycobacterial chemotherapy have been 
unsuccessful (Goodgame et al. 2001). In any case, the complex phenotypes of IBD cannot be 
fully explained either by environmental factors, or by a single gene. Increasing evidence suggest 
a multigenic nature in combination with the above-mentioned aspects.   
Crohn’s disease and UC share the same ethnic predisposition, and mixed families exist in which 
some members are affected with CD and others with UC. However, genetic data of susceptibility 
genes tend to differ between CD and UC.  Here, we review the progress in genetic analyses and 
genetic risk factors for CD. 
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GENETIC EPIDEMIOLOGY OF CROHN’S DISEASE 
The strong influence of genetic determinants in CD has been shown by familial clustering 
(Peeters et al. 1996), and the high concordance rate, about 20-44%, in monozygotic twins (Tysk 
et al. 1988; Hugot et al. 1996; Thompson et al. 1996; Halfvarson et al. 2003). First-degree 
relatives of affected individuals show a 20 to 50-fold higher risk for developing CD (Monsen et 
al. 1991). The sibling relative risk for CD is 36.5, which is higher than the risk reported for other 
complex diseases such as diabetes type I and schizophrenia (Hugot et al. 1996; Peeters et al. 
1996; Satsangi et al. 1996a). Moreover, siblings are frequently affected at similar ages, and 
concordance rates reach 80% for disease site, behavior and presence of extra-intestinal 
manifestations (Halfvarson et al. 2003). Ethnic differences in disease frequency have been 
shown. For instance, the prevalence among Ashkenazi Jews is much higher than among 
Sephardic Jews, even though they share a similar living environment in the same community 
(Fidder et al. 2003). An increased mother to child transmission has been observed (Akolkar et al. 
1997), suggesting that one of the genetic risk factor is an imprinted gene, which is in agreement 
with the linkage of CD to the X chromosome shown in several studies (Vermeire et al. 2001; van 
Heel et al. 2003). All these observations are considered to be evidence for a strong genetic 
predisposition to the etiology of CD. 
The incomplete concordance rate in monozygotic twins suggests that genetic factors are not 
enough to develop CD. Furthermore, the incidence of CD in immigrant populations is often 
different from the incidence of the population of origin, but also slightly different from the 
incidence in the new country (Odes et al. 1989). The strongest environmental risk factor for IBD 
is tobacco smoking. Remarkably, the risk in UC and CD is different. Smoking is harmful in both 
the disease progression and in the onset of CD (Cosnes et al. 2001), while it has a positive 
influence on the symptoms in UC (Beaugerie et al. 2001). In fact, many people who stop 
smoking develop UC. Risk factors influencing the disease progression include CD affecting the 
small intestine, age of onset above 40 years and oral contraceptive use (Logan 1999). Recently, 
environmental factors that might be etiologically related to CD were determined in a study based 
on interviewing members of affected and control families (Van Kruiningen et al. 2005). Besides 
smoking and appendicitis, dietary factors represented potential risk factors for CD. These dietary 
components included drinking of well water, less frequent consumption of oats, rye, and bran 
and more frequent eating of unpasteurized cheeses. Childhood infections, birth by caesarean 
section and bottle feeding have all been suggested as possible risk factors for the development 
for CD (Timmer 2003). 
Introduction to the molecular genetics of Crohn’s disease 
 11 
In general, two complementary approaches are used to identify determinants underlying 
genetically complex traits such as CD: candidate gene association studies and genetic linkage. In 
the candidate gene approach, functionally interesting genes are screened for polymorphisms in a 
limited number of patients, followed by comparing frequencies in large disease and control 
populations. In genetic linkage, candidate regions associated with disease are identified, 
scanning the entire chromosome for microsatellite markers. These so-called disease loci are 
usually very broad and can rarely be narrowed down to less than a few megabases. If the 
candidate region contains an amenable number of genes, a candidate gene is chosen by virtue of 
a known property, e.g. function, tissue-specific expression or structural motif, which is referred 
to as positional cloning. However, the mapping of CD loci is hampered by variability in 
phenotype, genetic heterogeneity across populations, uncontrolled environmental influences and 
limited statistical power. For instance, in CD, each genome scan results in a minimum of 3 loci, 
reflecting that more than one gene is involved in pathogenesis. The number of genes involved in 
the etiology of CD is unknown. Furthermore, the question remains whether common variants of 
a limited number of genes, each adding up small effects, account for such a common disease, or 
whether rare variants with a dominant effect underlie genetic susceptibility. 
Although not all CD patients have a positive family history, the question arises as to the precise 
relationship between sporadic and familial cases of CD. Will genetic variants identified in 
familial cases also be pathogenic in sporadic CD patients? In a recent study addressing this 
question, no difference in frequency of three CD-associated variants within the CARD15 gene 
(see below) was found between familial and non-familial cases (Vermeire et al. 2002). This 
suggested that these variants are partly causative for idiopathic CD patients, and are also 
transmitted within CD families (Esters et al. 2004). 
GENOME-WIDE LINKAGE STUDIES IN IBD 
At present, 13 genome-wide linkage studies have been performed in IBD (Hugot et al. 1996; 
Satsangi et al. 1996b; Cho et al. 1998; Hampe et al. 1999; Ma et al. 1999; Duerr et al. 2000; 
Rioux et al. 2000; Cavanaugh 2001; Paavola-Sakki et al. 2003; Shaw et al. 2003; van Heel et al. 
2003; Barmada et al. 2004; Vermeire et al. 2004). More than 20 loci have been identified, and 
many of them have been independently replicated (IBD1-9, 3q, 4q, 6q, 7q, 8q, 10p, 22q, Xp). 
Table 1 covers all original articles on linkage analysis performed on IBD or mixed families from 
1996 until now. Data on UC only were not included. These analyses uncover great ethnic 
differences as to loci and degree of linkage. Identification of the precise genes within these loci  
Chapter 1 
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Table 1 Susceptibility loci for Crohn’s disease 
 
IBD Locus Chromosomal position Marker at highest score Score Population Reference 
IBD7 1p13.1 D1S252 NPL 2.61 Flemish IBD (Vermeire et al. 2004) 
IBD7 1p33-32.3 D1S197 NPL 2.07 Flemish IBD (Vermeire et al. 2004) 
IBD7 1p36.13-36.11 D1S552-D1S234 LOD 2.64 Non-Jewish American (Cho et al. 1998) 
 1q21.3 D1S305 NPL 2.97 Flemish IBD (Vermeire et al. 2004) 
 1q43-q44 D1S2670-D1S2682 LOD 2.08 North European IBD (Hampe et al. 1999) 
 2q32.3 D2S117 LOD 1.25 American IBD (Duerr et al. 2000) 
IBD9 3p14.2-14.1 D3S1766-D3S1285 LOD 2.4 Canadian IBD (Rioux et al. 2000) 
IBD9 3p21.31 D3S1573 LOD 2.69 North European IBD (Satsangi et al. 1996b) 
 3q13.12 D3S3045 LOD 1.31 American IBD (Duerr et al. 2000) 
 3q25.1-26.31 D3S1279-D3S3725 LOD 2.1 North European CD (van Heel et al. 2003) 
 3q26.31 D3S3053-D3S2427 LOD 3.23 American IBD (Cho et al. 1998) 
 4q25 D4S406 NPL 2.07 Finnish IBD (Paavola-Sakki et al. 2003) 
 4q25 D4S406 NPL 2.17 Flemish IBD (Vermeire et al. 2004) 
 4q25 D4S2623 LOD 3.0 American IBD (Cho et al. 1998) 
 5q14.1 D5S1501 LOD 1.69 Caucasian CD (Barmada et al. 2004) 
IBD5 5q33-35 - LOD 2.2 Jewish American CD (Ma et al. 1999) 
IBD3 6p D6S197 LOD 3.06 North European CD (Shaw et al. 2003) 
IBD3 6p22.2 D6S2439 LOD 2.6 Caucasian CD (Barmada et al. 2004) 
IBD3 6p22.2-21.2 D6S1281-D6S1019 LOD 2.3 Canadian IBD (Rioux et al. 2000) 
IBD3 6p23-22.3-22.2 D6S289-D6S276 LOD 2.07 North European IBD (Hampe et al. 1999) 
 6q24.1 D6S314 NPL 2.44 Flemish IBD (Vermeire et al. 2004) 
 6q25.2-26 D6S2436-D6S305 LOD 2.21 Caucasian IBD (Barmada et al. 2004) 
 7q21.11 D7S669 LOD 3.08 North European IBD (Satsangi et al. 1996) 
 7q32.1-31.33 D7S40-D7S648 LOD 0.91 American IBD (Duerr et al. 2000) 
 8q12.1-13.1 D8S1113-D8S1136 LOD 1.57 Caucasian IBD (Barmada et al. 2004) 
IBD2 12q21.1-21.2 D12S303-D12S326 LOD 1.82 North European CD (Hampe et al. 1999) 
IBD2 12q23.3 D12S78 LOD 2.34 Finnish CD (Paavola-Sakki et al. 2003) 
IBD4 14q11.2  - LOD 8.2 American CD (Ma et al. 1999) 
IBD4 14q11.2 D14S261 LOD 3.6 American CD (Duerr et al. 2000) 
IBD4 14q11.2 D14S50 LOD 2.34 Flemish IBD (Vermeire et al. 2004) 
IBD4 14q12 D14S80 LOD 2.04 Flemish IBD (Vermeire et al. 2004) 
IBD4 14q13.1 D14S49 LOD 2.44 Flemish IBD (Vermeire et al. 2004) 
 15q26.1 D15S652 LOD 1.82 Caucasian IBD (Vermeire et al. 2004) 
 15q26.1-26.2 D15S652-D15S816 LOD 2.02 Caucasian IBD (Barmada et al. 2004) 
IBD8 16p13.13 D16S748 NPL 2.49 American CD (Cho et al. 1998) 
IBD1 16q12.1 D16S411-D16S419 LOD 5.79 multicentre (IBDIGC) (Cavanaugh et al. 2001) 
IBD1 16q12.1 D16S409-D16S411 LOD 1.71 European CD (Hampe et al. 1999) 
IBD1 16q12.1-12.2 D16S409, D16S419 - Caucasian CD (Hugot et al. 1996) 
 16q21-23.1 D16S514-D16S515 LOD 2.2 North European CD (Van Heel et al. 2003) 
 18p11.31 D18S62 NPL 2.3 Flemish IBD (Vermeire et al. 2004) 
 18q22.2 D18S61 LOD 1.15 American IBD (Duerr et al. 2000) 
IBD6 19p13.3 D19S591-GATA21G05 LOD 4.6 Canadian CD (Rioux et al. 2000) 
IBD6 19p13.3-13.2 D19S1034-D19S586 LOD 1.38 American IBD (Cho et al. 1998) 
 19q13.31 D19S217 LOD 2.9 North European CD  (Van Heel et al. 2003) 
 20p12.3 D20S192 NPL 2.6 Flemish IBD (Vermeire et al. 2004) 
 22q11.23-12.1 D22S315-D22S421 LOD 1.52 North European IBD (Hampe et al. 1999) 
 22q12.1 D22S689 LOD 1.5 Caucasian IBD (Barmada et al. 2004) 
 22q13.31 D22S274 NPL 1.19 Flemish IBD (Vermeire et al. 2004) 
 Xp21.2-21.3 DXS1202-DXS1214 LOD 2.0 North European IBD (Hampe et al. 1999) 
 Xp22.11-21.2 DXS1226-DXS1214 LOD 1.59 North European CD (Van Heel et al. 2003) 
  Xq28 DXS99 LOD 1.7 Flemish IBD (Vermeire et al. 2004) 
 
LOD: logarithm of the odds; NPL: non-parametric LOD score 
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is now a crucial step in understanding the contribution and interaction of different gene products 
in disease onset and pathology. Typically, genome-wide scans identify large loci, spanning 
several hundreds of genes. Fine mapping of these loci is subsequently used to finally end up with 
an amenable  amount  of  genes  for  further  study.   The latter approach has been successfully 
employed for the IBD1 locus (16q12), which has resulted in the identification of the first major 
susceptibility gene for CD, CARD15 (see next paragraph). 
The ultimate goal of characterizing new susceptibility genes is a more accurate prediction of 
disease, which might permit the use of more specific therapy adapted to an individual’s 
genotype. Furthermore, the identification of these variants offers the possibility to stratify 
genome-wide linkage studies, increasing the power of identification of new loci (Shaw et al. 
2003; van Heel et al. 2003). 
 
SUSCEPTIBILITY GENES AND DETERMINANTS FOR CD 
 
The majority of early studies of genetic susceptibility in CD used case-control association 
studies, in which allele frequencies of candidate genes are compared between patients and 
healthy controls. However, such studies have been criticized, basically because of the lack of 
reproducibility: original association studies often indicate a much stronger effect than subsequent 
ones. The reasons for failing to replicate disease associations have been discussed elsewhere 
(Colhoun et al. 2003). On the other hand, positional cloning has led to the identification of major 
genetic variants associated with CD on chromosome 16 (IBD1 locus, CARD15) (Hugot et al. 
2001), chromosome 10 (DLG5) (Stoll et al. 2004) and chromosome 5 (IBD5 locus, 5q31 risk 
haplotype) (Rioux et al. 2001). These genes will be discussed below.  
 
CARD15 
The IBD1 locus represents the best replicated region, showing linkage to CD and specifically not 
to UC. It was originally mapped in 1996 (Hugot et al. 1996), and has since been replicated in 
many studies (Table 1) (Ohmen et al. 1996; Cho et al. 1997; Brant et al. 1998; Cavanaugh et al. 
1998; Curran et al. 1998; Annese et al. 1999; Hampe et al. 1999; Akolkar et al. 2001). 
Furthermore, an international collaborative study on IBD reported a remarkable high linkage 
score for CD at position D16S411 (Cavanaugh 2001). In 2001, two groups simultaneously 
identified NOD2 (nucleotide oligomerization domain 2), now officially called CARD15 (caspase 
activation and recruitment domain 15), as the first susceptibility gene for CD (Hugot et al. 2001; 
Ogura et al. 2001a). Hugot and colleagues employed the positional cloning strategy while Ogura 
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and co-workers identified CARD15 by the positional candidate gene approach. European and 
North American patients with CD, including those without a family history, are more likely to 
have variants in CARD15 than those without CD. It must, however, be noted that another gene 
within IBD1 might additionally be responsible for the linkage with this region. This became even 
more clear when a genome-wide linkage study was stratified with the CARD15 variants, and 
linkage to chromosome 16 was observed in CD patients ~25 centimorgan q telomeric of 
CARD15 (van Heel et al. 2003). 
A recent study comparing a European and Korean cohort for the common CARD15 variants 
illustrated that these variants do not exist in the Korean cohort. Moreover, in this study, no 
association was found between other SNPs in CARD15 and CD (Croucher et al. 2003). This 
implicates that the CD-associated polymorphisms arose after the European/Asian separation. 
Similarly, no CARD15 mutations were found in the Chinese (Leong et al. 2003) and Japanese 
(Inoue et al. 2002) population, and the association of CARD15 variants is not as strong among 
the Finns (Helio et al. 2003), Irish (Bairead et al. 2003), New Zealands (Leung et al. 2005) and 
the Scottish (Arnott et al. 2004). Hence, although ethnically divergent populations may present 
identical phenotypes, they do not necessarily share the same set of predisposing genes.  
 
Polymorphisms in CARD15 associated with CD. The CARD15 protein belongs to the 
NOD1/Apaf-1 family, which comprises cytosolic proteins that are composed of an N-terminal 
caspase
 
recruitment domain (CARD), a centrally located nucleotide-binding domain (NBD), and 
a C-terminal
 
leucine-rich regulatory (LRR) domain (Bertin et al. 1999; Inohara et al. 1999; 
Ogura et al. 2001b). Three common single nucleotide polymorphisms (SNPs) in CARD15 were 
independently associated with CD (Figure 2): two missense mutations R702W (c.2104C>T, 
SNP8) and G908R (c.2722G>C, SNP12), and one frameshift mutation 1007fs (c.3020insC, 
SNP13), which truncates the protein with 30 amino acids (Hugot et al. 2001). All three variants 
alter the C-terminal third of the protein, and are within or close to the LRR domain, which is 
involved in ligand recognition. The heterozygous carrier frequency of these variants within CD 
ranges from 30 to 50%, while 3 to 15% is homozygous or compound heterozygote, meaning that 
they carry two variants (Hugot et al. 2001; Ogura et al. 2001a; Abreu et al. 2002; Ahmad et al. 
2002; Hampe et al. 2002). By comparison, 8 to 15% of healthy controls are heterozygous and 0 
to 1% carries a homozygous variant. The relative risk of developing CD if someone carries one 
of these variants is increased by a factor of 1.5 to 3 for heterozygous carriers, but the risk 
increases with a factor of 20 to 40 if someone is homozygous or compound heterozygous. 
Although this relative risk seems high, it must be stated that the absolute risk for developing CD 
Introduction to the molecular genetics of Crohn’s disease 
 15 
                  
 
 
 
                 (Schwede et al. 2003) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 
 16
is no more than 1 in 25 for homozygous carriers. This reduced penetrance can undoubtedly be 
explained by the requisite of environmental risk factors and/or additional genetic determinants.  
A number of recent reports indicate that common genetic variation in the human genome exists 
as discrete haplotype blocks, each with a limited diversity. The haplotype structure in a 177-kb 
region surrounding the CARD15 gene has been determined (Vermeire et al. 2002). A specific 
haplotype was association with CD, and the three CD-associated SNPs were all unique 
subvariants of this haplotype.  
Different mutations in CARD15 have been associated with increased susceptibility to psoriatic 
arthritis (Rahman et al. 2003), and to Blau syndrome (Miceli-Richard et al. 2001), a rare 
autosomal dominant disorder characterized by early-onset granulomatous arthritis, uveitis, and 
skin rash with camptodactyly. Interestingly, the mutations found in Blau syndrome are located in 
the NBD, suggesting a different molecular pathogenesis between Blau syndrome and CD.  
 
Functional studies on CARD15 and implications for CD. The Nod1/Apaf-1 family of proteins 
displays striking similarity to a class of disease resistance
 
(R) proteins found in plants. Following 
specific recognition of pathogen
 
products, these R proteins mediate a defence response 
associated
 
with metabolic alterations and localized cell death at the site
 
of pathogen invasion. 
The LRR domains of R proteins are highly
 
diverse and appear to be involved in the recognition 
of a wide
 
array of pathogen components (Dixon et al. 2000). Similar to the R proteins, CARD15 
appears to play an important role in innate and acquired immunity as a sensor of bacterial 
components. Specifically, CARD15 participates in the signalling events triggered by host 
recognition of specific bacterial motifs, and subsequently activates NFκB, the key mediator in 
the production of pro-inflammatory mediators (Inohara and Nunez 2003). Naturally occurring 
peptidoglycan (PG) fragments were identified as the microbial motifs sensed by CARD15, more 
specifically muramyl dipeptide (MDP, GlcNAc-MurNAc), found in Gram-negative and Gram-
positive bacterial PGs (Girardin et al. 2003). However, direct binding of MDP to CARD15 has 
not yet been demonstrated.  
The expression of CARD15 was first thought to be restricted to cells of the myeloid lineage, 
primarily to monocytes (Ogura et al. 2001b; Gutierrez et al. 2002). With more accurate 
techniques, however, expression of CARD15 was shown in epithelial cells (Hisamatsu et al. 
2003; Rosenstiel et al. 2003), keratinocytes (Voss et al. 2005), vascular endothelial cells (Oh et 
al. 2005) and paneth cells (Lala et al. 2003; Ogura et al. 2003). Moreover, its expression is 
enhanced by pro-inflammatory cytokines and bacterial components via NFκB, a mechanism that 
may contribute to the amplification of the innate immune response (Gutierrez et al. 2002; 
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Rosenstiel et al. 2003). Consistent with this observation, an elevated expression of CARD15 has 
been shown in inflamed areas of colonic tissue of CD patients (Berrebi et al. 2003). 
Although the function of CARD15 in bacterial sensing is widely accepted, its physiological 
function is less well understood. Consequently, the implications of the CD-associated mutations 
in disease onset and progression remain unclear. Taken together, five hypotheses have been 
postulated, and they involve both loss-of-function and gain-of-function of the CARD15 
mutations, although the gain-of-function hypotheses have been criticized (Figure 3). The gain-
of-function hypotheses evolved from CARD15 knockout and transgenic mice, but are not 
consistent with what is seen in humans. It is important to note that these hypotheses are not 
mutually exclusive, and may be physiologically relevant in combination. 
In vitro and ex vivo experiments indicated that the three CD-associated polymorphisms actually 
decreased the activation of NFκB and pro-inflammatory cytokine production, which is 
inconsistent with the observation that NFκB is up-regulated in patients (Ogura et al. 2001b; 
Bonen et al. 2003; Hisamatsu et al. 2003). However, this might reflect a lack of triggering a 
primary innate immune response to bacterial invasion. Since the three CD-associated variants of 
CARD15 are located in or near the LRR (Figure 2), it was suggested that bacterial sensing is 
impaired, thus explaining the susceptibility to disease. As a consequence, clearing of bacterial 
products is inefficient, which might lead to a secondary, compensatory activation of NFκB 
independent from CARD15 (Figure 3A).  Notably, peripheral blood mononuclear cells (PBMC) 
from individuals
 
homozygous for the major disease-associated SNP13 mutation
 
did not respond 
to synthetic MDP (Chamaillard et al. 2003; Inohara et al. 2003; Inohara et al. 2005). They also 
show a defective pro-inflammatory cytokine release after stimulation of mononuclear cells with 
MDP (Li et al. 2004; Netea et al. 2004; Netea et al. 2005). We have recently shown that PBMC 
isolated from CD patients carrying CARD15 polymorphisms, produced significantly less IL1β, 
IL6 and IL10 after stimulation with adherent-invasive E. coli LF82 in a gene-dose effect (Peeters 
et al. 2006). This was the first study where aberrations were found in heterozygous carriers of 
SNP8 and SNP12 CARD15 mutations, which is the largest group of patients. Moreover, 
CARD15 1007fs carriage was also associated in a gene-dose-dependent manner with low 
mononuclear cell TNF release by stimulation with a combination of interferon gamma (IFNG) 
and GM-CSF (Halme et al. 2004). 
The finding that CARD15 is expressed in paneth cells is particularly of interest, because these 
cells provide the host defence against microbes in the ileum, while they are not present in the 
normal colon. Paneth cells secrete a number of antibacterial substances in the lumen of the crypt, 
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like lysozyme, phospholipase A and α- and β-defensins (Ouellette and Bevins 2001). Lysosyme 
is an enzyme that breaks down bacterial cell wall components into MDP, which is in turn 
recognized by CARD15. Moreover, the ileum is an important pathological site in CD, and 
CARD15 mutations are primarily present in patients with ileal involvement (Cuthbert et al. 
2002). Ileal expression of the α-defensins was diminished in active regions in patients with 
CARD15 mutations, while this was not the case in the diseased colon (Wehkamp et al. 2004). 
CARD15 is also an inducer of β-defensins, an effect that is lost in CARD15 SNP13 homozygous 
patients, leading to a defective epithelial defence, proliferation of bacteria and potential loss of 
epithelial barrier function (Figure 3B). 
In human monocyte-derived dendritic cell cultures, CARD15 agonists synergistically induce 
IL12 production in combination with Toll-like receptor 3 (TLR3), TLR4, and TLR9 agonists to 
induce T helper type 1 (Th1)-lineage immune responses (Tada et al. 2005). This synergistic 
effect was lost in patients carrying a mutant CARD15 protein (van Heel et al. 2005b; Kramer et 
al. 2006). The inflammatory phenotype of CD is difficult to reconcile with a decrease in TNF 
and IL12 (Sartor 1994). However, it was recently demonstrated that the synergistic induction of 
IL10 in response to MDP and TLR-stimuli was lost in CARD15 mutant monocyte-deriven 
dendritic cells (Kramer et al. 2006). Interleukin 10 is crucially involved in the down-regulation 
of the inflammatory process. It was thus postulated that the IL10 mediated immune suppression 
is impaired and the counter-effect for pro-inflammatory cytokines is lost, thus contributing to 
chronic ongoing inflammation in CD (Figure 3C). 
Incubation of normal murine macrophages with MDP was shown to suppress IL12 secretion 
induced by stimulation with TLR2 ligands (Watanabe et al. 2004). This suppression did not 
occur in cells lacking CARD15 or cells expressing a mutant form of CARD15 in transfection 
experiments. Once secreted, IL12 promotes IFNG and growth and differentiation of Th1 cells 
(Figure 3D). A major concern however is the reproducibility of these results (Kobayashi et al. 
2005). Furthermore, CARD15 and TLR2 stimulation of human PBMC isolated from patients 
with the 1007fs mutation, led to a loss of synergistic induction of pro-inflammatory cytokines, 
which is also inconsistent with a TLR2 inhibitory function of CARD15 (van Heel et al. 2005a). 
Macrophages of mice carrying a mutant CARD15 equivalent to the 1007fs mutation, were shown 
to secrete higher levels of the mature form of IL1β upon stimulation with MDP (Maeda et al. 
2005). This suggests that the variant CARD15 protein promotes processing of proIL1β to the 
mature IL1β. Given that IL1β-converting enzyme (ICE) is critical for this processing, it is 
plausible to assume that mutant CARD15 can activate ICE in response to MDP (Figure 3E).  
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However, macrophages from patients with mutant CARD15 were shown to have reduced IL1β 
release upon MDP stimulation (Li et al. 2004). The last two observations may indicate important 
differences in the function of CARD15 in murine versus human cells.  
Recently, the pathway  for  CARD15  signalling  has  been  studied.    Upon binding  of   MDP, 
CARD15 interacts with RIPK2 (receptor-interacting serine-threonine kinase 2), a kinase that 
phosphorylates the inhibitor of NFκB kinase, through homophilic CARD-CARD interaction, 
leading to the nuclear translocation of NFκB (Kobayashi et al. 2002). CARD15 activation also 
leads to ubiquitinylation of the NFκB essential modulator (NEMO) (Abbott et al. 2004), and has 
also been shown to interact with erbb2 interacting protein (ERBIN) (Chen et al. 2004) and 
GRIM-19, a protein with homology to the NADPH dehydrogenase complex (Barnich et al. 
2005b), both essential for NFκB activation. It was shown that membrane targeting, which is 
crucial for NFκB activation is impaired in the presence of a SNP13 mutation (Barnich et al. 
2005a). Two leucine residues and a tryptophan-containing motif in the C-terminal domain of 
CARD15 mediate this membrane interaction. 
The association
 
of CARD15 with CD may provide a unifying explanation for several
 
factors 
influencing the development of this disease. Firstly,
 
CARD15 responds to bacterial cell wall 
components, linking intra-luminal
 
bacteria to CD. Secondly, mutations of the LRR domain affect
 
its sensing function leading to aberrant activation of the NFκB
 
pathway, which is abnormally 
activated in CD (Schreiber et al. 1998; Tanabe et al. 2004). Thirdly, several
 
studies have 
indicated that mutations of the CARD15 gene are associated
 
with ileal involvement (Ahmad et 
al. 2002; Cuthbert et al. 2002; Lesage et al. 2002), where CARD15 is highly expressed.
 
Thus, 
CARD15 seems to be important for the pathogenesis of CD. 
Together with association of CD with TLR4 and CD14 (see p.23-25), the involvement of 
CARD15 demonstrates the importance of the innate immune response in the pathogenesis of CD, 
which was discussed in the introduction.  
 
DLG5 
IBD-associated variants responsible for the linkage observed at 10q23 (Hampe et al. 1999) were 
attributed to the disk large gene 5 (DLG5) by positional cloning (Stoll et al. 2004). 
Association with the IBD phenotype was strongest, and it was higher in the CD subgroup as 
compared to the UC subgroup, although this could be ascribed to the smaller UC sample size in 
this study. This association has since been replicated in three studies (Daly et al. 2005; Newman 
et al. 2006; Tenesa et al. 2006), while two other studies could not confirm these results (Noble et 
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al. 2005b; Torok et al. 2005). Two distinct haplotypes were identified with a distortion of 
transmission in trios. One of the risk-associated DLG5 haplotypes was distinguished from the 
common haplotype by a nonsynonymous SNP c.113G>A, resulting in the amino acid 
substitution R30Q. This SNP was significantly associated with IBD, as was another 
nonsynonymous SNP c.4136C>A resulting in a P1371Q substitution. Furthermore, a significant 
difference in association of the 113A variant with CD was observed in affected individuals 
carrying the risk associated CARD15 alleles. This suggests a complex pattern of gene-gene 
interaction between DLG5 and CARD15. 
DLG5 was first cloned in 1998 as a homolog of the drosophila DLG by searching expressed 
sequence tag databases for related sequences (Nakamura et al. 1998). It encodes a scaffolding 
protein essential for the maintenance of epithelial integrity (Humbert et al. 2003). DLG5 co-
localizes to vinexin, involved in cytoskeletal organization and signal transduction, and to β-
catenin, a major adherens junction protein (Wakabayashi et al. 2003). The expression of DLG5 
has been shown in the intestine and isolated epithelial cells, and thus it seems plausible that 
mutations in this gene might disrupt epithelial barrier function of the intestine (Stoll et al. 2004). 
In silico analysis of the R30Q and P1371Q suggested that both variants probably impair 
scaffolding functions of DLG5. 
 
OCTN1 and OCTN2 
A locus of approximately 250 kb at 5q31 (IBD5) was previously associated with CD (Ma et al. 
1999; Rioux et al. 2000; Giallourakis et al. 2003; Negoro et al. 2003). It was an interesting 
region because it harbours a cytokine cluster (Rioux et al. 2001). Peltekova and co-workers re-
sequenced five genes included within this region, and reported two variants in the organic cation 
transporter gene cluster (OCTN): a missense substitution in SLC22A4, coding for OCTN1 
(c.1672C>T, L503F) and a G>C transversion in the promoter of SLC22A5, coding for OCTN2 
(c.-207G>C) (Peltekova et al. 2004). They are both part of a haplotype associated with CD. 
Moreover, the risk for disease was greater in the presence of both the IBD5 haplotype and the 
CD-associated CARD15 alleles. These observations have since been repeated twice, and 
genotype-phenotype analysis revealed an association particularly with colonic disease (Torok et 
al. 2005; Waller et al. 2005). However, a study from Noble and co-workers could not find an 
association between the OCTN1/2 variants and CD in the absence of the IBD5 haplotype (Noble 
et al. 2005a), thus a causative role for these genes remains plausible but is not yet proven. 
Further genetic and functional data are required to fully designate these genes as susceptibility 
genes. In a recent study, an association was found between the promoter polymorphism in 
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SLC22A5 and psoriatic arthritis (Ho et al. 2005), another chronic inflammatory disease that 
previously has been associated with CARD15 (Rahman et al. 2003). 
OCTN1 and OCTN2 are transmembrane proteins that regulate carnitine and cation transport 
(Burckhardt and Wolff 2000). They are expressed in cell types that are affected in CD, including 
epithelial cells, macrophages and T cells (Peltekova et al. 2004). The L503F variant is located 
within the transport domain, and thus alters its transport function: carnitine uptake in fibroblasts 
was lower in the L503F variant, while tetraethyl ammonium uptake was increased. The promoter 
polymorphism in SLC22A5 impaired the binding of the heat shock transcription factor 1. 
Consequently, the expression of c.-207C OCTN2 was less induced in response to heat shock. 
These observations could be consistent with an altered uptake of physiological compounds or 
bacterial metabolites. 
 
Other gene associations for CD 
Many genes have been tested for association to CD or IBD in general, because they are 
positional or functional candidate genes (Table 2). We describe three genes that have been 
replicated in association studies (TLR4, CD14 and TNF), because of their regulatory role in 
innate immune responses and functional relevance in IBD pathogenesis. 
 
TLR4. Lipopolysaccharide (LPS), a cell wall component of Gram-negative bacteria, is a major 
inducer of inflammation, and its signalling is mediated through the cell surface TLR4. During 
intestinal inflammation, TLR4 is up-regulated on epithelial cells, macrophages and dendritic 
cells, thus providing a first line defence against enteric Gram-negative bacteria. An association 
between a polymorphism in the LRR region of TLR4 (c.896A>G, D299G) has been reported 
within a Dutch CD and UC cohort (Franchimont et al. 2004). Allele frequencies of 10.9% were 
found in CD patients, versus 5% in healthy controls. The association was replicated twice (Braat 
et al. 2005; Gazouli et al. 2005), but could not be reproduced in three other studies (Arnott et al. 
2004; Torok et al. 2004; Lakatos et al. 2005). This mutation was previously linked to a 
decreased bronchial responsiveness to LPS (Arbour et al. 2000), and impairs LPS signaling. 
However, no functional defect, e.g. cytokine release, LPS recognition, has been attributed to 
heterozygous carriership of this mutant in CD patients (Erridge et al. 2003; von Aulock et al. 
2003). A transcriptome analysis of monocyte-deriven dendritic cells, isolated from homozygous 
CARD15 and TLR4 patients, revealed that a large number of genes are differentially regulated in 
both groups (Braat et al. 2005). This suggests that mutations in different genes can cause similar 
effects on gene transcription and can thus result in a similar phenotype.  
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CD14. The CD14 gene is located within the IBD5 locus, and encodes two protein forms: a 
glycosylphosphatidylinositol-anchored membrane protein and a monocyte- or liver-derived 
soluble serum protein that lacks the anchor. Both molecules are critical for LPS dependent signal  
transduction (Wright et al. 1990). Klein and co-workers described an increased incidence of 
CD14 c.-159C>T heterozygous
 
and homozygous mutants in CD patients compared to healthy
 
controls (Klein et al. 2002). This association was replicated in a Greek population (Gazouli et al. 
2005), but it was not observed in three other studies (Arnott et al. 2004; Torok et al. 2004; Peters 
et al. 2005). An interaction between CARD15 and CD14 has been observed (Klein et al. 2003). 
Although the expression of CD14 on monocytes is higher in CD as compared to healthy 
controls, its expression did not correlate to the CD14 genotype (Griga et al. 2005). Similarly, 
CD14 expression is higher in inflamed intestinal mucosa (Rogler et al. 1997), but the association 
to the CD14 genotype was not found in this study.   
 
TNF. Tumor necrosis factor alpha (TNF) is a pro-inflammatory cytokine that provides a rapid 
form of host defence against infection but is fatal in excess. It was a strong candidate gene 
within IBD3, because TNF levels are increased in the serum, mucosa and stool of IBD patients, 
while anti-TNF therapy is very efficacious in IBD (Targan et al. 1997; Present et al. 1999).   
TNF production is under a strong genetic influence (Westendorp et al. 1997). Three SNPs in the 
promoter of TNF (c.-1031C, c.-863A and c.-857T) were associated with susceptibility to CD in a 
Japanese population (Negoro et al. 1999). In contrast, none of these SNPs could be associated 
with IBD in two independent Caucasian populations, while the c.-857C allele was more 
prevalent in IBD and UC (van Heel et al. 2002). Interestingly, this variant was also associated 
with CD when they left out the common CARD15 allele carriers, meaning that these genes act 
independently to confer CD susceptibility. Ex vivo LPS challenging of monocytes resulted in a 
higher production of TNF in c.-857C homozygous individuals. In addition, the transcription 
factor OCT1, an inhibitor of NFκB transactivation, specifically binds to the c.-857T variant, and 
not to the c.-857C.  
Pediatric onset, colonic disease and familial aggregation of CD was associated with a frequent 
polymorphism in the binding site for NFκB in the TNF promoter, c.-863C>A (Levine et al. 
2005).  Electrophoretic mobility shift assay and transfection experiments demonstrated that 
MDP exposure stimulates TNF gene transcription, as a result of CARD15-induced NFκB 
activation (Linderson et al. 2005). When the CD-associated CARD15 1007fs variant was 
analyzed, induction of TNF promoter activity was found to be defective. Different combinations 
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of CARD15 and TNF promoter polymorphisms gave rise to distinct TNF transcription levels, 
which means that CARD15 and TNF promoter polymorphisms interact to exert a functional 
effect on MDP induced TNF production. This gene-gene interaction may contribute to inter-
individual variation in susceptibility to CD. The different findings between these studies may 
reflect genuine population differences, or it could mean that the specifically tested variants are 
not directly pathogenic.  
 
CONCLUSION 
 
Epidemiologic data strongly suggest that genetic susceptibility is a major contributing factor to 
CD. Viewing the association studies, many allelic variants are involved, and great discrepancies 
can be found. Usually, this is explained by the widespread heterogeneity of CD, and the fact that 
single genes contribute little to the complex phenotype. Most associations of candidate genes 
could not be reproduced, didn’t aid in understanding pathogenesis, or didn’t facilitate diagnosis. 
Alternatively, genome-wide screening is less biased, and has been proven very useful with the 
identification of IBD1 and CARD15, which has been replicated many times. Several aspects of 
future linkage and association analysis should be taken into account: 1) clinical classifications of 
individuals should be more conform; 2) sample size is a critical determinant for false-negative 
errors in such studies, especially when stratifying to phenotype or genotype; 3) association of 
genes is usually performed with selected variants of the gene, instead of sequencing the whole 
gene.  In addition, knowledge of the haplotype structure surrounding genes of interest, allows for 
common variation in a gene to be tested with more statistical power, even if the causal variant 
within the shared haplotype block has not been identified (Daly et al. 2001).  
In 1997, a group of scientists and clinicians founded the IBD International Genetic Consortium 
(IBDIGC), now a group of twelve research groups involved in the study of genes that are 
implicated in IBD (Cavanaugh 2003). They collaboratively study large numbers of well-
documented families for linkage. Similarly, small-scale pooling of populations may significantly 
increase the power of linkage and association studies. Finally, the correct choice of candidate 
genes is another major issue. The IBD loci that have been repeatedly verified are to be selected 
preferentially, especially if functional data regarding the gene is available through other analysis 
such as expression data.  
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ABSTRACT 
 
Background & aims: Three polymorphisms within the CARD15 gene have been independently 
associated with Crohn’s disease (CD). Although this association is strong, an average of 60 to 
70% of CD patients do not have any of these three mutations. Furthermore, they do not account 
for all of the linkage observed between CD and the IBD1 locus. Since CARD15 is highly up-
regulated during inflammation, we looked for polymorphisms in the CARD15 promoter region. 
Methods: The promoter region of CARD15 was sequenced in 28 Flemish CD patients, and a 
polymorphism was genotyped in 104 CD patients and 60 controls. An in vitro gene reporter 
assay was used to assess the functionality of the promoter polymorphism in response to tumor 
necrosis factor alpha (TNF). Public HapMap data from CEPH trios were used to determine the 
haplotype structure surrounding CARD15. 
Results: Sequencing of the promoter region revealed a c.-59G>A polymorphism in the 5’ 
untranslated region (5’UTR), contained within a conserved potential binding site for the E2F 
transcription factor. This polymorphism was significantly associated with CD. However, in 99% 
of the cases, the CD-associated CARD15 mutations occur in the c-59G>A background, 
suggesting that they are linked. In addition, the infrequent c.-59A allele was less responsive to 
TNF stimulation. The complete CARD15 gene is located within a single haplotype block.  
Conclusions: A functional promoter polymorphism, linked to the common CD-associated 
mutations, was identified in the CARD15 5’UTR. The complete CARD15 gene is located in a 
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single haplotype block, and we are currently determining the haplotype structure in our patient 
population to evaluate the transmission of the CARD15 promoter polymorphism. 
 
INTRODUCTION 
 
Crohn’s disease (CD, MIM 266600) is an inflammatory condition of the gastrointestinal tract. 
The disease is believed to result from an interaction between environmental factors and genetic 
predisposition. Since 1996, a locus at 16q12 has been repeatedly associated with increased 
susceptibility to CD (Hugot et al. 1996). In 2001, two groups independently identified the first 
strongly CD-associated gene called NOD2, later referred to as CARD15 (Hugot et al. 2001; 
Ogura et al. 2001a). CARD15 is a cytosolic receptor for bacterial components and initiates an 
inflammatory response following bacterial challenge. Both groups found the same gene using a 
different approach. Hugot and co-workers systematically refined the susceptibility locus of 
chromosome 16. They characterized CARD15 within this region, and sequenced the 11 exons of 
this gene in 50 unrelated CD patients. Three haplotypes with preferential transmission to 
affected individuals were identified, each containing one rare allele of single nucleotide 
polymorphism (SNP) 8 (c.2104C>T), SNP12 (c.2722G>C) or SNP13 (c.3020insC) in the 
context of a common background. SNP8 and SNP12 result in non-conservative amino acid 
substitutions R702W and G908R respectively. SNP13 is a frameshift mutation (1007fs), which 
truncates the tenth leucine-rich repeat of CARD15. On the other hand, Ogura and colleagues 
used the candidate gene approach, which is based on an intelligent search for genes within 
regions of linkage. They identified the SNP13 mutation, which was preferentially transmitted, 
and assessed this SNP in a large case-control study. The association of the three mutations have 
since been confirmed in many studies. In Europe, they are found in approximately one third of 
CD patients, especially in those with ileal disease (Cuthbert et al. 2002). 
The observed linkage of CD to chromosome 16 can not be entirely explained by the present 
associations (Hugot et al. 2001). Furthermore, linkage to chromosome 16 was still observed in 
CD patients not possessing one of the three CARD15 mutations (Hampe et al. 2002; Shaw et al. 
2003; van Heel et al. 2003). Thus, other variants of this gene or variations in neighbouring genes 
on chromosome 16 may be involved in CD susceptibility.  
The expression of the CARD15 protein in normal colon is restricted to scattered mononuclear 
cells in the lamina propria (Berrebi et al. 2003), and in paneth cells in the ileum (Ogura et al. 
2003). In the CD colon, however, the number of positive cells is correlated with the 
inflammatory infiltrate. In severely inflamed CD colon samples, intestinal epithelial cells were 
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also CARD15 positive. Together with the observation that CARD15 is up-regulated in acute 
appendicitis, this favours the hypothesis that CARD15 is induced upon inflammatory stimuli. 
Furthermore, it was shown that tumor necrosis factor alpha (TNF), a potent pro-inflammatory 
cytokine, up-regulates CARD15 via NFκB in epithelial cell lines (Rosenstiel et al. 2003). In 
accordance, two functional NFκB binding sites were found within the CARD15 promoter. 
Therefore, CARD15 expression regulation could be an important mechanism in innate immune 
response in intestinal epithelial cells. We wondered whether polymorphisms are present within 
the promoter of CARD15, which might influence their expression. We sequenced a part of the 
promoter region in CARD15, and found a promoter polymorphism in the 5’ untranslated region 
(5’UTR), c.-59G>A, located within a DNA stretch that potentially binds the E2F transcription 
factor. The functionality of both alleles was tested in an in vitro gene reporter system.  
 
MATERIALS AND METHODS 
 
Sequencing and genotyping of c.-59G>A polymorphism 
Genomic DNA was extracted from whole blood using the Qiagen blood and cell culture DNA 
kit. The promoter region of CARD15 was PCR-amplified in 28 Flemish CD patients using 
forward primer: 5’-GGC CTG TCC CCT CGT GAA TG-3’ and reverse primer: 5’-GTC GCG 
GCC AAG GAT GAA AG-3’. This product was sequenced with the BigDye Terminator v3.1 
Cycle Sequencing kit and analyzed on an ABI3700 analyzer (Applied Biosystems).  
The c.-59G>A polymorphism was genotyped by RFLP-PCR in 104 unrelated CD patients and 
60 healthy controls. A fragment containing the polymorphism was amplified with the following 
primers: forward: 5’-GGC GGA GGT TGG AGT TGA AAA TAA-3’; reverse: 5’-GGA AGC 
CAG GAT CTA AGG TA-3’. The PCR product was precipitated with SeeDNA (Amersham 
Biosciences), digested with BsmI, and restriction fragments were analyzed on a 2% agarose gel. 
The presence of the c.-59A allele creates a BsmI site, resulting in two bands of 1108 and 510 bp, 
instead of a single 1618 bp band in the presence of the c.-59G allele.   
Genotyping for the three CD-associated CARD15 polymorphisms c.2104C>T, c.2722G>C and 
c.3020insC was performed using RFLP-PCR as previously described (Laukens et al. 2005). 
 
Constructs 
Genomic  PCR  fragments  of  155 bp  of the promoter  region of CARD15,  starting at base -1 to  
-155 upstream from the initiation codon, were cloned between the SacI and KpnI sites of the 
PGL3basic luciferase reporter vector (Promega Corporation Benelux). This generated PGL3-
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59A and PGL3-59G constructs. Both constructs were sequence verified. The β-galactosidase 
expressing pUT651 vector (Eurogentec, Belgium) was used for normalizing transfection 
efficiencies. 
 
Transfection and gene reporter assay 
HEK293T cells (ATCC CRL1573) were seeded in 24-well plates at 5x10
5
 cells per well the day 
before transfection.  Cells were cotransfected with 100 ng pUT651 and 100 ng of PGL3-59G or 
PGL3-59A in triplicate using the calcium phosphate method. Twenty-four hours 
posttransfection, cells were incubated with 1000 U/ml recombinant human TNF purified from E. 
coli (produced in-house). After 24 hours, cells were lysed in 150 µl lysis buffer (25 mM Tris pH 
7.8, 2 mM DTT, 2mM CDTA, 10% glycerol and 1% Triton X-100) for 15 minutes. Lysates were 
analyzed for luciferase activity by mixing 50 µl of lysate with 50 µl of luciferase assay buffer 
(20 mM tricine, 1.07 mM (MgCO3)4M(OH)2, 2.67 mM MgSO4, 33.3 mM DTT, 0.1 mM EDTA, 
270 µM CoA, 530 µM ATP and 470 µM luciferin). Luciferase activity was measured in a 
TopCount luminescence counter (Packard). β-galactosidase activity was analyzed by mixing 20 
µl of lysate with 160 µl of substrate buffer (60 mM Na2HPO4 pH 7.0, 10mM KCl, 1mM β-
mercaptoethanol) and 20 µl of chlorophenolred-β-D-galactopyranoside  (CPRG) substrate 
(Roche Diagnostics NV, Belgium). After 30 minutes, β-galactosidase activity was measured at 
540 nm in a microplate reader (BioRad Laboratories, Belgium).  
 
Haplotype structure 
Public data of the International HapMap Project (http://www.hapmap.org) were used to identify 
the haplotype structure surrounding CARD15, using the CEPH (Centre d'Etude du 
Polymorphisme Humain) population data, who are all Utah (USA) residents with ancestry from 
northern and western Europe. The criteria used to assign membership in the CEPH population 
have not been specified, except that all donors were residents of Utah. 
 
Statistics 
Luciferase induction was represented as mean of triplicates + SD. The Student’s t test was used 
to compare groups. Allele frequencies between controls and CD patients were compared using 
Pearson’s χ
2
 test. Two-tailed probabilities were calculated, and P-values of less than 0.05 were 
considered statistically significant. 
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RESULTS 
 
A polymorphism in the promoter region of CARD15 is linked to CD-associated mutations 
To search for polymorphisms in the promoter of CARD15, a 425 bp region surrounding the most 
functional NFκB binding site (Rosenstiel et al. 2003) was sequenced in 28 unrelated CD 
patients. One polymorphism was found, c.-59G>A, and subsequently typed in 104 CD patients 
and 60 controls (Table 1). An association with CD patients was found for SNP8, SNP12, SNP13 
and c.-59G>A, but the latter significance is because it is in linkage disequilibrium (LD) with 
SNP8 (R²=0.224, LOD 11.76). If we omit the patients carrying a CARD15 mutation, the 
association of c.-59A with CD is lost. Furthermore, no correlation was found with a specific 
phenotype of CD, e.g. disease location, age of onset or structuring disease (data not shown). 
 
Table 1 Frequencies for SNP8, SNP12, SNP13 and c.-59G>A in our study 
population 
 
 % rare allele frequency in 
 CD patients 
(N=208) 
controls 
(N=120) 
P-value 
SNP8 17.7 4.2 0.002 
SNP12 3.8 0.08 0.043 
SNP13 10.1 0.03 0.001 
c.-59G>A 47.1 26.6 0.003 
c.-59G>A no CARD15 53.2 42.3 0.119 
 
 
The c.-59G>A polymorphism is located within a conserved binding site for E2F 
A search for transcription factor binding sites using the TRANSFAC database revealed that the 
c.-59G>A is located within a potential binding site for the E2F transcription factor (Figure 1). To 
determine whether this binding site is conserved, a search of E2F binding sites in the murine 
CARD15 gene and in other members of the Nod1/Apaf1 family (Ogura et al. 2001b) was 
performed. The human CARD15, NOD1 and the murine CARD15 contain 1 potential binding site 
for E2F within a 800 bp promoter region upstream of the coding sequence. The Apaf1 promoter 
contains 2 of these sites. The conservation of the E2F binding region suggests that regulation of 
CARD15 by E2F might be an essential mechanism in the function of CARD15. 
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Figure 1 Part of the promoter region of CARD15, containing a functional NFκB site and a potential binding site 
for E2F. The c.-59G>A polymorphism in the 5’UTR (grey box) is located within the potential binding site for 
E2F. The E2F consensus sequence is T/C T T C/G G/C C G. The coding sequence of exon 1 is boxed. 
 
The c.-59A allele impairs CARD15 induction by tumor necrosis factor alpha 
Because the c.-59G>A polymorphism is located within a potential binding site for the E2F 
transcription factor, we assessed whether the distinct alleles influence the promoter induction 
after stimulation with tumor necrosis factor alpha (TNF). Therefore, we generated two plasmids 
containing the c.-59G (PGL3-59G) or c.-59A allele (PGL3-59A), together with the functional 
NFκB site in a gene reporter system. After 24 hours of TNF stimulation, luciferase activity 
induction in HEK293T cells transfected with the PGL3-59A construct was significantly less as 
compared with PGL3-59G construct (Figure 2). A similar result was obtained when HT29 
colonic epithelial cells were used as an acceptor cell (data not shown). 
 
CARD15 is contained within a single haplotype block  
The haplotype structure surrounding CARD15 was determined using public CEPH data from the 
HapMap project. The complete CARD15 gene is located within a single haplotype block (Figure 
3). 
 
CONCLUSION 
 
We identified a polymorphism within the CARD15 5’UTR that differs in responsiveness to TNF 
induction. This polymorphism, currently present in the SNP database as rs.5743266, is in LD 
with SNP8, a common CD-associated polymorphism.  
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Figure 2 Luciferase induction controlled 
by a part of the CARD15 promoter in 
response to 24 hours of TNF induction is 
lower in the presence of the c.-59A allele 
(PGL3-59A) as compared to the c.-59G 
allele (PGL3-59G). 
**P<0.005 
 
 
 
 
 
 
Because the function of the three polymorphisms in CARD15 is not completely understood, and 
because other genetic variants in or close to CARD15 are supposed to be present, we focused on 
a promoter polymorphism, which influences the expression of CARD15. Several reports have 
shown that CARD15 expression is induced by TNF and under inflammatory conditions (Berrebi 
et al. 2003; Rosenstiel et al. 2003). It is however not known whether the three CD-associated 
mutations influence CARD15 expression. In a small cohort, there appeared to be no correlation 
between CARD15 mutations and CARD15 expression in the colon. However, only 4 out of 8 CD 
patients carried one of the CARD15 mutations (Berrebi et al. 2003). Therefore, a detailed 
expression study of colonic and ileal CARD15 in relation to the common mutations needs to be 
performed. Moreover, the importance of CARD15 expression has not been extensively studied. 
It was shown that overexpression of CARD15 in intestinal epithelial cells leads to a higher IL8 
secretion in response to lipopolysaccharide (Rosenstiel et al. 2003). The IL8 cytokine is a 
chemotactic protein, which recruits neutrophils, and is a major mediator of the inflammatory 
response. Up-regulation of CARD15 in intestinal inflammation may therefore represent a 
generic response to bacterial invasion.  
The induction of CARD15 transcription in response to inflammation is probably mediated 
through two functional NFκB sites in the promoter (Rosenstiel et al. 2003). The c.-59G>A 
polymorphism is located within a potential binding site for the E2F transcription factor. E2F is 
involved in cell cycle progression (Fang and Han 2006). To establish a true functional 
consequence of the polymorphism, DNA binding of E2F to both alleles needs to be determined. 
Because the c.-59A allele is the common background of SNP8, SNP12 and SNP13, the question 
arises as to the importance of the common mutations in CD. Interestingly, c.-59G>A occurs 
within the same haplotype block as the CD-associated CARD15 polymorphisms. The precise 
haplotypes have to be defined. Therefore, we are currently identifying the haplotype structure in 
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relation to the promoter polymorphism. It was shown that CARD15 with the SNP13 mutation is 
functionally unable to detect bacterial peptides, resulting in less NFκB activation (Chamaillard et 
al. 2003; Inohara et al. 2003; Inohara et al. 2005). We here showed that a promoter 
polymorphism c.-59G>A influences the expression of CARD15 in response to TNF. Perhaps it is 
the combination of SNP8, SNP12 or SNP13 with the promoter polymorphism that causes 
susceptibility to CD.  
 
Figure 3 LD across CARD15 and flanking genomic region, based on public CEPH data. R
2
 values for pairwise LD 
between each marker are represented (white: r2=0, shades of grey: 0>r2>1, black: r2=1). The top of the figure 
shows distances between markers. Most markers within the CARD15 gene are in strong LD. 
 
In summary, we found a new functional promoter polymorphism in CARD15, but to fully 
understand its association to CD, detailed haplotype analysis in our patient population is 
currently ongoing. 
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ABSTRACT  
 
Background & aims: Crohn’s disease (CD) is a multifactorial disorder involving both genetic 
and environmental factors. This study aimed at identifying and characterizing new candidate 
susceptibility genes for CD by integrating known disease loci with gene expression variation in 
non-inflamed colon biopsies of CD patients. 
Methods: Sixteen CD patients and 11 controls were subjected to microarray analysis. Expression 
of metallothionein (MT) was analyzed in intestine and blood by quantitative PCR and 
immunohistochemistry. MT-knockdown HT29 cells were generated by small interfering RNA. 
MT1M, and its transcriptional regulator MRE-binding transcription factor 1 (MTF1), were 
screened for mutations by sequencing. 
Results: Eighteen differentially expressed baseline genes were identified. We focused on the 
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reduced expression of MT in intestine and blood of CD patients with colonic involvement. We 
showed that MT induction was not impaired in these patients. To model lowered MT expression 
in epithelial cells, we created MT-knockdown HT29 cells. These showed a reduced IL8 secretion 
in response to bacterial challenge, suggesting deficient inflammatory responses in the CD colon. 
No mutations were found in MT1M exons and its promoter region. A polymorphism in MTF1 
(IVS1-128A>T) was associated with disease location. Gene-gene interaction of MTF1 and 
CARD15 predisposes individuals to a high risk for ileal disease. 
Conclusions: Combining microarray screening with genetic linkage data is an effective tool for 
identifying novel candidate susceptibility genes. We showed that deficient basal MT expression 
in CD patients with colonic involvement is genetically determined. The IVS1-128A>T 
polymorphism in MTF1 is linked to disease location and serves as a new disease-modifying 
gene.  
 
INTRODUCTION 
 
The strong influence of genetic determinants in Crohn’s disease (CD, MIM 266600) has been 
shown by familial clustering, and by the high concordance rate in monogenic twins. First-degree 
relatives of affected individuals show a 20 to 50-fold higher risk for developing CD. Moreover, 
affected siblings frequently develop the disease at similar ages, and concordance rates reach 80% 
for disease site, behaviour and presence of extra-intestinal manifestations (Peeters et al. 1996; 
Halfvarson et al. 2003). The mode of inheritance of CD is complex, and the number of genes 
predisposing to CD or modifying its course is currently unknown. However, it is not expected 
that a single risk gene is sufficient for disease development.  
Two complementary approaches are used to identify determinants underlying genetically 
complex traits such as CD: candidate gene association studies and genetic linkage. In the 
candidate gene approach, genes that might be involved are screened for polymorphisms in a 
limited number of patients, and then frequencies in large populations of patients and controls are 
compared. In genetic linkage, candidate regions are identified by scanning the entire 
chromosome with microsatellite markers. These so-called disease loci can rarely be narrowed 
down to less than a few megabases. Nevertheless, if the candidate region contains a manageable 
number of genes, a candidate gene is chosen on the basis of a known property, e.g. function or 
tissue-specific expression. Unfortunately, mapping CD loci is hampered by phenotypic 
variability, genetic heterogeneity across populations, uncontrolled environmental influences, 
reduced penetrance, and limited statistical power in such studies. Nevertheless, several CD loci 
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have been corroborated by more than one independent study. The most frequently identified 
locus for CD is 16q12 (IBD1), which led to the mapping of the first gene to be firmly associated 
with CD, called CARD15 (Hugot et al. 2001; Ogura et al. 2001). Today, there is evidence for 
more than 20 loci, but the identity of the causative genes remains largely unknown (Brant and 
Shugart 2004a). In addition, success in finding susceptibility genes has been limited by the 
modest effect of individual genes on the complex phenotype. 
We applied a complementary approach to identify new potential susceptibility genes. Because 
much of the variation in gene expression is genetically transmitted (Cheung and Spielman 2002),  
we evaluated variation of gene expression in unaffected biopsies from CD patients, and 
combined these results with known linkage data. For this purpose, we looked at gene expression 
in biopsies taken from non-inflamed regions of the colon from CD patients and healthy controls. 
We selected genes that show variation in baseline expression and that are also located near a 
locus for CD. We focused on characterizing one of the candidate genes, metallothionein (MT), 
and the consequences of its altered expression. This led to the identification of a new disease-
modifying gene, MTF1, located at 1p33 (IBD7). 
 
MATERIALS AND METHODS 
 
Patients and biopsies. CD was diagnosed according to clinical, endoscopic and histological 
criteria. Patients were classified according to the Vienna classification (Gasche et al. 2000). 
Disease location, however, was defined as the maximal spread of inflammation during the entire 
follow-up. We thus defined three subgroups: pure colonic involvement (C), both ileal and 
colonic involvement (IC), and ileal involvement only (I). For RNA extraction, 3 colon biopsies 
from each of 54 CD patients and 30 controls were collected during colonoscopy. All biopsies 
were taken from endoscopically normal regions of the sigmoid, immediately placed in RNAlater 
(Ambion, Cambridgeshire, UK) and stored at -80°C.  For immunohistochemical analysis, colon 
biopsies were collected from 22 CD patients and 8 controls. Additional ileal biopsies were 
collected from 12 CD patients and 8 controls. Biopsy specimens were immersed in 4% formalin 
(Labonord, France).  
  
RNA extraction. Total RNA was extracted from biopsies using the RNeasy Mini Kit (Qiagen, 
Westburg BV, The Netherlands) with on-column DNAse treatment (Qiagen). Needle 
homogenization was performed. The quality of RNA used for microarray analysis was checked 
on the Agilent 2100 Bioanalyzer (Agilent Technologies, Germany). Total RNA from 3 ml of 
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whole blood was extracted using the RNeasy Midi Kit (Qiagen) following lysis of red blood 
cells with erythrocyte lysis buffer (Qiagen). Concentration and purity (ratio OD260/OD280 
between 1.8 and 2.2) of the RNA used for quantitative real-time PCR was checked on a 
spectrophotometer (UV-1601, Shimadzu Benelux, Belgium). 
 
Microarray hybridization, scanning and analysis. The construction of the focus microarray 
chip, containing 6,779 expressed sequence tags and specifically designed for the study of colonic 
gene expression, has been described (Laukens et al. 2006). Total RNA (5 µg) was amplified 
using a modified protocol for in vitro transcription (Puskas et al. 2002). Probe labelling, 
hybridization, washing and scanning were carried out at the MicroArray Facility (MAF, Leuven, 
Belgium) of the Flanders Interuniversity Institute for Biotechnology (VIB) as described on 
http://www.microarrays.be/service.htm. Images were analyzed with ArrayVision (Imaging 
Research Inc., Canada). Each hybridization was repeated in a dye swap experiment. Spot 
intensities were measured, corrected for local background, and those that exceeded the 
background by more than two standard deviations (SD) were included in the analysis. For each 
gene, ratios of red (Cy-5) to green (Cy-3) intensities (I) were calculated and normalized via a 
Lowess Fit of the log2 ratios [log2(ICy-5 / ICy-3)] over the log2 total intensity [log2(ICy-5 × ICy-
3)].  
A mixture of RNA from 5 CD patients, 5 non-CD inflammatory controls and 5 healthy controls 
served as reference RNA for comparison of the microarray datasets. This reference sample 
provides a positive hybridization signal at each probe element on the microarray, which is 
essential when calculating and comparing fluorescence ratios. The data were imported into 
GeneMaths XT (Applied Maths, Belgium). Weighted mean ratios and their corresponding error 
(pixel SD) were calculated from the dye swap. Data were normalized over all arrays, and 
missing values were imputed using k-nearest neighbour algorithm (20 neighbours). GeneMaths 
XT was used to perform all subsequent analyses.   
 
Quantitative real-time PCR (qPCR). One µg of total RNA was converted to single stranded 
complementary DNA (cDNA) by reverse transcription (Superscript, Gibco, Invitrogen, Belgium) 
with oligo dT priming. One tenth of the cDNA was used in real-time quantification using the 
SYBR green kit (Eurogentec, Belgium) and 300 nM of each primer. A two-step program was run 
on the iCycler (BioRad Laboratories, Belgium). Cycling conditions were 95°C for 10 minutes 
and 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. Melting curve analysis and direct 
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sequencing of amplicons on the ABI3700 analyzer (Perkin Elmer, Applied Biosystems, 
Belgium) confirmed primer specificities. All reactions were run in duplicate and normalized to 
glyceraldehyde phosphate dehydrogenase (GAPDH) levels. GAPDH was chosen after checking 
the expression stability of a set of housekeeping genes in biopsies of CD patients and controls 
using the Genorm software (Vandesompele et al. 2002). Primers were designed using the 
Beacon Designer software (PREMIER Biosoft International, USA). Sequences of all primer sets 
are listed in Table 1. 
 
Table 1 Sequences of qPCR primer sets 
 
Immunohistochemistry. Colon and ileum biopsies fixed in formalin were embedded in paraffin 
according to standard procedures. Sections were rehydrated by serial immersion in xylene and 
ethanol. Immunostaining was performed on a NexES IHC automated staining system (Ventana 
Medical Systems, France) using a 1:10 dilution of a mouse monoclonal anti-metallothionein 
antibody (clone E9, Zymed Laboratories, Sanbio, The Netherlands). An isotype-specific 
irrelevant antibody (X0931, DakoCytomation, Belgium) was used to control for non-specific 
binding of the primary antibody. Slides were blindly scored by two pathologists. Semi-
quantitative scoring was based on staining intensity and the number of positive cells. 
 
Induction assays. The mononuclear cell fraction (PBMC) was isolated from 30 ml of venous 
blood by density gradient centrifugation in Ficoll-Pacque (Amersham Biosciences, The 
Netherlands). PBMCs were seeded in 6-well plates at 106 cells per well in RPMI medium 
(Gibco, Invitrogen) supplemented with 10% FCS. The next day, they were stimulated with 200 
µM ZnSO4 (Sigma, Belgium), 2 µM dexamethasone (Sigma), 10 ng/ml recombinant human IL6 
(Peprotech, Campro Scientific, The Netherlands), 1000 U/ml human recombinant 
Gene 
symbol 
Reference 
sequence 
Forward primer Reverse primer 
GAPDH NM_002046 TGC ACC ACC AAC TGC TTA GC GGC ATG GAC TGT GGT CAT GAG 
MT1A NM_005946 GCA AAG GGG CAT CAG AGA AGT G AAA TAC AGT AAA TGG GTC AGG GTT G 
MT1B NM_005947 AAG TGC TGC TGC TCT TGC TG TGG TTG CTC TAT TTA TGT CTG GGA G 
MT1E NM_175617 GCA TCC TCT GGG TCT GGG TTC AAC AGC AGC CTG GGG AAG AAG 
MT1F NM_005949 GCG ACT GAT GCC AGG ACA AC CAC AGG AAA AGG AAT GTA GCA AAT G 
MT1G NM_005950 GCA AAG GGG CAT CGG AGA AGT G AAG GGA ATG TAG CAA AGG GGT CAA G 
MT1J AF348994 GCT GTG CCT GAT GTG GGA AC AAA TGC AGC AAA TGG CTC AGT ATT G 
MT1M NM_176870 CTG CAA AGG GAC GTT GGA GAA C CAG CAA ATG GCT CAG TAT CGT ATT 
MT2A NM_005953 AAA GGG GCG TCG GAC AAG TG GAA TAT AGC AAA CGG TCA CGG TCA G 
MTF1 NM_005955 TAA GAC TCA ATT GAT TCA GGG ACG AGA 
GC 
CAG TTG TGA GAA ATG AAA ACG TAA TGA 
C 
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TNF (produced in-house) or 200 U/ml human recombinant IFNγ (Biosource Europe, Belgium).  
The cells were lysed in 350 µl RLT buffer (Qiagen) after 3, 6 or 24 hours. To induce oxidative 
stress, PBMCs were incubated with 100 µM H2O2 (Sigma), which was washed off with PBS 
after 10 minutes. Cells were lysed after 2, 4 or 6 hours. Total RNA was isolated using the 
Rneasy Mini Kit (Qiagen), and converted to cDNA for subsequent qPCR. Normalized Ct values 
were corrected for background at each time point (e.g. dCt induced, t1 - dCt un-induced, t1), and plotted 
against time (0, 3, 6 and 24 hours, or 0, 2, 4 and 6 hours for H2O2). Induction was calculated as 
the area under the curve (AUC) for the three time points (AUCs are shaped as triangles and 
rectangles, and their summation or integration gives the same result): 
AUC = 
0
∫
3
(m1.x)dx + 
3
∫
6
(m2.x + b)dx +
6
∫
24
(m3.x + c)dx, 
where m1 = the slope of the 0-3 line, m2 = the slope of the 3-6 line, m3 = the slope of the 6-24 
line, b = the y-intercept of the 3-6 line, and c =  the y-intercept of the 6-24 line. 
HT29 human colon epithelial cells (American Type Culture Collection (ATTC) HTB38) and 
MT-knockdown cells (HT29MTkd) were seeded in 24-well plates at 106 cells per well in RPMI 
supplemented with 10% FCS. The following day, cells were infected in triplicate at multiplicities 
of infection (MOI) of 100 with adherent-invasive Escherichia coli strain LF82, isolated from a 
patient with CD, (a gift from A. Darfeuille-Michaud) (Darfeuille-Michaud et al. 2004) for 1 
hour, followed by gentamycin treatment (100 µg/ml) for 1 hour. Supernatants were collected 
after 8, 24 and 48 hours of infection/induction. 
 
Small interfering RNA (siRNA). The short hairpin RNA (shRNA) fused to an H1 promoter 
was synthesized by PCR on the pSUPER vector (Tronolab, Switzerland), using primers: 5’-CAA 
TCT CTT GAA TTG CAC TTG CAG GAG CCG GGG GGA TCT GTG GTC TCA TAC 
AGA ACT TAT AA-3’ and 5’-CCA TCG ATT TCC AAA AAC CGG CTC CTG CAA GTG 
CAA TCT CTT GAA TTG C-3’. The sequence in bold is a 19-mer that specifically targets MT, 
and is present in MT1B, MT1E, MT1H, MT1J and MT1M. The PCR fragment was cloned in 
pLVTH-siGFP (Tronolab, Switzerland). To produce virus for delivery of the shRNA, HEK293T 
cells (ATCC CRL1573) were transfected by the calcium phosphate method with 3 µg pCMV-
d8.91 (Tronolab, Switzerland), 1.5 µg PMDG2 (Tronolab, Switzerland) and 1.5 µg of the 
shRNA construct. After 48 hours, supernatant containing viral particles was harvested, and put 
through a 0.45 µm filter. One day before viral transduction, HT29 cells were seeded at 5x104 
cells per well in a 24-well plate. They were overlaid with viral supernatant, and centrifuged for 1 
hour at 32°C. This procedure was repeated with 72-hour viral supernatant. Cells expressing high 
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levels of GFP were subsequently sorted with the EPICS altra cell sorter (Beckman Coulter, The 
Netherlands). 
 
Cytometric Bead Array immunoassay. Concentrations of IL1β, IL6, IL8, IL10, IL12p70 and 
TNF in the culture supernatants were measured simultaneously using Cytometric Bead Array 
(CBA) (Human Inflammation Kit, Pharmingen, Becton Dickinson, Belgium) according to the 
manufacturer’s instructions.  Concentrations of the cytokines were obtained by comparing the 
mean fluorescence intensity of the samples with that of the corresponding standard curves. Flow 
cytometric analysis was performed using a BD FACS scan. Data acquisition and analysis was 
done using BD CBA software. 
 
IL8 ELISA. IL8 concentrations in supernatants were assessed in dilution series by sandwich 
ELISA. Microtiter plates (Nunc, USA) were coated with 2 µg/ml anti-IL8 antibody 
(Pharmingen) in PBS for 2 hours at RT, and non-specific binding sites were blocked with 0.1% 
casein-PBS at 4°C overnight. Dilution series of the supernatant (1:2) were incubated for 2 hours 
at RT in 0.1% casein-PBS, and detected with 1:1000 biotinylated anti-IL8 antibody 
(Pharmingen) and 1:500 streptavidin-HRP (Pharmingen) in 0.1% casein-PBS for 1 hour. 
Substrate was added and the reaction was stopped after 30 minutes with 1 M H2SO4. Plates were 
read at 450 and 595 nm in a microplate reader (BioRad).  
  
Mutation screening of MT1M and MTF1. Genomic DNA was extracted from whole blood 
using the Qiagen blood and cell culture DNA kit. The sequence encompassing the MT1M gene 
and ~600 bases upstream of the transcription start site was PCR-amplified in 25 randomly 
selected CD patients and 6 controls (forward primer: 5’-GAG GCC GAC CAG TGT TC-3’, 
reverse primer: 5’-AGT CTC TGG ATG AAA ATG TGA G-3’). The PCR product was 
sequenced with BigDye Terminator v3.1 Cycle Sequencing kit and analyzed on an ABI3700 
analyzer (Applied Biosystems) with the former and the following primers: exon 1: 5’-CCC AGC 
CCA GCC CAG GAC CG-3’; exon 2: 5’-TCA CTG CCC ACT GCG TTT TTC TC-3’; exon 3: 
5’-CAA GTC TAC TGC TAC CTC TC-3’. 
Mutation analysis of MTF1 was performed in 95 randomly selected CD patients using flanking 
intronic primers for all exons and overlapping primers for 1 kb of the upstream regulatory 
region.  PCR primers were designed using the SNPbox software (Weckx et al. 2005a). A total of 
28 primer sets were used (primer sequences are available on request). PCR fragments were 
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sequenced with BigDye Terminator v3.1 Cycle Sequencing kit (Perkin-Elmer, Applied 
Biosystems), and analyzed on an ABI3730 DNA analyzer (Applied Biosystems). The 
sequencing trace files were analyzed for the presence of variants using novoSNP (Weckx et al. 
2005b). 
 
CARD15 and MTF1 genotyping. The 3 CD-associated CARD15 polymorphisms R702W 
(SNP8), G908R (SNP12) and 1007fs (SNP13), as well as MTF1 IVS1-128A>T, were genotyped 
in a cohort of 222 randomly selected CD patients and 63 controls using RFLP-PCR as previously 
described (Laukens et al. 2005). MTF1 IVS1-128A>T genotyping was also done by RFLP-PCR. 
A fragment containing the polymorphism was amplified with the following primers: forward 5’-
TAA GAC TCA ATT GAT TCA GGG ACG AGA GC-3’, reverse 5’-CAG TTG TGA GAA 
ATG AAA ACG TAA TGA C-3’. The PCR product was precipitated with SeeDNA (Amersham 
Biosciences), digested with DraI, and restriction fragments were analyzed on a 2% agarose gel. 
The presence of the IVS1-128T allele abolishes a DraI site, resulting in a band of 271 bp, instead 
of 251 bp in the presence of the IVS1-128A allele.   
 
Statistical analysis. Statistical analyses were performed using SPSS software (SPSS inc., USA). 
Differences between groups in immunohistochemical scores and induction AUCs were 
calculated using the Mann-Whitney U test. Correlations between metric data were calculated 
using Pearson’s Rho, and those between rank data with Spearman’s Rho. Rank data for 
histological scores were 0-1 = 1, 1-2 = 2, 2-3 = 3 and for RNA levels <1,000 = 1, 1,000-10,000 = 
2, >10,000 = 3. Odds ratios and their 95% confidence intervals (CI) were calculated with 
Pearson’s χ² test. Logistic regression was used to evaluate independence and interaction between 
parameters. Significance of differences in ELISA IL8 concentrations between time-series were 
calculated using a general linear model, error bars are calculated from 4 dilutions. Two-tailed 
probabilities were calculated, and P-values of less than 0.05 were considered statistically 
significant. 
 
RESULTS  
 
Identification of potential candidate genes for CD. Gene expression in normal colon biopsies 
of 16 CD patients and 11 healthy controls (Table 2) was analyzed on a focus microarray chip 
containing 6,779 expressed sequence tags. We aimed at identifying potential candidate 
susceptibility genes for subsequent validation and mutation screening. This process was 
Reduced metallothionein expression in Crohn’s disease 
 57 
performed in two steps. First, we characterized genes that were differentially expressed between 
CD patients and controls using an independent t-test (P<0.01, N=240). We then selected the 
genes that were located near a chromosomal region that has been linked to CD in at least two 
independent studies (Table 3). We also included the loci that were found in a study performed on 
a Flemish cohort (Vermeire et al. 2004a), because the patients in our study live in this area of 
Belgium. We employed an arbitrary distance of 5 megabases around markers that showed the 
highest linkage. The exact chromosomal locations of the markers and genes were explored using 
the genome browser at http://genome.ucsc.edu. In this way, 18 genes were selected (Table 4), 
and all clones of the respective genes were sequence verified and annotated correctly. 
 
Table 2 Clinical characteristics of CD patients analyzed by microarrays  
 
 
A1: <40 years; A2: ≥ 40 years; B1: non-stricturing, non-penetrating; B2: stricturing; B3: penetrating; disease location is defined as 
maximal extension of inflammation during total follow-up of patients with I: ileal involvement only, C: colonic involvement only, 
IC: ileal and colonic involvement; mutant CARD15: carriage of at least one mutant allele for SNP8, SNP12 or SNP13 (according to 
Hugot et al. 2001); wt CARD15: not carrying a mutant allele for SNP8, SNP12 or SNP13; 5-ASA: 5-aminosalicylates 
 
Metallothioneins are down-regulated in colon, ileum and whole blood of CD patients with 
colonic involvement.  
Metallothionein RNA expression. In the microarray screen we found two closely related 
metallothionein (MT) transcripts, MT1F and MT1M, that were down-regulated in CD patients. 
Although other genes may show lower P-values, we chose to focus on these genes, because they 
are located near the  IBD1 locus,  which has been  linked to CD in almost every linkage analysis, 
Patient Sex Familial 
CD 
Age of 
onset 
Behaviour Disease 
location 
CARD15 
status 
Operations Medication 
1 F no A1 B1 IC wt no immunosuppressives 
2 M no A1 B3 IC ND no no 
3 M no A2 B1 IC mutant no 5-ASA 
4 F yes A1 B3 IC wt resection corticosteroids 
5 M no A1 B3 IC mutant fistula 5-ASA 
6 F no A1 B2 C mutant resection Remicade 
7 M no A2 B2 I wt resection 5-ASA 
8 F no A1 B3 IC wt resection immunosuppressives 
9 F yes A1 B3 IC wt fistula immunosuppressives 
10 F yes A2 B2 I wt resection immunosuppressives 
11 F no A1 B3 IC mutant fistula immunosuppressives 
12 M yes A1 B2 I wt no 5-ASA 
13 F no A1 B3 C wt resection immunosuppressives 
14 F no A1 B1 IC wt no 5-ASA 
15 F no A1 B3 IC wt fistula, resection corticosteroids 
16 F no A1 B3 IC wt fistel 5-ASA 
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Table 3 Differentially expressed genes in colon biopsies of CD patients located near a locus for CD 
 
Unigene Gene 
symbol 
Gene description Chromosomal 
location 
Expression in 
CD 
P-value 
Hs.486246 PHTF1 putative homeodomain transcription factor 1 1p13 ↑ 0.000099 
Hs.77955 MEF2D MADS box transcription enhancer factor 2, polypeptide D 1q22 ↓ 0.0035 
Hs.106674 BAP1 BRCA1 associated protein 3p21.31-p21.2 ↓ 0.0017 
Hs.438691 GMPPB GDP-mannose pyrophosphorylase B 3p21.31 ↓ 0.0013 
Hs.302047 PLCL3 phospholipase C-like 3 3q25.31 ↓ 0.0048 
Hs.318567 NDRG1 N-myc downstream regulated gene 1 8q24.3 ↓ 0.00038 
Hs.84072 TM4SF3 transmembrane 4 superfamily member 3 12q12.1 ↑ 0.0046 
Hs.85951 XPOT exportin, tRNA (nuclear export receptor for tRNAs) 12q14.1 ↑ 0.0021 
Hs.419776 NAP1L1 nucleosome assembly protein 1-like 1 12q21.1 ↓ 0.0088 
Hs.159481 GALGT UDP-N-acetyl-alpha-D-galactosamine 12q13.3 ↓ 0.00054 
Hs.438737 MT1F metallothionein 1F  16q12.2 ↓ 0.001 
Hs.188518 MT1M metallothionein 1M 16q12.2 ↓ 0.00058 
Hs.100914 CEP192 Centrosomal protein 192kDa 18p11.21 ↑ 0.000042 
Hs.512640 PRKCSH protein kinase C substrate 80K-H 19p13.2 ↓ 0.00042 
Hs.134074 SLC35E1 solute carrier family 35, member E1  19p13.11 ↑ 0.006 
Hs.437     TCF15 transcription factor 15 (basic helix-loop-helix)  20p13 ↓ 0.0024 
Hs.102336 ARHGAP8 Rho GTPase activating protein 8  22q13.31 ↓ 0.0093 
Hs.28491 SAT spermidine/spermine N1-acetyltransferase Xp22.1 ↑ 0.0035 
 
↑: up-regulated in CD; ↓: down-regulated in CD 
 
 
and which contains CARD15. Metallothioneins are involved in a variety of metal scavenging 
processes, and they possess both bactericidal and anti-inflammatory activities (Zangger et al. 
2001; Itoh et al. 2005). In humans, at least 18 MT gene isoforms exist (MT1A-MT1X, MT2A, 
MT3 and MT4), but only MT1 and MT2 are inducible. We performed a detailed expression study 
on different MT isoforms using qPCR on an independent population of 38 CD patients and 19 
controls. Because of the high sequence homology between MT isoforms, we first determined 
whether both MT1M and MT1F were specifically down-regulated. To this end, we designed 
primers for MT1M and MT1F, as well as for MT1E, MT1J and MT2A (Table 1).  
Primer specificities were confirmed by the presence of a single melting peak after denaturation 
of the amplicons, and by direct sequencing. The expression of MT1M in CD patients with 
colonic involvement (subgroups C and IC) was significantly less than in patients with pure ileal 
involvement (P=0.0244, Figure 1) and in controls (P=0.0076). Furthermore, the expression of 
MT1M in all biopsies tested was significantly correlated with expression of the other isoforms 
tested (Table 5). This indicates that at least these MT isoforms share the same regulatory 
machinery for basal expression in the colon. The highest expression in colon biopsies was 
observed for MT1E, followed by MT2A>MT1J>MT1F>MT1M. 
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Table 4 Correlations of MT isoform expression in colon biopsies 
of CD patients and controls 
 
 MT1E MT1F MT1J MT1M MT2A 
MT1E    Pearson’s Rho 1 0.631 0.496 0.500 0.499 
P-value  <0.01 <0.01 <0.01 0.058 
N  65 55 66 15 
MT1F    Pearson’s Rho  1 0.589 0.378 0.784 
P-value   <0.01 <0.01 <0.01 
N   55 62 15 
MT1J     Pearson’s Rho   1 0.609 0.805 
P-value    <0.01 <0.01 
N    53 13 
MT1K    Pearson’s Rho    1 0.615 
P-value     <0.05 
N     15 
MT12A  Pearson’s Rho     1 
P-value      
N      
 
 
Basal transcript levels of MT1F were measured in whole blood of 15 CD patients and 13 
controls, and were found to be down-regulated in CD patients with colonic involvement 
(P=0.026, Figure 2). MT1M levels were too low for reliable quantitative measurement. None of 
the patients and none of the controls had elevated C-reactive protein levels at the time of blood 
sampling. Therefore, changes in MT expression due to systemic inflammation is not likely 
(Vermeire et al. 2004b).  
 
Metallothionein protein expression. MT protein expression was evaluated semi-quantitatively in 
colon and ileum biopsies of CD patients and controls using immunohistochemical staining with a 
mouse monoclonal anti-metallothionein antibody (cloneE9, Zymed Laboratories). This antibody 
however, cannot distinguish between MT isoforms, because all of them have the epitope it 
recognizes. Overall, the expression of MT in colon was significantly lower than in the ileum 
(P=0.042). No conclusions could be drawn about MT expression in the colon, because the scores 
rarely reached 2. Compared to controls, a significant decrease in MT protein expression was 
found in CD patients with colonic involvement (subgroups C and IC) in ileum biopsies, again 
indicating a possible fundamental defect in MT expression in these patients (data not shown). A 
correlation was found between RNA expression as assessed by qPCR and the 
immunohistochemical  score  of  protein  expression  (Spearman’s Rho: 0.826, P=0.001, N=12). 
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Figure 1 MT1M expression is down-regulated 
in colon biopsies of CD patients with colonic 
involvement. CD colitis: subgroups IC + C 
(N=20), CD ileitis: subgroup I (N=18), control 
(N=19). 
  
 
 
 
 
 
 
 
 
 
This finding is interesting because in each individual, the biopsies used for RNA extraction and 
those used for staining were not obtained at the same time, again indicating a stable inherent 
basal expression of MT. Epithelial cells were primarily positive for MT staining. The strongest 
expression was found at the base of the villi, within paneth cells, and in rapidly proliferating 
epithelial cells in the crypts (Figure 3). 
 
 
Metallothionein induction in response to oxidative stress is higher in CD patients. Because 
MT expression is decreased in the colon, ileum and whole blood of CD patients with colonic 
involvement, we examined whether this was due to impaired induction. We stimulated PBMC 
isolated from 10 CD patients (subgroups C: 2, IC: 4, I: 4) and 9 controls with known MT 
inducers (10 ng/ml IL6, 1000 U/ml TNF, 200 µM ZnSO4, 200 U/ml IFNγ and 2 µM 
dexamethasone), and measured MT1M expression by qPCR. No difference in induction was 
found between CD patients and controls. However, induction following exposure to 100 µM 
H2O2 for 10 minutes was significantly higher in CD patients, independently of the disease 
location (P=0.0015, Figure 4).  
 
Colonic epithelial cells defective in metallothionein expression secrete less IL8 in response 
to LPS or adherent-invasive E. coli. Because we observed MT expression mainly in epithelial 
cells, we investigated whether a low basal expression of MT in epithelial cells has consequences 
upon challenge  with bacteria.   We used small interfering RNA (siRNA) to create HT29 colonic 
epithelial cells deficient in MT expression (HT29MTkd). Although the siRNA sequence was 
targeted against MT1B, MT1E, MT1H, MT1J and MT1M, the RNA expression of most MT 
isoforms  was  lowered  approximately  twofold  as  assessed  by  qPCR (Figure 5).   Diminished 
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Figure 2 MT1F expression in blood is down-
regulated in CD patients with colonic 
involvement. CD colitis: subgroups IC + C 
(N=11), CD ileitis: subgroup I (N=4), control 
(N=13). 
 
 
 
 
 
 
 
 
protein expression was shown by immunofluorescence using the monoclonal anti-
metallothionein antibody (data not shown). Cytokine secretion in response to stimulation with 
adherent-invasive E. Coli (AIEC LF82) was tested with the Human inflammation kit (Becton 
Dickinson). We could only measure IL8 secretion after bacterial challenge with this technique. 
The secretion of IL8 was significantly lower in HT29MTkd cells than in normal HT29 cells 
(Figure 6). 
 
Screening for mutations in the MT1M gene. We screened the complete MT1M gene (~1.4 kb) 
and its promoter region (~600 bases upstream of the transcriptional start site), using NM_176870 
as reference sequence, in 25 CD patients and 6 controls. Two intronic polymorphisms, IVS1-
366C>T and IVS2-49C>T, and one 3’ untranslated region (3’UTR) polymorphism, c.286A>G, 
were found. The absence of promoter or coding mutations in MT1M that would cause its down-
regulation was not too surprising, since the down-regulation was not confined to MT1M. Better 
candidates for mutation screening are probably upstream factors regulating all MT isoforms, and 
so we proceeded in that direction. 
 
A polymorphism in the first intron of the MTF1 transcription factor gene is associated with 
ileal disease. One of the best-characterized transcription factors regulating MT expression is 
MRE-binding transcription factor 1 or MTF1, an essential zinc finger protein that binds to 
specific DNA motifs termed metal-response elements (MRE). Furthermore, this protein is 
responsible for both basal and inducible expression of MT (Samson and Gedamu 1998), and the 
gene  is located  at  1p33 (IBD7),  a locus  that has  been linked to  CD in a  Flemish  population  
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Figure 3 Metallothionein staining of 
representative samples of non-inflamed ileal 
biopsies of (A) a control and (B) a CD patient. 
Control ileum shows strong immunoreactivity 
for MT in epithelial cells, with stronger 
reactivity in the proliferative cells of the crypts 
and at the base of the villi. In CD patients, MT 
expression is significantly decreased.  
Bar=100 µm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Vermeire et al. 2004a). We show that expression of the transcription factor MTF1 in blood of 
CD patients and controls correlates with the expression of MT1F (Pearson’s Rho: 0.572, 
P=0.001, N=20). All 11 exons and the promoter region (~1000 bp upstream of the transcription 
start site) were screened for mutations in 95 CD patients, using NM_005955 as a reference 
sequence. Two missense mutations were found: c.198C>G (Asp63Glu) in 4 patients, and 
c.1253G>A (Glu385Lys) in 2 patients. The functional relevance of these mutations still needs to 
be investigated.  Moreover, a potential polymorphism at the splice site junction between exons 8 
and 9, c.1270A>G, was frequently found. Yet no alternative splice variant could be detected in 
cDNA from blood of patients with different genotypes (data not shown). Here, we focused on a 
polymorphism in the first intron of MTF1, IVS1-128A>T, because of its potential influence  on 
gene  expression (Kleinjan and van Heyningen 2005).    No difference in frequency between a 
cohort of 222 CD patients and 63 controls was detected (data not shown). However, genotype-
phenotype  analysis  revealed that IVS1-128A>T  had  considerable influence  on the  location of  
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Figure 4 MT1M RNA induction in 
response to oxidative stress is higher in 
CD patients (N=10) than in controls 
(N=9), irrespective of the disease location 
(P=0.0015). 
 
 
 
 
 
 
 
 
 
disease: the IVS1-128T  allele was  associated with ileal disease (subgroups I and IC). In the 
presence of the IVS1-128T allele, 139/166 patients (84%) had ileal disease, compared to 38/56 
(68%) of those with the AA genotype (OR: 2.4, CI: 1.216-4.891, P=0.011). Because we 
observed that CARD15 mutations were also highly correlated with ileal disease (subgroups I and 
IC, P<0.0001), which has also been observed by others (Ahmad et al. 2002; Cuthbert et al. 2002; 
Lesage et al. 2002), we investigated whether the combined presence of CARD15 and MTF1 risk 
genotypes had a substantially higher impact on disease location than either of them alone.  The 
odds ratio for developing ileal disease (subgroups I and IC) in CARD15 mutation carriers is 4.2 
(CI: 1.980-9.098) and in IVS-128T allele carriers 2.4 (CI: 1.216-4.891). Moreover, logistic 
regression revealed significant interaction between the two genetic markers: carriage of an IVS-
128T allele increased the risk of ileal disease by 12% in CARD15 wild type patients (from 60 to 
72%, Figure 7), and in carriers of CARD15 mutations by 23% (from 74 to 97%). This means that 
both genes contribute to the location of inflammation, and mutually interact. 
The IVS-128A>T polymorphism is located in the first intron of MTF1, which is located within 
the 5’UTR. It is not contained within a CpG island. A search for transcription factor binding 
sites using the transcription factor database (TRANSFAC) revealed a potential binding site for 
GATA binding protein 4 (GATA4). 
 
DISCUSSION 
 
Identification of susceptibility genes, their interaction, and their relationship to specific clinical 
manifestations  is  an important  step in  understanding  CD  and  developing  improved   clinical 
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Figure 5. The RNA expression of 
different MT isoforms in 
HT29MTkd cells is down-
regulated in comparison to HT29. 
The solid line represents a twofold 
change in expression. The short 
hairpin RNA was targeted at 
MT1B, MT1E, MT1H, MT1J and 
MT1M (black bars), but the other 
isoforms tested (MT1A, MT1F, 
MT1G, MT1X and MT2A) also 
show reduced expression. 
 
 
 
 
management or therapy. We used an alternative, hypothesis-independent strategy to identify 
novel candidate genes. Transcriptome analysis of non-inflamed colon biopsies of CD patients 
and controls revealed 18 novel potential candidate genes localized to CD loci.  
Many genome-wide linkage studies of CD have been performed (Brant and Shugart 2004b). This 
led to the identification of the first gene strongly associated with CD, CARD15 (Hugot et al. 
2001; Ogura et al. 2001). Nevertheless, despite its strong association with CD, CARD15 is 
difficult to relate causally to CD. Polymorphisms show very limited penetrance, occurring in 
approximately 40% of patients (predominantly those with ileal disease), as well as in 15% of 
healthy individuals. Furthermore, linkage to chromosome 16 was still observed in CD patients 
not carrying common CARD15 mutations (Hampe et al. 2002; Shaw et al. 2003; van Heel et al. 
2003). An alternative explanation is that polymorphisms in CARD15 are not in themselves 
causal, but modify the immune response in inflammatory lesions elicited by some other 
mechanism. An interesting theory based on evolutionary benefit was suggested by Hugot and co-
workers (Hugot et al. 2003). They stated that a mutated CARD15 protein would have been 
beneficial during the outbreak of the plague in Europe, but it somehow represents a disadvantage 
in the pathogenesis of CD. The identification of CARD15 and the insights into its role in innate 
immunity and CD pathology (Eckmann and Karin 2005) highlight the importance of mapping 
susceptibility genes.  
Two of the 18 potential candidate genes we identified belong to the family of closely related 
metallothioneins (MT).  They are located in tandem within the IBD1 locus and arose by non-
processed gene duplications (Karin et al. 1984). Furthermore, they are involved in protecting 
cells against toxic levels of metal ions, radicals and bacterial infections. Four MT classes exist in 
humans, but only MT1 and MT2 isoforms are inducible by cytokines, hormones, metals and 
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Figure 6. IL8 secretion in response to bacterial challenge is lower in MT-knockdown cells 
(HT29MTkd) than in HT29 cells. +AIEC: stimulated with adherent-invasive E. coli LF82 MOI 
100; unst: unstimulated (P<0.05).  
 
stress in general (Haq et al. 2003). We showed that MT was significantly down-regulated in CD 
patients with colonic involvement as compared to healthy controls. In addition, detailed 
expression analysis of different MT isoforms revealed that their expression is highly correlated 
at basal level. Low RNA expression levels were linked to reduced protein expression. 
Furthermore, we provide evidence that a low expression level of MT in CD patients with colonic 
involvement results from a genetic predisposition rather than from an early inflammation event. 
Indeed, the down-regulation was not only found in colon but also in ileum biopsies, both 
sampled from non-inflamed areas, as well as in whole blood samples regardless of C-reactive 
protein levels.   Remarkably, MT RNA levels correlated with protein expression in biopsies that 
were not time matched, contributing to the idea that MT expression is stable and potentially 
inherited. Two studies have previously shown an up-regulation of MT in CD (Bruwer et al. 
2001; Dooley et al. 2004), while we and others found a down-regulation (Clarkson et al. 1985; 
Elmes et al. 1986; Ioachim et al. 2003; Kruidenier et al. 2003). Moreover, MT quantification in 
CD based on radioimmunoassay (Mulder et al. 1991), microarray (Lawrance et al. 2001) and 
silver-saturation assay (Sturniolo et al. 1998) also reported a down-regulation. 
We further demonstrated that although basal MT levels were reduced in CD patients with 
colonic involvement, they are still inducible by conventional stimuli in peripheral blood. 
Unexpectedly, MT induction with oxidative stress was higher in CD patients, independent of 
disease location.  Relative overreaction in CD patients might reflect the fact that basal low levels 
of MT result in more free hydroxide radicals that can activate the MT transcription factor, 
MTF1, resulting in the overall increased transcription of MT (Zhang et al. 2003).  Alternatively,  
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Figure 7 The presence of the 
MTF1 IVS-128T allele and 
CARD15 mutations contribute 
to ileal disease. Percentages 
represent number of patients 
positive or negative for 
CARD15 mutations that are 
positive or negative for the 
IVS-128T allele. Logistic 
regression revealed a gene-
gene interaction between 
CARD15 and MTF1. 
 
 
 
 
 
 
the higher basal MT level in controls may not permit further induction, because a certain 
threshold is reached.   
In order to clarify the potential functional consequence of reduced basal levels, we generated 
MT-knockdown colonic epithelial HT29 cells using small interfering RNA. We report that, in 
response to bacterial challenge with a CD-associated E. coli strain (Darfeuille-Michaud et al. 
2004), reduced expression of MT in epithelial cells correlated with reduced IL8 secretion. This 
observation is in accordance with the recent finding that IL8 up-regulation is impaired in 
response to acute trauma to colon and skin of CD patients (Marks et al. 2006). IL8 is a potent 
chemoattractant and activator of neutrophils, which respond rapidly to different types of 
infections, and play an essential role in the inflammatory response. They release antimicrobial 
peptides as well as reactive oxygen intermediates that may cause tissue damage. We hypothesize 
that the intestinal epithelial cell lining of CD patients with colonic involvement expresses less 
MT and initially secretes less IL8 in response to bacteria. This might secure an exaggerated 
secondary, compensatory immune response.  
It is unlikely that polymorphisms in the MT genes themselves would be responsible for their low 
expression, since we showed that they are down-regulated as a group. Yet, in our knockdown 
model for MT, we see a similar decrease in expression of MT isoforms that were not targeted 
with the short hairpin RNA. Thus, the possibility of a positive feedback loop for MT expression 
via its own transcriptional regulator cannot be ruled out (Kimura et al. 2002). We could not find 
coding or promoter polymorphisms in MT1M, but other isoforms need to be screened. 
Alternatively, epigenetic mechanisms such as DNA methylation might be responsible for the 
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down-regulation of MT genes in CD patients (Smith et al. 2005). 
In searching for mutations in MTF1 (IBD7), a transcription factor that regulates basal expression 
of MT, we focused on a polymorphism within the first intron, IVS1-128A>T, because regulating 
regions are frequently found there. This polymorphism predisposes to inflammation at specific 
sites in the intestine. Disease location is a phenotypic characteristic that remains stable over 
time. Similar to CARD15, the association of MTF1 with ileal disease offers a new candidate 
disease-modifying gene, rather than a disease-predisposing gene (Gasche et al. 2003). In 
addition, the two genes interact to bring about ileal disease. If we regard pure colonic CD on one 
end of a continuum with ulcerative colitis (UC) on the other end, this polymorphism in UC 
patients is worthy of study. 
The links of CARD15 and MTF1 with disease location might reflect the functions of these 
proteins at their sites of expression: CARD15 is expressed in paneth cells of the ileum, and the 
expression of MT in ileum is much higher than in colon. Both proteins are probably crucially 
involved in maintaining a low bacterial count in the ileum. A fully functional CARD15 or MTF1 
might be crucial in this process. However, they might be disadvantageous in the colon, where 
bacterial load is high. In the colon, a weakly functional CARD15 can be beneficial, because 
inappropriately intense immune responses will not be elicited. Greater MT expression in the 
colon can also be beneficial because it can lead to efficient clearance of mucosal infection. 
The association of the IVS1-128T allele in MTF1 with low MT expression needs investigation. 
However, to fully understand the genetic contribution of IVS-128A>T in CD, the haplotype 
structure surrounding this polymorphism needs to be determined. The mutation causing altered 
transcription of MTF1 could be located elsewhere within the same haplotype block. MTF1 
regulates basal expression of MT (Samson and Gedamu 1998). Therefore, a difference in MTF1 
expression will be directly linked to altered MT expression. Indeed, we showed a correlation 
between MT1F and MTF1 levels in peripheral blood. The IVS-128T allele is located within a 
potential binding site for GATA4, a transcription factor that is expressed in the ileal enterocytes 
in the small intestine, but not in the colon (Boudreau et al. 2002). Therefore, a primary goal in 
this context is to study GATA4 binding to the MTF1 gene. 
Loss of MTF1 in mouse embryonic fibroblasts results in enhanced collagen deposition, which is 
an important complication of CD (Haroon et al. 2004). In these fibroblasts, transforming growth 
factor-beta is activated. This protein has potent anti-inflammatory properties, but at the same 
time it drives the process of fibrosis in the deeper layers of the gut (Van Assche et al. 2004). 
Nonetheless, we could not find an association between the IVS-128A>T polymorphism and 
stricturing disease, indicating that additional risk factors influence this particular phenotype. 
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Interestingly, though, the IVS-128T allele in MTF1 is associated with CD of the ileum, which 
has a higher likelihood of stricturing than does colonic CD.  
We used microarray screenings in unaffected tissues for human genetic studies. A similar study 
was performed by Lawrance and colleagues, with the exception that they used moderately 
inflamed resected colonic tissue (Lawrance et al. 2001). We used non-inflamed tissue to target 
basal differences in gene expression due to genetic variation, and not due to inflammation-
related events. Significant evidence was found for the genetic transmission of variation in gene 
expression (Lo et al. 2003; Pastinen et al. 2004). The variation in expression level is highest 
among unrelated individuals, and smallest between monozygotic twins, indicating that germ-line 
differences contribute to variation in gene expression (Cheung et al. 2003; Correa and Cheung 
2004).  
In summary, screening unaffected colon biopsies by microarrays proved to be useful in the 
identification of new candidate genes for CD. A cluster of MT genes located at IBD1 is 
consistently down-regulated in CD patients with colonic involvement. Subsequently, we 
identified a new disease-modifying gene, MTF1, that is associated with ileal disease, and 
together with CARD15 serves as a good predictor of disease location in CD patients. 
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ABSTRACT 
 
Metallothioneins (MT) are ubiquitous metal-binding proteins that are highly conserved 
throughout evolution. Although the exact physiological function is not completely understood, it 
is clear that they are involved in a variety of processes including metal detoxification, free 
radical scavenging, metal homeostasis and cell proliferation. The human MT family consists of 
at least 18 different isoforms, containing pseudogenes as well as functional proteins. They can be 
induced by a wide variety of substances, e.g. metals, cytokines and hormones.  In addition, 
different cell types express discrete MT isoforms, reflecting the specifically adapted functions of 
MT isoforms, and hence a divergence in their regulation. Aberrant expression of MT has been 
described in a number of apparently diverse diseases, including inflammatory bowel disease, 
cancer, Alzheimer’s disease, amyotrophic lateral sclerosis and Menkes disease. Therefore, a 
thorough understanding of the regulation of MT expression is important. To date, the regulation 
of transcription of these genes has primarily been studied in mice. Unfortunately, the situation in 
mice is somehow less complicated, since only 4 isoforms are expressed.  Nevertheless, the high 
homology between mouse and human MTs allows us to evaluate regulatory regions in their 
respective promoters. Here, we review the aberrant expression of human MT in disease, and the 
mechanisms that regulate MT expression. 
 
Chapter 4 
 74
INTRODUCTION 
 
Metallothioneins (MT) are a family of small, highly conserved proteins with the specific capacity 
to bind metal ions. The MT protein was first purified from the equine renal cortex in 1960 (Kagi 
and Valee 1960). Since, they were described in a wide variety of species, including vertebrates, 
invertebrates, plants, fungi and some prokaryotes. A great deal of sequence and structural 
homology exists between MT proteins in different species, underlining its important biological 
role. Mammalian MT proteins typically consist of 61 to 68 amino acids, with a high content of 
polar, highly catalytic cysteine residues. These cysteins are strictly conserved and arranged in 
motifs that form the framework of two distinct metal-binding domains, linked by a short peptide 
(Figure 1). Initially, the biological function of MT was centralized to their unique metal-binding 
capacity. In normal conditions, excessive concentrations of essential and nonessential metal ions 
like cadmium, mercury, and lead can be toxic. Most organisms use a redundant array of cellular 
mechanisms to limit toxicity of metal ions (Dameron and Harrison 1998), one of which is 
sequestration by MT. They thus provide homeostasis of metal ions and protect cells from acute 
heavy metal toxicity. Through participating in zinc metabolism, they regulate the activity of fast 
exchanging metalloproteins, such as NFκB (Sakurai et al. 1999; Kim et al. 2003) and the tumor 
suppressor gene p53 (Ostrakhovitch et al. 2006). It is now clear that the function of MT is not 
restricted to this metal-binding activity. They are rapidly induced during specific phases of the 
cell cycle and by diverse stimuli, such as metals, hormones and cytokines, thus they participate 
in cell cycle and diverse protective functions. Metallothioneins are capable of scavenging free 
radicals and thus play a role in protection of tissues against various forms of oxidative injury, 
including radiation, lipid peroxidation, oxidative stress conditions of hyperoxia. In addition, 
extracellular MT has been shown. Elevated serum and urine MT was found in cadmium-exposed 
individuals (Falck et al. 1983). Moreover, MT in the extracellular environment may act as a 
“danger-signal” promoting movement of leukocytes to the site of inflammation (Yin et al. 2005). 
A significant role for a strictly controlled regulation of MT in both growth of cells and in their 
response towards several stimuli is obvious. It is therefore plausible that defects in the one of 
these restricted mechanisms can lead to pathological situations, like for example tumor growth. 
Good knowledge of their regulation is thus crucial in understanding their role in pathogenesis. 
 
THE HUMAN METALLOTHIONEIN FAMILY 
 
The classification of metallothioneins has been revised in 1999, and is based on evolutionary  
The regulation of human metallothionein 
 75 
Figure 1 Homology model of human 
metallothionein 1A. Cysteine residues are 
shown as yellow sticks, metal ions are 
shown in red (Cd
2+
), green (Zn
2+
) and 
orange (Na
+
). The model was constructed 
using the Swiss Model web server 
(Schwede et al. 2003) with the crystal 
structure of the rat metallothionein 1A 
protein (PDB ID 4MT2) as template 
structure. 
 
       (Schwede et al. 2003) 
 
 
 
 
 
data (Binz 1999). Rodents have four MT isoforms, MT1 to MT4, while all primates examined so 
far contain multiple copies of the MT1 isoform. The situation is most complex in humans: a total 
of 18 MT isoforms and 5 MT-like genes have been cloned so far, many of which only differ in 
distinct amino acids (Table 1). At least five of the isoforms are non-processed pseudogenes. 
Seventeen out of 18 isoforms cluster together on chromosome 16q13 (Figure 2) (Karin et al. 
1984). Apparently, chromosome 16 is one of the most enriched chromosomes for 
intrachromosomal duplications as compared to the human genomic average (Martin et al. 2004), 
and includes for example the cadherin gene cluster. It is not clear whether some of the MT 
pseudogenes are functional: MT1J and MT1M contain a promoter, are transcribed, but contain a 
premature stop codon.  
The various MT isoforms differ mainly in their expression pattern:  MT3 an MT4 are 
constitutively expressed in specific cell types, while MT1 and MT2 are highly inducible and 
ubiquitously expressed (Table 1). 
By comparing the coding sequences of rodent and primate MT genes, it was shown that human 
MT1 isoforms show less divergence from human MT2 than from mouse MT1, suggesting that 
these two isoforms arose after the emergence of primates (Schmidt et al. 1985). Similarly, MT3 
and MT4 probably diverged prior to the primate/rodent divergence (Figure 3). In addition, MT1 
and MT2 isoforms are clearly separated from the MT3 and MT4 clusters, probably reflecting 
their unique functions in the organism. Moreover, this means that MT1 and MT2 proteins might 
have a very similar function in mice and in humans. 
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Table 1 Annotated human metallothionein genes and their characteristics 
 
Symbol Chromosomal 
location 
Aliases Protein length Refseq status Expression 
MT:      
MT4 16q13  62 provisional squamous epithelium 
MT3 16q13 GIF 68 validated brain, kidney, reproductive system 
MT2A 16q13 MT2 61 provisional ubiquitous 
MT1A 16q13 MT1S 61 validated ubiquitous 
MT1B 16q13 MT1Q 61 provisional ubiquitous 
MT1E 16q13  61 validated ubiquitous 
MT1F 16q13  61 provisional ubiquitous 
MT1G 16q13  61 provisional ubiquitous 
MT1H 16q13 MT-0 61 provisional ubiquitous 
MT1J 16q13 MT1NP 40 provisional         ? 
MT1M 16q13 MT1K 61 provisional ubiquitous 
MTM 16q13  49 provisional         ? 
MT1X 16q13  61 provisional ubiquitous 
MT pseudogenes:      
MT1I 16q13?  - withdrawn         - 
MT1L 16q13 MT1R - provisional         - 
MT1CP 16q13  -          - 
MT1DP 16q13  -          - 
MT2P1 4q13  - provisional         - 
MT-like:      
MTL1 1p  ?          ? 
MTL2 1p22  ?          ? 
MTL3 18  ?          ? 
MTL4 20  ?          ? 
MTL5 11q13 TESMIN 178  reviewed testis 
 
 
METALLOTHIONEIN IN DISEASE  
 
Metallothionein expression has been studied in various pathological conditions. Unfortunately, 
contradictory results complicate the interpretation of the involvement of these proteins in 
diseases.   Expression  data obtained by immunohistochemistry, semi-quantitative PCR and more 
 
Figure 2 Genomic organization of the human metallothionein family on chromosome 16. Pseudogenes are 
represented in grey. 
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recent techniques such as quantitative PCR (qPCR) are not always comparable. The early studies 
relied on immunohistochemistry using antibodies, which cannot distinguish between MT 
isoforms, because they share the antigenic epitope. Furthermore, in normal tissues, MT 
expression is usually undetectable by immunohistochemistry, except in myoepithelial (van den 
Oord and De Ley 1994), renal (Mitropoulos et al. 2005), intestinal (Laukens et al. 2006) and 
thyroid epithelial cells, pancreas (Tomita and Matsubara 2000) and fetal liver (Fuller et al. 
1990). On the other hand, strong staining was found in pathological tissues, especially in many 
tumors (Theocharis et al. 2004). Here, we summarize data of deviant MT expression in several 
diseases. 
 
 
 
Figure 3 Phylogenetic tree of human and mouse metallothionein protein isoforms. Metallothionein 3 and 4 probably 
arose prior to the divergence of primates and rodents, while MT1 and MT2 genes arose later. Mouse MT genes are 
designated as mMT1, mMT2, mMT3 and mMT4. 
 
Metallothionein and inflammatory bowel disease 
Inflammatory bowel disease (IBD), comprises both Crohn’s disease (CD) and ulcerative colitis 
(UC). They are chronic inflammatory diseases of the intestine. In CD, the complete bowel wall 
is affected, while in UC, only the superficial layers become inflamed. In the normal intestine, we 
found that MT RNA and protein expression is highest in the ileum as compared to other 
compartments of the gut (Laukens et al. 2006). Metallothionein is localized in the enterocytes, 
predominantly at the base of crypts, probably due to the high proliferative state of these cells. 
The immunopositivity decreases towards the top of the villi. Focal staining is often observed in 
the intestine, as a result of the uniform staining in distinct single crypts. It was suggested that this 
might be the consequence of somatic mutations in stem cells, leading to strong clonal expression 
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of MT in the entire crypt (Jasani et al. 1998). Aberrant protein expression was found in tissue 
samples originating from IBD patients. Down-regulation as well as up-regulation has been 
reported. Two papers reported an up-regulation (Bruwer et al. 2001; Dooley et al. 2004), while 
we and others found a down-regulation of MT in IBD (Clarkson et al. 1985; Elmes et al. 1986; 
Ioachim et al. 2003; Kruidenier et al. 2003; Laukens et al. 2006). Moreover, MT quantification 
in IBD based on radioimmunoassay (Mulder et al. 1991), microarray (Lawrance et al. 2001) and 
silver-saturation assay (Sturniolo et al. 1998) also reported a down-regulation. Using qPCR, we 
were able to show a decreased expression of a large proportion of MT1 isoforms and MT2 at 
basal level in colon biopsies, ileum biopsies and whole blood samples of CD patients that have 
colonic involvement (Laukens et al. 2006). This lowered mRNA expression level correlated with 
protein expression, even though biopsies were not acquired at the same time. These results 
suggested that the deficient MT expression in CD patients with colonic disease is genetically 
determined, and not the result of an early inflammation event. Interestingly, the MT gene cluster 
is located in IBD1, a locus that was significantly associated to CD in many genome scans 
(Mathew and Lewis 2004). In murine IBD models, however, MT does not appear to influence 
the development or progression of intestinal pathology in the DSS (Oz et al. 2005). 
Zinc is often decreased in IBD patients. This element plays an important role in the prevention of 
free radical formation and in protection of biological structures from damage (Stefanidou et al. 
2006). It was shown that dietary zinc causes an MT increase in all gut regions in rats (Tran et al. 
1999; Szczurek et al. 2001). On the other hand, zinc supplementation in IBD patients did not 
change concentrations of MT in plasma and erythrocytes (Mulder et al. 1994), and the MT 
concentration in both inflamed and non-inflamed intestinal mucosa was only slightly higher. 
Histological inflammation scores of intestinal biopsies, plasma albumin levels, and the disease 
activity index of the patients did not change during the study. However, in this study, only 
inactive to moderately active patients were included. 
A decreased MT level in CD patients could indicate a hampered maintenance of free radicals. 
Indeed, human monocytic cells that were transfected with an MT-antisense vector, produce more 
hydrogen peroxide than control THP-1 cells in the absence of a stimulus (Leibbrandt et al. 
1994). The exact role of MT in CD pathogenesis has to be established in future studies. 
 
Metallothionein and cancer 
Immunocytochemically detectable MT overexpression was described in a variety of human 
tumors, and has been extensively reviewed recently (Theocharis et al. 2004). As such, we will 
not focus on this issue here.  
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The expression of MT is not universal to all human tumors, but may depend on their 
differentiation status and proliferative index. Metallothionein overexpression is associated with 
resistance to anticancer drugs and is combined with a poor prognosis. However, its use as a 
marker of tumour differentiation, cell proliferation and prognosis predictor remains unclear. On 
the other hand, gastric carcinomas and colorectal adenomas are apparently accompanied by a 
decreased expression of MT, however, those with a relatively high level seem to have an 
increased malignant potential (Janssen et al. 2000).  
Cell-type specific differential regulation of human MT genes was found in different cancer cell 
lines, correlating with DNA methylation and chromatin structure (see later) (Jahroudi et al. 
1990) . Tumor cell-lines arising from paraxial mesoderm and endoderm have MT2A and MT1E 
genes in fully inducible form and the MT1F in the refractory state (Schmidt et al. 1985). On the 
other hand, tumours originating from ectoderm, intermediate and lateral mesoderm exhibit 
MT2A and MT1F genes in inducible form and the MT1E gene in a refractory form. 
       
Metallothionein, Alzheimer’s disease and amyotrophic lateral sclerosis 
Metallothionein 3 was first cloned as growth inhibitory factor (GIF), which showed a decreased 
RNA expression in Alzheimer’s disease (AD). Metallothionein 3 suppresses the neurotrophic 
activity present in the normal human brain (Tsuji et al. 1992b). The down-regulation of MT3 in 
AD has been confirmed by two recent studies. In the first study, MT3 expression was determined 
in a large number of AD cases by qPCR as well as by immunohistochemistry and Western 
blotting (Yu et al. 2001). In the second study, DNA microarrays were used to compare RNA 
levels from control and AD hippocampal regions and found, amongst others, MT3 down-
regulation (Colangelo et al. 2002). However, Erickson and colleagues (Erickson et al. 1994) 
disputed that neuronal changes in AD are related to a decrease in MT3, since they could not find 
a significant down-regulation in neither RNA nor protein expression in their AD population. 
There is more consensus on the overexpression of MT1 and MT2 in the astrocytes from AD as 
well as other neurological disorders (Duguid et al. 1989; Adlard et al. 1998; Zambenedetti et al. 
1998; Chung et al. 2004). In the brain, astrocytes are the main source of MT1 and MT2, 
although other cell types, such as choroid plexus epithelia, endothelium and meningeal cells may 
also express these isoforms (Penkowa 2006). In neurodegenerative diseases such as AD, 
astrocytes become abundant and activated in the affected areas. While in other organs, the main 
function of MT is related to zinc metabolism and protection against heavy metal and/or oxidative 
damage, the key role of MTs in the brain seems to be a protection in the cellular response to 
neuronal injury. It was suggested that the specific increase in MTs was associated with the initial 
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stages of the disease process (Adlard et al. 1998). The precise mechanisms downstream of MT 
have not been fully established, but convincing data showed that they are essential in dealing 
with neuropathology and for brain recovery in AD as well as other brain pathologies. MTs might 
even be used as therapeutic and/or preventive drugs for a range of brain disorders (Penkowa 
2006). 
Amyotrophic lateral sclerosis (ALS) is a progressive, invariably fatal neurological disease due to 
degeneration of the nerve cells responsible for controlling voluntary muscles.  In ALS, motor 
neurons in the brain stem, spinal cord and motor cortex degenerate or die, ceasing to send 
messages to muscles. Consequently, the muscles gradually weaken, waste away, and twitch. 
Fifteen to 20% of cases of familial amyotrophic lateral sclerosis are associated with mutations in 
the superoxide dismutase 1 gene (SOD1). Elevated levels of MT have been found in spinal cord, 
kidney and liver of patients with ALS (Sillevis Smitt et al. 1992a; Sillevis Smitt et al. 1992b), 
but not in serum (Sillevis Smitt et al. 1994). A detailed study on different MT isoform 
expression revealed no evidence for either the induction of a specific MT repertoire, or for the 
inability of glia to express any MT gene (Blaauwgeers et al. 1996). Probably, the enhanced 
expression of MT in ALS reflects an early protective function. This was also concluded from a 
study on MT expression in mice carrying the SOD1 mutation (Gong and Elliott 2000). These 
mice were backcrossed with MT-knockout mice. The offspring reached the onset of clinical 
signs significantly earlier in response to the reduction of protein expression. These results 
indicated that the copper-mediated free radical generation derived from mutant SOD1 might be 
related to the degeneration of motor neurons in ALS and that MT might play a protective role 
against the expression of the disease (Nagano et al. 2001). 
Recently, MT3 was screened for mutations in 20 patients with ALS, but no functionally relevant 
polymorphism could be associated with the disease (Morahan et al. 2005). 
 
Metallothionein, Menkes disease and Wilson disease 
Menkes disease is an X-linked, recessive disorder of the copper metabolism that occurs in less 
than 1 in 200,000 live births. The condition is characterized by early retardation in growth, 
peculiar hair, focal cerebral and cerebellar degeneration, skeletal abnormalities, and patient 
mortality in early childhood (Bankier 1995). Three independent research groups cloned the 
Menkes gene, a copper transporting ATPase, ATP7A, to the long arm of the X chromosome 
(Chelly et al. 1993; Mercer et al. 1993; Vulpe et al. 1993). A spectrum of mutations adversely 
affecting protein expression have been observed in severely affected Menkes patients (Kodama 
and Murata 1999). The genetic defect in Menkes syndrome leads to a progressive copper 
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deficiency and copper-dependent enzymes fail in most tissues.  
Using cultured fibroblasts, it was shown that low
 
extracellular copper concentrations induce 
synthesis of MT in Menkes' cells but not in normal cells (Hamer 1987). Therefore, in the early 
studies on tissue abnormalities in Menkes disease, MT were believed to be involved in 
pathogenesis (Garnica et al. 1978; Schmidt et al. 1984). Now, it is clear that a defect in efflux 
and consequently intracellular accumulation of copper, due to mutations in ATP7A, is 
responsible for this up-regulation in Menkes’ cells. As a result of accumulation of copper in the 
cell MTs are up-regulated, but they are as such not causative for pathogenesis in Menkes disease. 
In affected cells, copper accumulates bound to MT in the cytosol, while its transport to the 
organelles, as well as copper efflux, is disturbed. The low activity of metalloenzymes is believed 
to contribute significantly to the pathogenesis of this condition. 
 Wilson disease is an autosomal recessive disorder characterized by dramatic build-up of 
intracellular hepatic copper with subsequent hepatic and neurologic abnormalities. Copper 
toxicity occurs when the liver is overloaded and non-ceruloplasmin-bound copper is released 
into the bloodstream, from where it can diffuse into the brain. Today, the treatment of Wilson 
disease is no longer aimed at ‘decoppering’, the removal of accumulated copper, but at the 
normalization of the free copper concentration in blood, to reverse the copper poisoning. 
Therefore, new therapy is aimed at administration of zinc to these patients, because this 
increases MT expression and sequesters the excess of copper in the blood (Hoogenraad 2006). 
 
HUMAN METALOTHIONEIN GENE REGULATION 
  
Because MT expression is involved in a number of pathological conditions, the transcriptional 
control of MT has become a major topic. Metallothioneins are induced by a wide variety of 
physiological and chemical agents like cytokines, metals, hormones, and stress in general 
(Borghesi and Lynes 1996). Furthermore, they are transiently induced after tissue injury caused 
by e.g. inflammation or irradiation (Manuel et al. 1992). It is generally accepted that MT1 and 
MT2 genes are inducible, while MT3 and MT4 are constitutively expressed. Metallothionein 1 
isoforms have a restricted and transient role, perhaps in stress or during infection and the cell 
cycle. On the other hand, MT2A is ubiquitously expressed, and plays a general role in cellular 
physiology, possibly in zinc metabolism. Metallothionein 3 is predominantly expressed in the 
central nervous system (Tsuji et al. 1992a; Blaauwgeers et al. 1996), but also in the kidney 
(Hoey et al. 1997), prostate (Dutta et al. 2002), retina (Tate et al. 2002), salivary glands (Irie et 
al. 2004) and reproductive system (Moffatt and Seguin 1998). The mouse MT4 is expressed in 
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stratified squamous epithelium of the tongue (Quaife et al. 1994), but there are so far no data on 
human MT4 expression. 
Most of the functional studies on MT transcription were performed in mice. However, in mice, 
MT1 and MT2 isoforms are co-ordinately regulated (Searle et al. 1984), while the many human 
MT isoforms are regulated in a cell-type specific manner (Schmidt and Hamer 1986; Varshney 
et al. 1986; Laukens et al. 2006). This probably resulted from the adaptation of the MT isoforms 
to more specific functions throughout evolution. Phylogenetic tree analysis of the promoter 
region of mouse and human MT isoforms shows that MT2, MT3 and MT4 promoters are highly 
homologue between mouse and human, which might reflect their more strictly regulated 
expression pattern. Human MT1 isoforms are dispersed into two groups. Interestingly, these two 
clusters correlate to the physical location of the genes on chromosome 16 (Figure 2). On the 
other hand, the mouse MT1 promoter region is relatively unrelated to the human MT1 group 
(Figure 4). It is thus plausible that regulatory regions in the mouse and human promoter have 
adapted differently. Therefore, care must be taken when evaluating MT expression and maybe 
even function in the mouse, for solving questions related to human circumstances. Nevertheless, 
if common transcription factor binding sites are found in human and mouse promoters, we can 
extrapolate the experimental data on mouse MT1 regulation to the human situation.  
We performed a comparative study on the transcriptional control of MT in mice and humans, 
using in silico data of promoter transcription factor binding sites. Based on these common 
regulatory sites, we review the MT regulatory mechanisms. 
 
In silico analysis of human and mouse MT1 promoters 
Although marked sequence conservation exists, the RNA level for each MT isoform is unique. 
This is possibly due to inherent differences in promoter regulatory sequences. Promoters are 
organized with a variety of elements that contribute to promoter function. The elements found in 
any promoter differ in number, location and orientation.  
A difference distance matrix approach (De Bleser et al. 2006) was used to identify a set of 
transcription binding sites that are specifically highly present in following MT isoforms: MT1A, 
MT1B, MT1E, MT1F, MT1G, MT1E, MT1J, MT1M and MT1X (Table 2). Many of these 
binding sites and their transcription factors have been described in MT regulation, however, we 
found a number of unexplored regulatory regions. We next searched for these transcription 
factor binding sites in the mouse MT1 promoter, and for well-known mouse binding sites (USF, 
MLTF) in the promoters of human MTs. Below, we describe the involvement of these 
transcriptional regulators in more detail. 
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Figure 4 Phylogenetic tree analysis of the promoter regions of human and mouse MT isoforms. 
Promoter regions are defined from nucleotides -800 to -1 relative to the transcriptional start site. 
 
 
Table 2 Transcription factor binding sites in 800 bp of the promoter of human and mouse metallothionein 1 
isoforms 
 
 Transcription 
factor 
MT1A MT1B MT1E MT1F MT1G MT1H MT1J MT1M MT1X mMT1 
basal TBP + + - - + - - - + + 
 TFII-I 2 2 1 3 1 2 2 4 0 1 
 Sp1 5 1 1 8 5 2 2 4 3 3 
 AP2 0 1 1 1 1 3 1 0 0 0 
 USF/Nrf2 0 0 0 0 1 0 0 0 0 1 
induction ChCh 9 3 6 8 6 5 8 9 5 3 
 HELIOS 2 8 2 6 6 7 4 3 9 3 
 E2F 3 0 4 4 3 2 6 5 3 3 
 Spz1 4 4 5 4 2 5 3 6 1 2 
 Egr_1 4 0 3 5 0 0 3 8 4 1 
 GR 1 1 6 0 0 3 1 2 2 3 
 STAT 1 0 4 2 1 1 1 1 2 0 
 MTF1 2 4 1 5 2 5 2 2 3 3 
 RAR-a 2 5 1 5 3 3 3 2 3 3 
repression ETF 6 2 3 9 6 2 6 6 6 4 
 NFI 1 0 1 3 4 2 1 2 2 4 
 
The number of hits as found by MatchTM  (TRANSFAC PRO 8.4) using a core matrix match of 100% and a matrix match of 85%. Exceptions are 
IL6RE and MLTF for which consensus sequences were used in combination with PatchTM (TRANSFAC PRO 8.4). The Match procedure 
introduces false positives; therefore, the number of hits listed is an overestimation of the real hits. The MT isoforms with TBP consensus 
sequences located close tot the transcription start site are denoted with a plus (+). Those that do not contain a TBP close to the transcription start 
site are denoted with a minus (-). mMT1= mouse MT1 
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Basal expression 
RNA polymerase II is responsible for transcribing genes coding for messenger RNA (mRNA). 
The first step in transcription is the binding of the TFIID complex to a region upstream of a 
sequence called the TATA box. The TFIID complex consists of the TATA-binding protein 
(TBP) and TBP-associated factors (TAF). The location of the TATA box with respect to the start 
point is relatively fixed, usually located ~25 bp upstream of the transcriptional start site. 
Therefore, TATA box consensus sequences located further upstream are probably not functional. 
Metallothionein 1E, MT1F, MT1H, MT1J and MT1M contain TATA-less promoters. This could 
partly explain the observation that the MT1G promoter is five times more active than the MT1F 
promoter in transfection studies (Gedamu et al. 1987; Shworak et al. 1993). GC boxes, common 
promoter components involved in basal transcription, are frequently found in MT promoters, 
often clustered together close to the start site. It has been proposed that the Sp1 factor binds to 
multiple GC boxes, resulting in an interaction of GC box-bound Sp1 factors with each other to 
synergistically stimulate transcription. Furthermore, basal level enhancer sequences, binding 
activator protein-2 (AP2), are found in some human MTs, but not in the mouse MT1. TFII-I 
binds specifically to initiator elements (Inr), supporting basal transcription. An E box, binding 
the upstream stimulatory factor (USF) was only found in the mouse MT1 and the human MT1G. 
It was shown that TFII-I also binds to upstream E box, and that TFII-I and USF interact co-
operatively at both Inr and E box sites (Roy et al. 1991). The USF sequence overlaps with an 
antioxidant response element (ARE). These AREs are usually found in genes responsive to free 
radicals, through interaction of ARE with NF-E2-related factor 2 (Nrf2). However, this sequence 
is only found in the mouse MT1 and human MT1G, suggesting that they might be more 
responsive to free radical exposure. Nevertheless, response to oxidative stress can also be 
mediated by metal responsive elements (MRE) in the promoter (Dalton et al. 1994). MREs are 
recognized by the MRE-binding transcription factor 1 (MTF1), and are classically required for 
metal induction of MTs (see below). Nevertheless, they also participate in basal transcription. 
Indeed, the basal expression of MT is highly correlated to the activity of MTF1 (Ghoshal and 
Jacob 2001). Furthermore, we have recently shown that basal MT levels in whole blood vary 
considerably between individuals, but they correlate well with MTF1 expression (Laukens et al. 
2006).  
 
Inducible expression 
Metal induction. Metallothionein 1 and MT2 isoforms are highly inducible by many metal ions, 
including zinc, cadmium, bismuth, mercury, copper, nickel and cobalt.  The concentration of 
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metal ions to induce MTs depends on the type of ion and MT isoform. Metallothioneins are 
capable of binding most of these elements, however, they do not bind nickel and cobalt. The 
transcriptional regulation responsible for this metal induced expression, is controlled by MREs, 
present in the promoter of MT as multiple, non-identical copies. The mouse and human 
transcription factor that binds to these MRE elements is the MRE-binding transcription factor 1 
or MTF1. When this factor was first cloned (Brugnera et al. 1994),  it was shown that the human 
MTF1 was more effective than the mouse equivalent. MTF1 is absolutely necessary for both 
basal and metal inducible MT expression (Heuchel et al. 1994). Moreover, although MTF1 is 
activated by a number of metals, it absolutely requires zinc for its activity. It was hypothesized 
that inducing non-zinc metals can displace zinc from its storage proteins, resulting in a pool of 
free zinc available for activation of MTF1 (Jacob et al. 1998). These storage proteins could be 
MT itself, leading to a complex feedback interaction between MTF1 and MTs.  
Interestingly, treatment of cells with cadmium increases MT expression, although it does not 
influence the DNA binding activity of MTF1 to the MRE. This suggests that additional 
mechanisms play a role in metal induction. For example, cadmium induces oxidative stress, 
which could activate binding of USF to the E box. Alternatively, as stated before, cadmium 
might replace the intracellular zinc in storage proteins, which results in more free zinc to activate 
MTF1. 
In addition, posttranslational modification of MTF1 has been shown. Phosphorylation of MTF1 
plays a critical role in its activation by zinc and cadmium (Saydam et al. 2002). Several 
phosphorylation sites are present throughout the complete MTF1 protein. This was thought to be 
mediated through a complex pathway involving protein kinase C, tyrosine kinase, and casein 
kinase II.  
 
Stress and inflammation mediated induction. Similar to acute phase proteins, MT is induced by 
inflammation, bacterial infection and stress. Stress in general often results in the synthesis of 
glucocorticoid hormones, resulting in the suppression of inflammation and an increase in blood 
sugar levels. These steroid hormones are synthesized by the adrenal gland, and can enter the cell 
by simple diffusion. Within the cell, it binds to its receptor, the glucocorticoid receptor (GR), 
which in turn gets activated and translocates to the nucleus. There, it has high affinity for a 
consensus sequence called the glucocorticoid response element (GRE), and activates 
transcription from MTs and other GRE containing genes. Glucocorticoid hormones have been 
known for a long time as inducers of MT (Karin and Herschman 1979; Jacob et al. 1999). The 
human MT2 gene contains one GRE, while the mouse MT1 and MT2 genes contain two tandem 
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copies ~1kb upstream of the MT2 gene and ~7 kb of the MT1 gene (Kelly et al. 1997). In 
humans, MT2A is significantly more inducible by glucocorticoids as compared to MT1 isoforms 
(Schmidt and Hamer 1986). It was shown that dexamethasone, a synthetic glucocorticoid 
agonist, appears to have no significant effect on the expression of MT1F (Varshney et al. 1986). 
This can be explained by the fact that there is no GRE sequence in the promoter of MT1F. 
During acute inflammation, such as after tissue damage or during infection, macrophages are 
recruited and activated to the site of inflammation. They secrete pro-inflammatory cytokines 
such as IL6, TNF, IL1α and IL1β. These cytokines are able to induce MT (De et al. 1990). Fast 
MT up-regulation after challenge with IL1 is probably mediated through glucocorticoids (Coto 
et al. 1992). Interleukin 6 is one of the most potent inducers of MT (Schroeder and Cousins 
1990). Metallothioneins have IL6 response elements (IL6RE) in their promoter. These DNA 
stretches bind STAT transcription factors. A synergistic effect was demonstrated between IL6 
and glucocorticoid in MT induction (Kasutani et al. 1998), which is possibly mediated by the 
close proximity of the GRE and the IL6RE in the MT promoters.  
Interestingly, it was reported that MTs inhibit the release of pro-inflammatory cytokines 
(Kanekiyo et al. 2002; Inoue et al. 2006). This could be explained by the regulatory role of MT 
in NFκB activation (Sakurai et al. 1999). 
 
Cell cycle. Metallothioneins appear to play a major role during the cell cycle. A tenfold rise of 
MT synthesis was described in exponentially growing human hepatocytes (Nagel and Vallee 
1995; Studer et al. 1997), and peaks of MT expression were found in late G1 and G1/S transition 
in HT29 epithelial cells (Nagel and Vallee 1995). Similarly, in placental tissue, positive 
immunostaining for MT was found only in trophoblast and proliferating cells (Haerslev et al. 
1995). We have recently described that MT expression in the intestine was most apparent in the 
rapidly proliferating cells of the crypts (Laukens et al. 2006). Moreover, it was suggested that 
MT transcription is altered by the differentiation process. Indeed, it was shown that the 
differentiation of teratocarcinoma cells using retinoic acid is associated with a rise in MT 
expression. Retinoic acid receptors (RAR) are nuclear receptors related to the steroid and thyroid 
hormone receptors, a family of proteins that functions as ligand-dependent transcription factors. 
Retinoic acid is a regulator of differentiation at various stages of vertebrate embryogenesis. In 
accordance, multiple RAR receptor binding sites are found in human and mouse MT1. 
Although MT expression is generally cytosolic, nuclear translocation has been observed at 
G0/G1 to early S-phase (Cherian and Apostolova 2000). This nuclear and cytoplasmic 
localization of MT was also observed in several tumours, especially in regions of high 
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proliferation. Moreover, antisense down-regulation of MT1 in endothelial cells resulted in the 
cell cycle arrest at the G1 phase (Miyashita and Sato 2005), and cell growth was inhibited in 
MT1 antisense tumor cells (Takeda et al. 1997). Hesketh and colleagues have shown that the 
nuclear translocation is determined by the 3’ untranslated region of MT1 (Hesketh 2004). 
Recently, they identified a 11 nucleotide sequence in the 3’UTR, containing a CACC repeat, that 
is necessary for the nuclear translocation of MT1 (Nury et al. 2005).  
In the human and mouse MT1 promoters, potential binding sites for the E2F transcription factor 
are present. This transcription factor is a critical determinant of the G1/S-phase transition during 
the mammalian cell cycle, serving to activate the transcription of a group of genes that encode 
proteins necessary for DNA replication. In addition, E2F activity appears to be directly regulated 
by the action of retinoblastoma protein (Rb). Human DP-1 and E2F-1 associate both in vivo and 
in vitro, and this interaction leads to enhanced binding to E2F DNA-binding sites (Helin et al. 
1993). The association of E2F-1 and DP-1 leads to co-operative activation of an E2F-responsive 
promoter. It was also demonstrated that trans-activation by E2F-1/DP-1 heterodimers is inhibited 
by RB. Nevertheless, the actual binding of E2F to MT promoters needs to be determined.  
The nuclear need for MT at specific stages of the cell cycle might point towards a critical 
function of MT in regulating metalloproteins, or protection from DNA damage and apoptosis 
(Meplan et al. 1999).  
 
Development. Metallothionein expression is tightly regulated and activated during mammalian 
embryonic development. During early development of the mouse embryo, expression of MT1 is 
induced specifically in the endoderm cells of the visceral yolk sac (Andrews et al. 2001). It was 
shown that MTF1 is absolutely essential for up-regulation of MT1 gene expression in visceral 
endoderm cells and that optimal expression also involves the binding of USF to the promoter. 
Only the human MT1G promoter contains an E box, therefore, it is not known whether the 
human USF binding is necessary in development.  
 
Inhibition of transcription 
Contrary to the activation of MT expression, their down-regulation by cis-acting events has not 
been extensively studied. However, a reduced expression has been frequently found in many 
types of cancers and in IBD. Three factors are probably involved in suppression of MT: nuclear 
factor 1 (NFI), ZBTB11 and EGFR-specific transcription factor (ETF). Overexpression of NFI 
in human hepatoma cells suppressed both constitutive and metal induced activation of the MT1 
promoter (Majumder et al. 2001). NFI binds to an MRE-c’ sequence in the mouse promoter 
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(Datta and Jacob 1993). NFI sites are present in the mouse and all human promoters except 
MT1B. One study reports a 120 kDa zinc finger protein (PZ120) repressing the transcription of 
the human MT2A gene by binding to its transcription initiation site (Tang et al. 1999). The 
PZ120 gene is now replaced in the NCBI database as the zinc finger and BTB domain containing 
11 (ZBTB11). So far, no additional reports describing this transcription factor were published 
since. ETF is present in all MT isoforms, and has not been described in the context of MT 
inhibition. Overexpression of this factor in primate kidney CV1 cells showed that it represses 
expression originating from both the EGFR and beta-actin gene promoters (Kageyama and 
Pastan 1989).  
The influence of environmental factors on MT expression was illustrated by the inhibition of 
zinc induced MT induction by chromium, a major environmental carcinogen (Majumder et al. 
2003). This inhibition was working through interfering with MTF1.  
Treatment of mammalian cells with cycloheximide, a protein synthesis inhibitor, resulted in 
increased MT1 transcription (McCormick et al. 1991). Recently, the presence of a labile 
inhibitor of MT1 expression was suggested (Bi et al. 2006). This repressor negatively controls 
agonist-induced turnover of the MTF1 protein. 
       
Promoter methylation 
Methylation of cytosine residues in promoter sequences is generally associated with a low 
transcriptional level of the respective gene. In mammals, methylation is mainly found within so-
called CpG islands, regions of high CG content, thought to be involved in transcriptional 
regulation. The general rule is that CpG islands are not methylated, except for genes on the 
inactive X chromosome and at imprinted loci. Generally, to study the methylation status of a 
gene in a cell line or in tissue, its expression is correlated to the amount of methylated CG 
dinucleotides in genomic DNA isolated from the same source. If a correlation is found, e.g. low 
gene expression and a hypermethylation of the CpG island, the cells or tissue specimens are 
subjected to a demethylation agent, such as 5-azacytidine. If the demethylation results in an 
increased expression of the gene, a role for methylation in expression regulation of the gene is 
established. 
Rodent and human MT genes contain a CpG island in their promoter. Tissue specific 
methylation of MT1B has been demonstrated (Heguy et al. 1986). The MT1B gene is only 
expressed in human hepatoma and renal carcinoma cell lines, and not in HeLa cells, where the 5' 
flanking region of MT1B is highly methylated. MT3 hypermethylation has been shown in gastric 
cancer (Deng et al. 2003) and in oesophagal squamous carcinoma (Smith et al. 2005). 
The regulation of human metallothionein 
 89 
CONCLUSION 
 
The persistent differential expression of MTs in stress reaction and in pathological conditions 
suggests a strict regulation of these proteins. It is plausible that a change in e.g. cell cycle 
regulation of MT could influence cancer development. In addition, cell-type specific expression 
of MTs may indicate a divergence in functions within cell types or organs. For instance, 
disability of the tightly controlled proliferation of stem cells in the intestinal crypts may render 
individuals more susceptible for developing colon cancers. Similarly, a disturbed immune 
balance in the intestine due to changes in MT expression could be a prerequisite for IBD. Our in 
silico search for transcriptional regulatory regions in the MT promoters revealed new potential 
targets that could help to unravel some of the MT regulatory mechanisms. Future studies on the 
expression and regulation of MT genes are likely to provide insights to their role in both health 
and disease. Ultimately, novel strategies for manipulating intracellular MT levels could lead to 
new therapies. 
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INTRODUCTION 
 
The spondyloarthropathies (SpA) are a heterogeneous group of chronic inflammatory arthritides 
that share certain clinical features, and are linked by their association to the human leukocyte 
antigen class-I gene, HLA-B27 (Wright 1978). The most characteristic clinical feature is 
inflammatory back pain, caused by inflammation of the sacroiliac joints (sacroiliitis, Figure 1 
left), or the joints of the spinal vertebrae (spondylitis, Figure 1 middle). A specific characteristic 
of SpA is enthesitis, involving inflammation at the sites where tendons, ligaments or joint 
capsules are attached to the bone (Figure 1, right). Peripheral joint inflammation is frequently 
present in SpA, and is mostly pauciarticular (less than four joints), and affects predominantly the 
lower limbs. These are progressive diseases in which chronic inflammation leads to deterioration 
of the bone or cartilage. New bone formation in the spine or peripheral joints severely impairs 
movement in these patients. Usually, low back pain is the first symptom, which is worse at night, 
in the morning and after periods of inactivity. The course of SpA is highly variable and 
characterized by spontaneous remissions and flare-ups, particularly in the early stages. Often, 
extra-articular manifestations are associated with SpA, such as uveitis, psoriasis and 
inflammatory bowel disease (IBD), either Crohn’s disease (CD) or ulcerative colitis (UC). 
Since 1991, the European Spondyloarthropathy Study Group (ESSG) criteria are widely used for 
diagnosis of SpA (Dougados et al. 1991). The SpA group is generally divided into 5 main 
disease categories (Table 1): 1) ankylosing spondylitis (AS),  the most common form of SpA;  2)  
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Figure 1 Radiographs of (left) the pelvis in a patient with sacroiliitis showing sclerosis and erosion of the sacroiliac 
joints (arrows); (middle) the lumbar spine in a patient with ankylosing spondylitis with complete ossification of the 
annulus fibrosus; (right) the heel in a patient with periosteal reaction at the plantar fascia insertion and at the 
Achilles tendon insertion on the calcaneus. 
 
reactive arthritis (ReA), in patients with a recent history of a urogenital or an intestinal infection; 
3) psoriatic arthritis (PsA); 4) SpA associated with IBD (SpA-IBD); and 5) undifferentiated 
spondyloarthropathy (USpA), grouping patients that fulfil the criteria for SpA but are not 
classifiable in one of the former groups. 
There is an important overlap between the different disease manifestations of SpA in families. 
This argues for a genetic predisposition for SpA (Breban et al. 2003). As mentioned above, the 
SpAs are linked by a common genetic risk factor, HLA-B27, which is much more prevalent in 
SpA patients than in other rheumatic diseases or healthy controls (Table 1). HLA class I 
molecules are highly polymorphic membrane glycoproteins, and are specialized antigen-
presenting molecules that form stable complexes with antigenic peptides, displaying them for 
recognition by CD8
+
 T cells. It is anchored to the cell membrane by a short transmembrane 
segment, and consists of three α domains, non-covalently bounded to β2-microglobulin. There 
are currently 24 genotypic subtypes of HLA-B27 identified, and HLA-B*2705 bears the strongest 
association to SpA. HLA-B*2702, *2703, *2704, and *2707 are associated with AS. Worth 
mentioning is that the prevalence of SpA is correlated to the occurrence of HLA-B27. For 
example, SpA is frequent among Eskimo’s, where the prevalence of HLA-27 is 25 to 40% 
(Boyer et al. 1994). Conversely, SpA is rare in the Japanese population, where HLA-B27 
prevalence is less than 1% (Hukuda et al. 2001). The mechanism by which HLA- B27 confers 
susceptibility to SpA is not understood. Several hypothesis have been proposed (Kim et al. 
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2005), including the arthritogenic peptide theory, molecular mimicry and aberrant processing or 
folding of the heavy chain of HLA-B27.  
Although SpA is regarded as one entity of inflammatory arthritides, they display distinct clinical 
features. It is likely that interplay among genetic and environmental factors is responsible for the 
various clinical manifestations. Spondyloarthropathy is considered to result from infection or 
exposure to an unknown antigen in genetically susceptible patients. In the case of ReA, a known 
infection precedes the arthritis by several weeks. This arthritis is thought to be a post-infective 
phenomenon, rather than resulting from a direct infection, since up to now, no viable bacteria 
could be cultured from synovial fluid of inflamed joints. This phenomenon is also referred to as 
a sterile inflammation of the joint, as compared to infectious arthritis caused by direct invasion 
of the joint space by various micro-organisms. Nevertheless, bacterial antigens were commonly 
found in the synovium of SpA patients (see next paragraph). Thus, it can never be ruled out that 
an actual infection has occurred in the patient before the onset of SpA. It has been suggested that 
the gut is an important portal for antigenic uptake in SpA, and thus plays a pathogenic role in 
susceptible hosts. Here, we review this remarkable link between the bowel and the joint in SpA.  
 
INTESTINAL INFLAMMATION, SPONDYLOARTHROPATHY AND IBD 
 
An interesting link has been found between SpA, intestinal inflammation and IBD (Mielants et 
al. 2005). In 10 to 20% of IBD patients, inflammatory peripheral arthropathy has been observed, 
and 7 to 25% have axial involvement (de Vlam et al. 2000; De Vos 2004). Moreover, 
radiographic sacroiliitis is present in 20 to 25% of IBD patients. Clinically, these forms of 
arthritis are almost identical to SpA, although they are not associated with HLA-B27, indicating a 
different genetic predisposition. On the other hand, the gut is an important site of inflammation 
in patients with SpA. In ileocolonoscopic studies of SpA patients, histological signs of gut 
inflammation were found in more than half of the patients, mostly not presenting any clinical 
intestinal manifestations, while they were not seen in any other inflammatory joint disease (De 
Keyser et al. 1998). Remission of the joint inflammation was always linked with a disappearance 
of the gut inflammation. Two types of inflammation were distinguished: acute inflammation 
resembling infectious enterocolitis, and chronic inflammation more suggestive of early CD 
(Cuvelier et al. 1987). In the acute type of inflammation, the mucosal architecture is well 
preserved. The ileal villi and crypts are infiltrated by polymorphonuclear cells, while in the 
lamina propria, there is an increased number of inflammatory cells. The chronic type of 
inflammation is characterized by a clearly disturbed mucosal architecture, and is mostly 
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indistinguishable from CD. The villi are blunted and fused. The crypts are distorted and the 
lamina propria is edematous and infiltrated by mononuclear cells. Basal lymphoid follicles 
occur. In some cases, aphtoid ulcers and granulomas are present. The clinical significance of 
CD-like alterations in the bowel of SpA patients was shown in a prospective long-term study in 
which SpA patients were reviewed after several years (Mielants et al. 1995; De Vos et al. 1996). 
About 13% of patients who showed subclinical chronic gut inflammation on biopsies at the first 
investigation, developed full-blown CD. This supports the concept of subclinical CD in a 
subpopulation of SpA patients. Hence, SpA and CD could be regarded as a result of a common 
inflammatory pathway leading to phenotypes with comparable clinical and pathogenic features. 
A number of studies have been performed to provide molecular and genetic support for the 
clinical observation of the association between gut and joint inflammation in SpA. These are 
discussed in the next paragraphs. 
 
Genetic arguments for a joint-gut axis  
Several studies indicated the specific genetic contribution of intestinal inflammation in SpA 
patients. Bjarnason and co-workers assessed the presence and inheritance pattern of subclinical 
intestinal inflammation in first-degree relatives of patients with AS (Bjarnason et al. 2003).  
They appeared to have an inherited abnormality that leads to subclinical intestinal inflammation, 
suggesting that this feature is transmitted and thus genetically determined. Detailed genetic 
analysis to identify risk factors for intestinal inflammation still needs to be done. 
We recently performed a prospective clinical and radiological evaluation of 102 CD patients, 
and found an association between CD-associated CARD15 polymorphisms (Chapter 1) (Hugot et 
al. 2001; Ogura et al. 2001) and the presence of sacroiliitis: 78% of patients with sacroiliitis 
were carriers of a mutation in CARD15, compared to 48% of patients without sacroiliitis (Peeters 
et al. 2004). Here, the carriage of CARD15 mutations is predisposing for the onset of both 
chronic gut inflammation and sacroiliitis. The molecular mechanism of this association has yet 
to be investigated. However, replication of these results failed in a multicentre study, so caution 
must be taken in interpreting the involvement of CARD15 in sacroiliitis.  
The most convincing evidence for a joint-gut axis in SpA comes from the HLA-B27 transgenic 
rats. These animals develop an illness similar to SpA, with manifestations including sacroiliitis, 
enthesitis, arthritis, skin and nail lesions, ocular inflammation, cardiac inflammation, and 
inflammation of the gastrointestinal and male genitourinary tracts (Taurog et al. 1994). 
Furthermore, the severity of the clinical disease correlates with the number of copies of HLA-
B27 expressed in the transgenic animal. This model provides direct evidence that over-
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expression of the major risk factor in human SpA is causative for both arthritis and bowel 
inflammation, and supports the existence of an interplay between the gut and the joints.  
Moreover, if these HLA-B27 transgenic rats are raised in a germ-free environment, they do not 
develop clinical disease. Once introduced to a regular environment and exposed to bacteria, the 
rats develop clinical manifestations of SpA, suggesting that commensal flora and/or pathogens 
are required in the disease onset. In humans, HLA-B27 is strongly associated with AS and ReA 
(Table 1), and it is plausible that this protein can be pathogenically related to the rat model. 
Nevertheless, SpA with associated IBD is not highly correlated to HLA-B27: only 30% of this 
group of patients is positive for HLA-B27. In fact, of the HLA-B27 negative SpA patients, ReA 
or USpA was diagnosed (Mielants et al. 1993). One explanation might be that there are two 
forms of SpA related with IBD, one in which HLA-B27 is causative for both joint and gut 
inflammation, and one where another risk factor is involved. Genetically, it is possible that 
polymorphisms in another gene, located near HLA-B27, are associated with SpA, as it is believed 
that transmission of genetic information is confined to haplotype blocks, segments of DNA in 
which the chance of recombination is very low (Daly et al. 2001). On the other hand, the 
presence of HLA-B27 proteins might not be sufficient to disturb both joint and gut inflammatory 
pathways, a feature that is maybe not involved in rodents. Moreover, because the frequency of 
HLA-B27 in the population-at-large far exceeds that of SpA, suggests that there are more genetic 
determinants for SpA (Reveille 2004). The search for new genes that are both involved in IBD 
and SpA is a challenging prospect for the future. 
 
Immunologic arguments for a joint-gut axis 
The immune infiltrate in the gut mucosa of patients with SpA is significantly different from that 
of healthy controls, even in the absence of inflammation, suggesting the presence of early 
inflammatory changes in the intestine of SpA patients. Lymphoid follicles in the intestine are 
specialized microenvironments where naive T cells respond to specific antigens encountered in 
the intestinal lumen. Under normal conditions, the number of follicles is limited.  However, in 
the presence of inflammatory stimuli, their number increases. Similar to CD, the number of 
follicles is increased in the ileum and colon of SpA patients with microscopical normal gut 
biopsies (Demetter et al. 2002). The amount of leukocytes expressing CD11c was augmented in 
the ileum of SpA patients, while in the colon CD11a and VCAM-1 expressing leukocytes and 
CD68
+ 
macrophages were higher as compared to controls. The increase in CD68
+
 macrophages 
and adhesion molecules was also seen in CD (Bernstein et al. 1998). Moreover, the expression 
of αEβ7 integrin, a specific gut homing receptor for effector T cells, was up-regulated on gut 
Spondyloarthropathy as a model for early Crohn’s disease 
 107 
mucosal T cell lines isolated from SpA patients in the absence of inflammation (Elewaut et al. 
1999; Van Damme et al. 2001c). In addition, an up-regulation of E-cadherin, the ligand for 
αEβ7, and its associated catenins, crucial for intercellular adhesion in epithelial cells, has been 
demonstrated in clinically overt IBD (Demetter et al. 2000). These observations are indicative of 
an increased infiltration of T cells and macrophages in the epithelial lining of the gut of SpA 
patients. Macrophages carrying the scavenger receptor CD163 were increased in colonic mucosa 
of CD and SpA patients, but not in UC (Demetter et al. 2005). They were also increased in the 
synovium of SpA patients, where they correlated with inflammatory parameters (Baeten et al. 
2002). These CD163
+
 macrophages produce interleukin 1 (IL1) and tumor necrosis factor alpha 
(TNF), but not IL10 following lipopolysaccharide (LPS) challenge (Baeten et al. 2002). Thus, an 
imbalance in cytokine production might lead to chronic inflammatory process in the gut mucosa 
of SpA and CD patients. Finally, there is a similar predominance of T helper type 1 (Th1) 
producing mucosal T cells in both SpA and CD, most surprisingly with a proportional decrease 
of interferon gamma and IL2 producing lymphocytes (Van Damme et al. 2001a; Van Damme et 
al. 2001b).  
Overall, these observations point to the presence of early immune changes in the gut of patients 
with SpA, and an increased antigen handling and presentation, comparable to changes seen in 
CD. 
 
Therapeutical intervention is effective for treatment of both joint and gut inflammation 
Therapeutic intervention in SpA and CD can have a positive influence on both the articular and 
the intestinal inflammation. Sulfasalazine, which has been successfully used to treat colonic 
inflammation in UC and CD, was effective in the treatment of the peripheral arthritis 
accompanying SpA, especially if intestinal inflammation is present (Mielants et al. 1996).  
Therapy based on a chimeric monoclonal antibody to TNF, infliximab, was highly effective for 
the treatment of CD. A pilot study conducted in four patients with CD as well as SpA showed a 
remission of gut inflammation and a significant improvement of articular and axial symptoms 
(Van den Bosch et al. 2000). Based on these initial findings, the use of infliximab was explored 
in a number of studies in patients with different forms of active SpA, and high success rates were 
reported. Based on these findings, two double-blind, placebo controlled trials were conducted 
(Braun et al. 2002; Van Den Bosch et al. 2002). A fast and significant improvement of disease 
was shown in these patients. 
Although therapeutical improvement of both joint and gut inflammation is not a valid proof of a  
direct link between the two sites, it is however a nice example of how clinical observations led to 
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a significant improvement of treatment in these patients. 
 
MECHANISM OF JOINT-GUT AXIS 
 
The exact mechanism that links gut inflammation and joint inflammation is not completely 
understood. The main hypothesis states that exogenous factors, probably bacterial antigens, are 
permitted to enter the body through the gut. Bacterial antigens and LPS have been found in the 
synovial fluid of patients with ReA (Granfors et al. 1989; Granfors et al. 1990). In addition, 
evidence for the presence of bacterial DNA was shown by PCR in synovial fluid of patients with 
SpA (Pacheco-Tena et al. 2001). The delivery of bacterial antigens to the joint may trigger and 
perpetuate local inflammation, and is consistent with the parallelism of flare-ups of joint and 
intestinal inflammation. How these factors reach the joints is not known, given the fact that no 
live bacteria can be found. A role for T cells, HLA-B27 and macrophages has been postulated. 
Increased priming of T cells in the SpA gut fits with the concept that intestinal T cells are 
involved in the induction of arthritis in ReA (Gaston 1993). Arthritis might arise from a T cell 
mediated immune response to bacterial antigens and degradation products circulating from the 
gut to the joint. A proof of concept for the T cell re-circulation hypothesis was put forward by 
the identification of similar clonal T cell expansion in the colonic mucosa and synovium of a 
patient with enterogenic SpA (May et al. 2000). In addition, Yersinia specific antigenic 
proliferation of T cell clones, isolated from the synovial fluid of a Yersinia triggered ReA 
patients has been shown (Hermann et al. 1989). This could mean that the same antigenic 
compounds are present in the joints and the gut of these patients. On the other hand, it was 
shown that gut-derived leukocytes from patients with IBD bind well to venules in the synovial 
membrane (Salmi et al. 2001), suggesting that intestinally activated T cells have the capacity to 
enter the synovium. So far, it is not clear whether the presence of similar T cell clones in joint 
and gut is due to the presence of identical antigens or because the same set of homing molecules 
occur at both sites. One can speculate that if similar antigenic peptides are present in the gut and 
the joint, a sustained HLA-B27 mediated T cell response can trigger inflammation. 
Macrophages play a central role in the innate immune recognition of bacterial products. The 
finding that a similar subset of CD163
+
 macrophages was found in both the synovium and gut 
mucosa of SpA patients could reflect a similar pathophysiological condition leading to the influx 
or maturation of this particular macrophage subset at the two sites. It is surprising that 
stimulation of these cells with LPS does not induce IL10 secretion, while stimulation with the 
natural CD163 ligand, haptoglobin-hemoglobin complexes, does actually lead to an anti-
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inflammatory response of these cells (Ugocsai et al. 2006). It seems plausible that these cells 
may induce a similar dysregulation of the cytokine imbalance in the colon and synovium.  
 
CONCLUSION 
 
The ample clinical, immunological and genetic data support the existence of a joint-gut 
connection, explaining the important role of the gut in the pathogenesis of SpA. Maybe, these 
observations must not be separated from the involvement of other mucosal sites within the 
concept of SpA, e.g. uveitis and psoriasis. A similar mechanism might be involved in these 
clinical manifestations. Ultimately, knowledge of molecular events in these processes is 
important for classification, diagnosis and therapy of SpA patients. 
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ABSTRACT 
 
Background & aims: Association between spondyloarthropathy (SpA) and Crohn’s disease (CD) 
is a well-known phenomenon. A risk for evolution to CD was already demonstrated in the 
subgroup of SpA patients with associated chronic gut inflammation. We investigated whether the 
reported polymorphisms in the CARD15 gene, a susceptibility gene for CD, are associated with 
the presence of preclinical intestinal inflammation observed in SpA. 
Methods: We included 104 SpA patients who underwent an ileocolonoscopy with biopsies 
between 1983 and 2004. Using RFLP-PCR, we assessed the prevalence of three single 
nucleotide polymorphisms in the CARD15 gene (R702W, G908R and 1007fs) and compared 
them to an ethnically matched CD population and a control population. 
Results: The carrier frequency of R702W, G908R or 1007fs variants in the SpA populations 
(20%) was similar as in the control population (17%), but increased to 38% in the subgroup of 
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SpA patients with chronic gut inflammation. This was significantly higher than in the other SpA 
subgroups (P=0.001) and the control group (P=0.006) but not significantly different from the 
prevalence in CD (49%). This indicates that CARD15 polymorphisms are associated with a 
higher risk for development of chronic gut inflammation. 
Conclusions: CARD15 gene polymorphisms clearly identify a subgroup of patients with SpA 
associated with chronic intestinal inflammation. 
 
INTRODUCTION 
 
The spondyloarthropathies are a group of interrelated inflammatory diseases characterized by a 
pauciarticular, peripheral, asymmetrical arthritis and/or axial involvement with ankylosing 
spondylitis (AS) as prototype (Lawrence et al. 1998; Khan 2002). Reported prevalences of 
spondyloarthropathies vary between 0.2 and 1.9% (Braun et al. 1998). Although association with 
HLA-B27 is strong, recent genetic studies suggest a polygenic model of susceptibility (Brown et 
al. 1997; Said-Nahal et al. 2000; Reveille et al. 2001; Granfors et al. 2002). 
In up to 60% of spondyloarthropathy (SpA) patients, articular involvement is associated with 
subclinical histological evidence of chronic or acute gut inflammation in ileum or colon (De Vos 
1989; Simenon et al. 1990; Leirisalo-Repo et al. 1994). We described a long-term evolution to 
overt Crohn’s disease (CD) in 13% of patients with initial chronic gut inflammation (Mielants et 
al. 1995a; De Vos et al. 1996). The presence of chronic intestinal inflammation did not relate to 
HLA-B27, but a weak association was found with HLA-B62 (Mielants et al. 1995a). 
The observed immunologic similarities in SpA with gut inflammation and CD support the 
concept that this subgroup of SpA patients can be considered as a model for early immune 
alterations related to CD. An enrichment of gut mucosal T cell lines with αEβ7 integrin and an 
increased expression of its ligand, E-cadherin, was found in intestine of CD as well as SpA 
patients (Elewaut et al. 1998a; Demetter et al. 2000; Demetter et al. 2002). Re-circulation of T 
cells primed in the gut to synovial tissue is one potential mechanism by which gut and synovial 
inflammation could be linked. This hypothesis is supported by an altered expression of β7 
integrins, which are highly expressed within the gut, on synovial T cells from SpA patients 
compared to rheumatoid arthritis (Elewaut et al. 1998b).  Another potential mechanism includes 
trafficking of antigen presenting cells between gut and joint. Consistent with this was the 
augmented infiltration of gut mucosa and synovium with CD163
+
 macrophages (producing IL1 
and TNF) in both CD and SpA patients (Baeten et al. 2002; Demetter et al. 2005). Finally, a 
comparable beneficial clinical effect of infliximab, a monoclonal antibody to TNF suggests a 
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key role of this cytokine in both diseases (Van den Bosch et al. 2000; Van Den Bosch F 2002). 
In 2001, a correlation was reported between polymorphisms in the CARD15 gene and an 
increased susceptibility for CD (Hampe et al. 2001; Hugot et al. 2001; Ogura et al. 2001a). 
Three independent single nucleotide polymorphisms (SNPs) in CARD15 are associated with CD 
in about 30 to 46% of patients (1 frameshift mutation, 1007fs (SNP13), and 2 missense 
mutations, R702W (SNP8) and G908R (SNP12)) (Hugot et al. 2001; Esters et al. 2004). These 
variants increase the risk for CD by a factor of 3 for heterozygous and by a factor of 38 or 44 for 
respectively homozygous or compound heterozygous individuals (Hugot et al. 2001). Lower 
prevalences have been described in CD patients in Scotland, Ireland and Northern Europe, 
whereas no association could be found in Japan (Inoue et al. 2002; Yamazaki et al. 2002; Helio 
et al. 2003; Arnott et al. 2004). 
CARD15 encodes for an intracellular protein, which is expressed in monocytes, granulocytes, 
dendritic, epithelial and paneth cells, and has binding affinity for bacterial cell wall components 
like muramyldipeptides (Girardin et al. 2003). The CARD15 protein is involved in ΝFκΒ 
activation and in apoptosis by two N-terminal Caspase Recruitment Domains (hence the term 
CARD), although its precise pathogenic role in CD remains to be determined (Ogura et al. 
2001b; Bonen et al. 2003; Girardin et al. 2003).  
CARD15 gene polymorphisms have also been linked with another related syndrome, Blau’s 
syndrome, characterized by granulomatous inflammation of uvea, skin and joints (Miceli-
Richard et al. 2001).  
Several studies have been performed to investigate the role of CARD15 polymorphisms in SpA. 
These studies did not demonstrate an association with SpA or AS in particular (D'Amato 2002; 
Miceli-Richard et al. 2002; Breban et al. 2003; Ferreiros-Vidal et al. 2003; van der Paardt et al. 
2003). Yet an increased prevalence of CARD15 polymorphisms was found in psoriatic arthritis 
but not in psoriatic skin disease (Borgiani et al. 2002; Rahman et al. 2003; Young et al. 2003). A 
recent Italian study however could not confirm this association (Giardina et al. 2004). 
Nevertheless, this finding could emphasize the importance of investigating the possible role of 
these genetic variants in specific, clinical subpopulations of patients. In CD as well, CARD15 
polymorphisms seem to be related with certain clinical phenotypes (Abreu et al. 2002; Ahmad et 
al. 2002; Cuthbert et al. 2002; Lesage et al. 2002; Peeters et al. 2004).  
In view of the apparent correlation between gut inflammation in SpA and clinical evolution to 
CD, we investigated whether the presence of polymorphisms in this susceptibility gene for CD 
would be associated with gut inflammation in SpA patients. 
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MATERIALS AND METHODS 
 
Study population 
This study included 104 Caucasian SpA patients (according to the ESSG criteria (Dougados et 
al. 1991), who underwent an ileocolonoscopy with concomitant ileal and colonic biopsies 
between 1983 and 2004. This population consisted of 74 male and 30 female patients with a 
mean age of 46 years (range: 21-77 yrs). SpA patients were systematically referred by the 
rheumatologist for an ileocolonoscopy with biopsies, independent of the presence of GI 
symptoms.  
Patients with the diagnosis of clinical Crohn’s disease or psoriasis prior to the diagnosis of SpA, 
were excluded from the study. 
A subgroup of 54 patients, all having a long-term follow-up since their diagnosis of SpA 
(ranging from 17 to 49 years), was recently clinically reassessed. New follow-up colonoscopies 
were not performed. 
The total SpA population consisted of 75 patients with ankylosing spondylitis (AS) according to 
the modified New York criteria (van der Linden et al. 1984) and 29 patients with an 
undifferentiated form of SpA (uSpA). Eighteen AS patients only had axial involvement, whereas 
57 AS patients also had peripheral disease (defined as the history or presence of peripheral 
arthritis and/or enthesitis). Twenty-five uSpA patients had peripheral disease and 4 uSpA 
patients only had axial involvement. These 4 patients had inflammatory low back pain and 
fulfilled the ESSG criteria, however not the modified New York criteria for AS. 
HLA-B27 status was known in a total of 81 patients. In 53 patients both HLA-B27 and HLA-B62 
status were known.  
A population of 156 consecutive patients with proven CD on clinical, endoscopical and 
histological grounds was included as well. This cohort included 57 male and 99 female patients 
with a mean age of 38 years (range: 18-80 yrs). 
Prevalences were also compared to those observed in a control population including 140 
individuals. 
The study was approved by the local ethics committee. All patients signed an informed consent. 
 
Histological classification 
A classification of histologic lesions was used as reported in previous studies (De Vos 1989; 
Mielants et al. 1995a; Mielants et al. 1995b; Mielants et al. 1995c; De Vos et al. 1996). Three 
subgroups were distinguished: patients with normal gut histology, acute and chronic 
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inflammation (Cuvelier et al. 1987). In acute inflammatory lesions normal architecture was well 
preserved. A mucosal and epithelial infiltration by neutrophils and eosinophils was found, 
without a significant increase in lymphocytes. Small superficial ulcers covered with fibrin and 
neutrophils overlying hyperplastic lymphoid follicles were occasionally observed. The lamina 
propria was oedematous and hemorrhagic and contained mainly polymorphonuclear cells. The 
pattern of inflammation was similar to that seen in acute self-limiting bacterial enterocolitis. 
The principal features of chronic inflammatory lesions were mucosal architectural alterations 
with crypt distortion and atrophy in the colon and villous blunting and fusion in ileal mucosa. 
Both in ileum and colon there was an increased mixed cellularity and formation of basal 
lymphoid aggregates in the lamina propria. 
Whenever one of several biopsies featured chronic lesions, regardless of acute or active 
inflammation in other fragments, a diagnosis of chronic inflammation was made. 
Although NSAID may induce intestinal disorders, we and others excluded these drugs as 
aetiology of reported chronic inflammation (De Vos 1989; Simenon et al. 1990; Altomonte et al. 
1994).  
 
CARD15 genotyping (R702W, G908R and 1007fs), HLA-B27 and HLA-B62 typing  
Genomic DNA was extracted from whole blood using Qiagen blood and cell culture DNA kit 
(Westburg BV, Leusden, The Netherlands) and genotyped all patients for R702W, G908R and 
1007fs using RFLP-PCR, followed by separation of the DNA fragments on a 2.5% agarose gel. 
The missense mutation R702W (GenBank accession number G67950) abolishes the restriction 
site for MspI, resulting in an intact 130-bp band for mutant alleles compared to two bands of 54- 
and 76-bp for wild type alleles (forward primer: 5’-CAG CCC TGA TGA CAT TTC TCT T-3’, 
reverse primer: 5’-AGC CGC TCC TCC TGC ATC TCG TA-3’). The missense mutation 
G908R (GenBank accession number G67951) creates a restriction site for HinP1l. The 
frameshift mutation 1007fs (GenBank accession number G67955) creates a restriction site for 
NlaIV. The presence of a mutant allele results in two bands of 219 and 41 bp, while the wild 
type allele produces a single 260-bp product (forward primer: 5’-CTG AGC CTT TGT TGA 
TGA GC-3’, reverse primer: 5’-TCT TCC AAC CAC ATC CCC ATT-3’).  
In the patients with a known HLA-B27 and HLA-B62 status, typing of these markers had been 
performed using the micro-lymphocytotoxity test according to Terasaki and McClelland 
(Cuthbert et al. 2002). 
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Statistical analysis 
Statistical significance was determined by the χ
2 
test and Odds Ratio using SPSS (SPSS inc., 
Chicago, Illinois). Multivariate analysis (logistic regression) was performed to investigate 
whether an association, found through univariate analysis, was independent from other genetic 
markers. P values less than 0.05 were considered significant. 
 
RESULTS 
 
We subdivided our cohort in three groups according to the gut histology. Forty patients (38%) 
had a normal histology, 24 patients (23%) had acute gut inflammation and 40 (38%) showed 
chronic gut inflammation (Table 1).  
 
Table 1 Prevalence of CARD15 variants in the populations, according to subtypes defined at baseline 
 
*Chi-square: P<0.001 (carrier frequency in CD vs control population) 
§Chi-square: P=0.5 (carrier frequency in general SpA vs control population) 
‡Chi-square: P=0.001(chronic inflammation in patients with CARD15 variant vs. chronic inflammation in those without CARD15 
polymorphisms 
 
Univariate analysis 
Prevalence of CARD15 polymorphisms in the SpA, CD and control populations. The prevalences 
of CARD15 polymorphisms in the total SpA (20%), specific AS (21%) and uSpA (17%) 
population did not differ significantly (Table 1). All except one (homozygous for the 1007fs 
allelic variant) were heterozygous for at least one mutation. The prevalence of R702W, G908R 
and 1007fs allelic variants in this SpA population was 12%, 4% and 5% respectively (Table 2).  
No compound heterozygousity was found. All carriers of CARD15 polymorphisms in the SpA 
group  had  (a history of)  peripheral  disease  (Table 3).    There  were  no significant differences 
 
 N Carriers of CARD15 variant(s) 
Classification   
control  140 24 (17%) 
crohn  156 77 (49%)* 
spondyloarthropathy (SpA)  104 21 (20%)§ 
ankylosing Spondylitis (AS) 75 16 (21%) 
undifferentiated SpA (uSpA) 29 5 (17%) 
   
Gut histology in SpA population   
chronic inflammation 40 (38%) 15 (38%)‡ 
acute inflammation 24 (23%) 0 (0%) 
normal histology 40 (38%) 6 (15%) 
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Table 2 Carrier frequency of CARD15 variants in patients with SpA, CD and controls (%) 
 
Number of patients carrying R702W, G908R or 1007fs variants  
CARD15-/+: heterozygous; CARD15-/-: homozygous 
Overall = total number of patients in the group carrying at least 1 variant 
* The sum of all allelic CARD15 variants is greater than the overall number of patients at least carrying one variant, since some patients carry 2 
different SNP's, thus displaying a compound heterozygous status 
 
concerning the disease duration and the duration of the follow-up period between the SpA 
patients carrying CARD15 polymorphisms and the group of patients without these 
polymorphisms (data not shown). 
In the CD population, a carrier frequency of 49% (77 of 156 patients) was observed (Table 1). 
Forty-three CD patients carried at least one R702W polymorphism, 14 patients carried at least 
one G908R polymorphism and 27 patients carried at least one 1007fs polymorphism. Fourteen 
patients carried two polymorphisms of which 7 patients were homozygous and 7 patients 
compound heterozygous (Table 2).  
In the control group, 24 individuals (17%) carried CARD15 polymorphisms (Table 1). All except 
one (compound heterozygous for the R702W and 1007fs variant) were single heterozygous 
(Table 2). 
The prevalence of polymorphisms in the SpA cohort (20%) was not different from that observed 
in the control group (17%) (OR: 1.22, CI: 0.64–2.34, P=0.5) and significantly lower compared to 
the prevalence found in our CD population (49%) (OR: 3.85, CI: 2.17-6.83, P<0.001).  
 
Association between CARD15 polymorphisms and intestinal inflammation in SpA patients. The 
carrier frequency in the subpopulation of SpA patients with chronic gut inflammation was 38% 
(15 of 40 patients) which was significantly higher compared to the control population (OR: 2.9, 
CI: 1.33-6.30, P=0.006) and the other SpA populations (OR: 5.80, CI: 2.02-16.68, P=0.001) and 
not statistically different from that observed in our CD population (49%, OR: 1.62, CI: 0.80-
3.31, P=0.2) (Table 1). 
Of all SpA patients carrying CARD15 polymorphisms, 71% (15 out of 21 patients) had chronic 
gut inflammation, 0% acute inflammation and 29% presented with normal histology (Table 1). 
The only SpA patient carrying two CARD15 variants also had chronic gut inflammation. In 
 SpA (N=104) CD (N=156) Controls (N=140) 
 R702W G908R 1007fs overall* R702W G908R 1007fs overall* R702W G908R 1007fs overall* 
CARD15-/+ 
 
12 (12) 4 (4) 4 (4) 39 (25) 11 (7) 27 (17) 18 (13) 1 (1) 6 (4) 
CARD15-/- 
 
0 (0) 0 (0) 1 (1) 
 
21 (20) 
 
4 (3) 3 (2) 0 (0) 
 
77 (49) 
 
0 (0) 0 (0) 0 (0) 
24 (17) 
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contrast, only 25 out of 83 patients with a wild type genotype (30%) had chronic gut 
inflammation, 29% acute inflammation and 41% normal histology. Consequently, the presence 
of CARD15 polymorphisms was associated with a higher risk for development of chronic gut 
inflammation. 
There are no statistically significant differences between the AS and the uSpA group concerning 
the prevalence of CARD15 polymorphisms in patients with normal (3/29 in AS vs 3/11 in uSpA, 
OR: 3.3, CI: 0.5-19.4, P=0.3), acute (0/13 in AS vs 0/11 in uSpA) or chronic (13/33 in AS vs 2/7 
in uSpA, OR: 1.6, CI: 0.3-9.7, P=0.7) gut inflammation.  
In the subgroup of 54 patients who were clinically reassessed, 4 patients evolved from 
histological chronic gut inflammation towards clinically overt Crohn’s disease. Two of these 4 
patients carried CARD15 polymorphisms. The other 22 patients with chronic gut inflammation in 
this group did not develop clinical CD. 
 
Association between CARD15 polymorphisms and HLA-B27 in SpA patients. There was no 
significant association between the presence of these 2 genetic markers. Six of 34 HLA-B27 
negative patients carried CARD15 polymorphisms versus 13 of 47 HLA-B27 positive patients 
(OR: 1.8, CI: 0.6-5.3, P=0.3). 
 
Multivariate analysis 
In the subgroup of 53 SpA patients of whom both HLA-B27 and HLA-B62 status were known, 
logistic regression was performed (with the presence of chronic gut inflammation as dependent 
variable). This showed that the association between chronic gut inflammation and CARD15 
polymorphisms (OR: 17.3, CI: 2.0-152.3, P=0.01) is independent of HLA-B27 (OR: 1.7, CI: 0.5-
6.0, P=0.42) and HLA-B62 (OR: 2.5, CI: 0.5-13.0, P=0.28).  
 
CONCLUSION 
 
This study describes a novel and remarkably strong association between variants in a host 
defence gene located on chromosome 16, CARD15, and a chronic form of gut inflammation in 
patients with SpA. Interestingly, the prevalence of CARD15 polymorphisms in this subgroup of 
SpA patients was not significantly different from that observed in patients suffering from CD. 
Three single nucleotide polymorphisms have been associated with CD (Hampe et al. 2001; 
Hugot et al. 2001; Ogura et al. 2001a). One variant (1007fs) encodes a truncated protein which 
results in altered activation of NFκB in response to bacterial stimuli (Ogura et al. 2001b; Bonen 
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et al. 2003; Girardin et al. 2003). The two other single nucleotide polymorphisms (R702W and 
G908R) result in an amino acid substitution. 
 
Table 3 Prevalences of CARD15 polymorphisms according to the presence of mainly axial or peripheral 
involvement in the total SpA group, AS group and uSpA group 
 
 
 
 
 
 
 
 
 
 
More recently, several groups assessed the linkage of CARD15 variants in CD to particular 
clinical phenotypes but the results of these retrospective studies are disparate. The presence of 
two mutations has been linked to younger age at onset and preferential involvement of small 
bowel (Lesage et al. 2002). Preference for ileal involvement was also reported by Cuthbert 
(Cuthbert et al. 2002) and by Ahmad (Ahmad et al. 2002). Prevalence for fibrostenosing disease 
was dominant in a study of Abreu (Abreu et al. 2002). In these studies, no association of 
CARD15 variants with extra-intestinal involvement could be retained. 
The present study demonstrates a new association between these three CD-associated variants in 
the leucine-rich regulatory domain of the CARD15 gene and a distinct subpopulation of patients 
with spondyloarthropathies. Similarly to previous reports, the overall prevalence of mutations in 
SpA patients was not statistically different from the prevalence in our control population 
(D'Amato 2002; Miceli-Richard et al. 2002; Breban et al. 2003; Ferreiros-Vidal et al. 2003; van 
der Paardt et al. 2003). However, unlike the previous studies, we identified a distinct clinical 
subgroup, characterised by the presence of chronic inflammatory gut lesions, with a remarkably 
high prevalence (38%) of CARD15 polymorphisms, being not significantly different from the 
prevalence in the CD population (48%) and significantly higher compared to the control 
population (17%) and the other SpA patients. Previous studies from our group showed that in 
particular these patients with chronic gut inflammation were at risk for the progression to CD 
(Mielants et al. 1995a; De Vos et al. 1996).  
Striking in the present study, none of the SpA patients with only axial disease carried CARD15 
polymorphisms. Carriers of these polymorphisms all had (a history of) peripheral disease. This is 
in concordance with previous studies, where more chronic gut inflammation could be found in 
AS patients with peripheral disease compared to strict axial AS patients (Mielants et al. 1995a). 
total SpA group  (N=104) 
 
CARD15 P=0.006 
 wild type variant total 
axial 22 0 22 
peripheral 61 21 82 
total 83 21 104 
AS group (N=75) 
 
 
CARD15 P=0.006 
 wild type variant total 
axial 18 0 18 
peripheral 41 16 57 
total 59 16 75 
uSpA group  (N=29) 
 CARD15 P=1.0 
 wild type variant total 
axial 4 0 4 
peripheral 20 5 25 
total 24 5 29 
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One previous study investigated CARD15 polymorphisms in AS patients with CD and ulcerative 
colitis (UC) (Crane et al. 2002).  It did not show a higher prevalence of CARD15 variants in AS 
patients with CD compared to idiopathic AS, AS with UC or healthy controls. However, the low 
prevalence of CARD15 variants in the CD population with AS was not compared to the 
prevalence in a general CD population and it unexpectedly revealed a possible association 
between the G908R CARD15 variant and AS patients with ulcerative colitis. 
Moreover, in a recent study we found an association between CARD15 polymorphisms and the 
presence of radiological sacroiliitis in CD patients, unrelated to the HLA-B27 status of these 
subjects. These data already pointed at a role for the CARD15 gene in the link between gut and 
joint inflammation (Peeters et al. 2004). 
Our findings confirm the previous reported clinical, therapeutical and immunological links 
between SpA and CD and provide also genetic proof for the association between both diseases. 
Since the chronic gut inflammation in the majority of SpA patients remains asymptomatic, this 
might suggest that CARD15 polymorphisms could be linked with the development of 
(subclinical) chronic gut inflammation rather than with CD as such.  
The underlying pathogenetic mechanisms that could explain the phenotypic expression of 
CARD15 mutations in SpA need to be investigated. CARD15 encodes a cytosolic protein that 
could play a role in SpA by interference with transport of antigens by macrophages from 
mucosal surfaces to the joints (Salmi et al. 2001). CARD15 seems to function as an intracellular 
receptor for bacterial components, where the C-terminal leucine-rich regulatory domain is 
crucial for responsiveness. Cellular response to bacterial products was altered in HEK293T cells 
transfected with expression plasmids containing any of the three SNPs (Ogura et al. 2001b; 
Bonen et al. 2003; Girardin et al. 2003). Moreover, expression of CARD15 in myeloblastic and 
epithelial cells is enhanced by pro-inflammatory cytokines and bacterial components via NFκB 
(Ogura et al. 2001b; Gutierrez et al. 2002; Bonen et al. 2003). This response is likely to mediate 
cytokine production including TNF suggesting that up-regulation of CARD15 may be part of a 
positive regulatory loop and facilitate the response of the host to pathogens. A genetically 
determined disturbed handling of bacterial products in the intestinal tract, leading to an altered 
transport of antigens by T cells to synovial tissue, is an interesting hypothesis that should be 
investigated in spondyloarthropathy. A further identification and characterisation of 
inflammatory cells involved in gut and joint inflammation may also lead to new therapeutic 
targets. 
In conclusion, a distinct phenotype associated with the three main CD associated CARD15 
variants is reported in patients with SpA. Our data show that the presence of CARD15 variants in 
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SpA patients strongly predisposes to chronic intestinal inflammation, defining a population at 
risk for evolution to CD. However, the persistence of the subclinical character of the 
inflammation in a large part of patients may reflect that CD is a multigenic disease or 
alternatively that the heterozygous carriage of CARD15 polymorphisms predisposes only to a 
subclinical inflammation. 
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ABSTRACT 
 
Background & aims: Intestinal inflammation is a common feature of spondyloarthropathy (SpA) 
and Crohn's disease (CD). Inflammation is manifested clinically in CD, and subclinical in SpA. 
However, a fraction of SpA patients develop overt CD. The aim of this study was to investigate 
whether subclinical gut lesions in SpA patients are associated with transcriptome changes 
comparable to those seen in CD. We examined global gene expression in non-inflamed colon 
biopsies, and screened for differentially expressed genes. 
Methods: Macroarray analysis was used as an initial genome-wide screen for selecting a 
comprehensive set of genes relevant to CD and SpA. This led to the identification of 2,625 
expressed sequence tags (ESTs) that are differentially expressed in the colon of CD and/or SpA 
patients. These clones, together with appropriate controls (6,779 in total) were used to construct 
a glass-based microarray, which was then used to analyze colon biopsies from 15 SpA patients, 
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11 CD patients, and 10 controls. 
Results: Ninety-five genes were identified as differentially expressed in SpA patients with a 
history of subclinical chronic gut inflammation as well as in CD patients. Principal component 
analysis of this filtered set of genes successfully distinguished colon biopsies from the three 
groups studied. Spondyloarthropathy patients with subclinical chronic gut inflammation cluster 
together, and are more related to CD. 
Conclusions: The transcriptome in the intestine of SpA patients differs from that of controls. 
Moreover, these gene alterations are comparable to those seen in CD, confirming initial clinical 
observations. Based on these findings, new (genetic) markers for detection of early CD in SpA 
patients can be considered. 
 
INTRODUCTION 
 
The clinical association between Spondyloarthropathy (SpA) and Crohn’s disease (CD) is 
illustrated by the concurrence of similar arthropathy and intestinal inflammation in the two 
diseases, indicating a shared etiology and pathogenesis. Depending on the imaging technique 
used, up to one third of CD patients have peripheral and/or sacroiliac joint abnormalities similar 
to those seen in various SpA subgroups (Davis et al. 1978; Scott et al. 1990). In addition, 60% of 
SpA patients who have no evidence of CD exhibit endoscopic and/or histological signs of 
subclinical gut inflammation (Mielants et al. 1995a). In general, two types of inflammation are 
observed: acute inflammation as seen in infectious colitis, and chronic inflammation resembling 
that in CD (Mielants et al. 1995a). A striking parallel exists between the activity of inflammation 
at the joints and the intestine. Moreover, long-term evolution to CD was observed in 13% of 
SpA patients with initial chronic gut inflammation, supporting the concept of preclinical CD in 
those patients (De Vos et al. 1996). Since these clinical observations, several studies provided 
additional evidence for a joint-gut axis on the molecular as well as the genetic level. The early 
immune alterations observed are up-regulation of αEβ7 integrin on T-cell lines from SpA 
patients (Elewaut et al. 1998b), and an increase in lymphoid follicles and lamina propria 
mononuclear cells in intestinal biopsies (Demetter et al. 2000; Demetter et al. 2002). Increased 
expression of αΕβ7 and the E-cadherin/catenin complex was found in gut mucosa from CD and 
SpA patients (Elewaut et al. 1998a; Demetter et al. 2000). A specific subset of CD163
+
 
macrophages is augmented in both groups of patients, supporting the hypothesis of a 
recirculation of similar clones in the intestinal mucosa and synovium (Baeten et al. 2002). 
Both CD and SpA are termed complex genetic traits, because many genes are probably involved 
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in pathogenesis, and environmental factors have a substantial influence on the outcome of the 
disease. Evidence exists for a common genetic risk factor in the development of subclinical 
intestinal inflammation in first-degree relatives of patients with ankylosing spondylitis, which is 
the prototype of SpA (Bjarnason et al. 2003). Furthermore, we found that CARD15, which was 
the first CD susceptibility gene identified, is associated with chronic subclinical inflammation in 
patients with SpA (Laukens et al. 2004). In this regard, SpA patients can serve as a unique 
model for early CD. 
In order to determine whether the association between the two disorders occurs not only at the 
clinical but also at the transcriptome level, we compared global gene expression in non-inflamed 
colon biopsies from SpA and CD patients. We propose that it is possible to identify a set of 
genes that distinguish CD patients and SpA patients with a history of chronic gut inflammation 
from SpA patients without chronic gut inflammation and from controls. 
 
METHODS  
 
Patients, tissue collection and histological classification 
Colon biopsies from CD and SpA patients and healthy controls were obtained during 
colonoscopy. All biopsies were taken from non-inflamed sigmoid at 30 cm. Biopsy specimens 
were immediately placed in RNAlater (Ambion, Cambridgeshire, UK) and frozen at -80°C until 
sample processing. Three biopsies were obtained from each of 34 patients diagnosed with CD 
according to clinical, endoscopic and histological criteria, and 20 patients diagnosed with SpA 
according to ESSG criteria (Dougados et al. 1991). Sixteen patients without clinical 
manifestations of CD or SpA, who were undergoing colonoscopy for colon cancer screening, 
were included as a control population.  
Histological classification of the SpA ileum and colon was performed as in our previous studies 
(De Vos 1989; Mielants et al. 1995a; Mielants et al. 1995b; Mielants et al. 1995c; De Vos et al. 
1996). We distinguished three classes: patients with normal histology, patients with acute 
inflammatory lesions, and those with chronic inflammatory lesions (Cuvelier et al. 1987). In 
acute lesions, normal architecture was well preserved. There was infiltration by neutrophils and 
eosinophils without a considerable increase in lymphocytes. Small superficial ulcers covered 
with fibrin and neutrophils overlying hyperplastic lymphoid follicles were occasionally 
observed. The lamina propria was edematous and hemorrhagic, and contained mainly 
polymorphonuclear cells. The pattern of inflammation was similar to that seen in acute self-
limiting bacterial enterocolitis. The principal features of chronic lesions were crypt distortion, 
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atrophy of the villous surface of the mucosa, villous blunting and fusion, increased mixed 
cellularity, and basal lymphoid aggregates in the lamina propria. Though several biopsies were 
obtained from each patient, a diagnosis of chronic inflammation was made even if only one 
biopsy showed chronic lesions, regardless of acute or active inflammation in the other biopsies.  
SpA patients who had chronic inflammation in colon and/or ileum in previous examinations 
were termed SpA patients with chronic gut inflammation. 
 
RNA extraction 
Total RNA was extracted from biopsies using the Qiagen Rneasy Mini Kit (Westburg BV, 
Leusden, The Netherlands) with on-column DNAse treatment (Qiagen). Needle homogenization 
was performed. RNA quality and concentration were checked on the Agilent 2100 Bioanalyzer 
(Agilent Technologies, Germany).  
 
Macroarray hybridization and analysis 
Colony filters containing 74,828 expressed sequence tag (EST) clones (Human UniGene 
collection 2, RZPD, Germany) were used as initial screen. Radioactively labeled probes were 
produced by incorporation of [α33P]dCTP during reverse transcription of 50 µg total RNA 
(MMLV, Promega, Leiden, The Netherlands), using oligodT as primer. 
33
P-cDNA probes were 
purified on G-50 spin columns (Amersham Biosciences, Roosendaal, The Netherlands). 
Hybridization was performed at 10
6
 cpm/ml at 65°C for 20 hours. Images were acquired after 6, 
18 and 24 hours of exposure, using a Phosphorimager system (Amersham Biosciences). Spot 
definition and intensity measurement was done using Visualgrid (GPC Biotech AG, Munich, 
Germany). The raw expression data were processed with an in-house algorithm based on MS 
Access. Spot intensities were corrected for the local background, followed by a quality control of 
spots to exclude those influenced by intense signals of adjacent spots. The detection limit for 
expression values above background was calculated based on the variation of the local 
background intensity. Constitutive genes (those that show the lowest coefficient of variation over 
all arrays) were used for normalization. Subsequently, quantitative measures of each clone 
(gene) were calculated by log2 transformation of the ratio of the mean spot intensity of CD or 
SpA patients to the mean spot intensity of controls.  
 
Microarray hybridization, scanning and analysis 
Construction of a focus microarray chip, probe labeling, hybridization, washing and scanning 
were carried out at the MicroArray Facility of the Flanders Interuniversity Institute for 
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Biotechnology (MAF, Leuven, Belgium). Clones selected from the macroarray screen were 
PCR-amplified from RZPD clones using universal M13 primers. PCR fragments were purified 
on MultiScreen PCR plates (Millipore, Brussels, Belgium) and resuspended in 50% DMSO at an 
average concentration of 100 ng/µl. The PCR products were arrayed in duplicate on Type VII 
silane-coated slides using a Molecular Dynamics Generation III printer (Amersham Biosciences, 
Buckinghamshire, UK). Total RNA (5 µg) was amplified using a modified protocol of in vitro 
transcription as described (Puskas et al. 2002). Five µg of the amplified RNA were Cy3- or Cy5-
labeled as described at http:\\www.microarrays.be\service.htm. Arrays were scanned at 532 and 
635 nm using a Generation III scanner (Amersham BioSciences). Images were analyzed with 
ArrayVision (Imaging Research Inc., Ontario, Canada). Each hybridization was repeated in a 
dye swap experiment. Spot intensities were measured, corrected for local background, and those 
that exceeded the background by more than two standard deviations (SD) were included. For 
each gene, ratios of red (Cy-5) to green (Cy-3) intensities (I) were calculated and normalized via 
a Lowess Fit of the log2 ratios [log2(ICy-5 / ICy-3)] over the log2 total intensity [log2(ICy-5 × 
ICy-3)].  
For comparing the microarray datasets, a mixture of RNA from 5 CD patients, 5 SpA patients 
and 5 controls was used as reference RNA. This reference sample provides a positive 
hybridization signal at each probe element on the microarray, which is essential when 
calculating and comparing fluorescence ratios. The data were imported into GeneMaths

 XT 
(Applied Maths, St-Martens-Latem, Belgium). Weighted mean ratios and their corresponding 
error (pixel SD) were calculated from the dye swap. Data were normalized over all arrays, and 
missing values were imputed using k-nearest neighbor algorithm (20 neighbors). GeneMaths

 
XT was used to perform all subsequent supervised and unsupervised analyses.   
 
Statistics 
All P-values chosen for cut-off are subjective.  
 
RESULTS 
 
Design of the custom microarray 
In order to provide a practical and cost effective tool for conducting a large number of 
hybridizations, a self-designed focus microarray chip was constructed specifically for studying 
colonic gene expression in SpA and CD. To accomplish this, a genome-wide survey of gene 
expression in colon biopsies of 4 CD patients, 4 SpA patients and 6 controls was conducted 
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using high-density nylon arrays containing 74,828 cDNA sequences (Table 1, macroarrays).  
Spots that showed aberrant morphology, encompassed variation in replicates or were impaired 
because of over shining (characteristic of radioactive signals) were filtered out and considered as 
clones lost through experimental error. To select for clones that are differentially expressed in 
CD or SPA patients, we arbitrarily selected for those that have a log2 transformed mean ratio of 
less than -0.6 or more than +0.6 (1.5 fold down- or up-regulated). Genes that might be 
differentially expressed between groups (control versus CD or control versus SpA) were 
identified using a simple algorithm based on the t-test (P<0.05) and F-values (P<0.05) as 
selection criteria, providing that at least three consistent intensity values were present in each 
group. F-values were chosen for selection because we assumed that differences in variances 
within groups can be important. A total of 2,652 clones were identified as “potentially 
differentially expressed”. These genes, together with 4,127 ESTs lost through experimental error 
and which might include, beside control ESTs, additional differentially expressed genes, were 
used to produce a glass-based microarray platform. This allowed us to screen more patients in a 
more accurate and sensitive manner. 
 
Clustering of unfiltered data 
We hybridized an independent cohort of 15 SpA, 11 CD and 10 control patients to the focus 
microarray (Table 1, microarrays). Unsupervised clustering (without prior knowledge of groups) 
using all genes revealed no clustering with respect to disease or phenotype (e.g. type of intestinal 
inflammation). The inability to find discriminatory genes using unfiltered data is perhaps not too 
surprising, as we are analyzing the steady state transcriptome in non-inflamed tissue samples of 
complex inflammatory diseases. Subtle differences in only a few genes are lost in the vast 
number of random variations. The problem of detecting differentially expressed genes can be 
overcome by performing supervised clustering. To this end we divided the patients into four 
main groups: CD, SpA with chronic gut inflammation, SpA without chronic gut inflammation, 
and controls. Discriminant analysis can reduce N-dimensional data into a more visual 2-D or 3-D 
plot, with prior knowledge of groups (Figure 1). With this approach, the above-defined groups 
became clearly separated, indicating that our full dataset contains genes that can differentiate 
between these disease states.  
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Table 1 Study population 
 Diagnosis Sample Sex Age SpA Gut 
Histology 
Clinical 
CD 
CD 
Location 
Medication 
macroarrays Control 1 F 59 no normal no  - 
  2 F 45 no normal no  - 
  3 F 55 no normal no  - 
  4 M 30 no normal no  - 
  5 F 58 no normal no  - 
  6 M 40 no normal no  - 
 CD 7 M 21 no chronic yes IC - 
  8 F 48 no chronic yes IC 5-ASA 
  9 F 41 yes chronic yes C - 
  10 F 23 no chronic yes C AZA 
 SpA 11 M 47 yes normal no  - 
  12 F 85 yes normal no  - 
  13 F 60 yes normal no  - 
  14 F 43 yes chronic yes  - 
          
microarrays Control 1 M 54 no normal no  - 
  2 F 64 no normal no  - 
  3 F 72 no normal no  - 
  4 M 51 no normal no  - 
  5 F 21 no normal no  - 
  6 F 68 no normal no  - 
  7 F 32 no normal no  - 
  8 F 73 no normal no  - 
  9 F 66 no normal no  - 
  10 M 76 no normal no  - 
 CD 11 F 23 no chronic yes IC 5-ASA 
  12 F 39 yes chronic yes C - 
  13 M 51 no chronic yes C - 
  14 M 43 no chronic yes I - 
  15 M 36 no chronic yes IC - 
  16 F 27 no chronic yes IC - 
  17 F 46 yes chronic yes IC AZA 
  18 F 23 no chronic yes IC - 
  19 M 19 no chronic yes IC - 
  20 F 26 no chronic yes IC - 
  21 F 36 no chronic yes IC - 
 SpA 22 M 40 AS periph acute no  - 
  23 M 29 AS periph normal no  NSAID 
  24 M 42 AS periph acute no  - 
  25 M 31 AS periph acute no  NSAID 
  26 M 76 uSPA normal no  steroids 
  27 F 28 AS ax normal no  NSAID 
  28 M 58 AS periph normal no  - 
  29 M 38 AS ax normal no  sulfa 
  30 F 49 AS periph chronic no  sulfa 
  31 M 49 AS periph chronic no  - 
  32 M 45 AS periph chronic no  sulfa 
  33 M 29 uSPA acute no  sulfa+NSAID 
  34 M 48 AS periph normal no  NSAID 
  35 F 44 AS periph chronic yes IC sulfa+AZA 
  36 M 36 AS ax normal no  sulfa+NSAID 
 
UspA = undifferentiated SpA; AS ax = ankylosing spondylitis with only axial involvement; AS periph = ankylosing 
spondylitis with peripheral involvement; histology of SpA patients is a historical classification; IC = ileocolonic; I = 
ileal involvement only; C = colonic involvement only; 5-ASA = 5-aminosalicylates; AZA = azathioprine; NSAID = 
non-steroidal anti-inflammatory drugs; sulfa = sulfasalazine 
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Figure 1 Discriminant analysis of all patients using unfiltered data, illustrated in two 
directions. Four groups are clearly separated. CD (green), SpA without chronic inflammation 
(blue), SpA with chronic inflammation (yellow) and controls (red). 
 
 
Identification of genes whose differential regulation is common to both SpA with chronic 
gut inflammation and CD 
By using an independent t-test, we identified 123 genes that are expressed differentially between 
CD and control (P<0.01). With this set we were unable to discriminate SpA patients from 
controls, although three out of four of the SpA patients with chronic gut inflammation clustered 
together, indicating the presence of alterations similar to those observed in CD. Thus it was 
logical to screen for genes modulated commonly in CD and control on one hand, and SpA, SpA 
with chronic gut inflammation and control on the other hand. In order to include a larger number 
of genes in this analysis, the statistical significance level was lowered from P<0.01 to P<0.05. 
This led to the identification of two sets of genes whose expression pattern discriminates CD 
from control (P<0.05, N=630) and SpA from control (P<0.05, N=464). The latter significance 
level was determined by ANOVA, in which SpA patients with chronic gut inflammation were 
defined as a distinct group. The set of 95 genes that are differentially expressed in both CD and 
SpA could distinguish the three disease groups (Figure 2A, Table 2). In addition, SpA patients 
with chronic gut inflammation cluster together and are more related to the CD cluster than to the 
control/SpA cluster, but they remain a separate entity (Figure 2A). Principal component analysis 
using this set of 95 genes, another way of representing the data, clearly discriminates our patient 
groups (Figure 2B). Based on the identification of a set of genes involved in CD and also 
implicated in SpA, we attempted to identify genes that might render these individuals more 
susceptible to develop CD.  
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Genes within the CD/ SpA chronic cluster 
Genes whose expression is aberrant in both CD and SpA with chronic gut inflammation are 
represented in Table 2 (↑: up-regulated; ↓: down-regulated, P<0.05). Among them, two genes 
had already been described in the context of CD. Acyl-coenzyme A oxidase 1 (ACOX1), which 
is the first enzyme of the fatty acid beta-oxidation pathway, donates electrons directly to 
molecular oxygen, thereby producing hydrogen peroxide. The enzymatic activity of ACOX1 was 
diminished in both inflamed and non-inflamed areas in CD (Aimone-Gastin et al. 1994). Our 
observation of ACOX1 transcript down-regulation corroborates this report, and indicates a fault 
at the level of transcription or mRNA stability. 
Figure 2 A. Complete Linkage clustering 
based on a set of 95 genes whose expression 
is deviant in CD patients and in SpA patients 
with chronic gut inflammation as compared to 
healthy controls. Two main clusters mark a 
SpA/control cluster and a CD/SpA with 
chronic inflammation cluster. B. Principal 
Component Analysis-view using a set of 95 
genes whose expression is deviant in CD 
patients and in SpA patients with chronic gut 
inflammation. CD (green) SpA without 
chronic inflammation (blue), SpA with 
chronic inflammation (yellow) and controls 
(red). 
 
A B 
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Table 2 Ninety-five EST’s that cluster CD and SpA patients with chronic gut inflammation 
 
Accession Gene description Chromosomal 
location 
Expression in 
CD/SpA chronic 
Reference 
H81904 acetyl-Coenzyme A synthetase 2 (ADP forming) 20q11.22 ↓  
AI758270   ↓  
R20596 chromosome 6 open reading frame 32  6p22.3-p21.32   (Barmada et al. 2004) 
AI349525 hypothetical protein FLJ34790 17p13.1  ↓  
AI445844 pyruvate dehydrogenase kinase, 3 Xq22 ↓ (van Heel et al. 2004) 
H56656  5q12.3 ↓  
N22829 GDP dissociation inhibitor 2 10p15 ↓  
AI274555 TatD DNase domain containing  8q24.13   (Vermeire et al. 2004) 
H61436 sorting nexin 24 5q23.2    
H15751 poly (ADP-ribose) polymerase family, member 16  15q22.31  ↓  
H87107 ring finger protein 5 6p21.3 ↓ (Rioux et al. 2000) 
AI680066     
AI191504 adenylate kinase 7 14q32.2  ↓  
R17390 sorting nexin 15 11q12   
AA812701 hypothetical protein LOC340178 6q27    
AA825971  2q31   
AA291593 solute carrier family 39 (metal ion transporter) member 11 17q24.3-q25.1   
 myoglobin 22q13.1   (Barmada et al. 2004) 
AA420968 chromosome 6 open reading frame 112  6q21   
R08643 interferon regulatory factor 2 binding protein 2 1q42.3   
T83584 mannosidase, beta A, lysosomal 4q22-q25   (Vermeire et al. 2004) 
AA481482 E74-like factor 3 (ets domain transcription factor, epithelial-specific ) 1q32.2    
T78477 zinc finger protein 297 6p21.3  (Rioux et al. 2000) 
H27674 DAB2 interacting protein 9q33.1-q33.3   
R13194 BRF1 homolog, 14q    
R98758 hypothetical protein FLJ32731 8p11.1    
H96900 MGC2747  19p13.11    
N62199 kinesin family member 1B 1p36.2  ↓ (Cho et al. 2000) 
R51052 S-phase response (cyclin-related) 1q42.11-q42.3 ↓  
AI286348 SH3 domain containing ring finger 2 5q32   
R17478 proliferation-inducing protein 13  1q25   
AI916359 secretory pathway calcium ATPase 2  16q24.1    
H19034 bladder cancer associated protein 20q11.2-q12    
N39050 cDNA FLJ39784 fis, clone SPLEN2002314    
R13544 F-box and leucine-rich repeat protein 3A 13q22  ↓  
AI286163   ↓  
R07321 Acyl-Coenzyme A oxidase 1, palmitoyl  17q24-17q25  ↓  
R12168 staufen, RNA binding protein, homolog 2 (Drosophila) 8q13-q21.1 ↓  
H85472 N-myc downstream regulated gene 1 8q24.3  ↓  
AA513663   ↓  
R97820 zinc finger CCCH type, antiviral 1 7q34 ↓  
N62837 leukocyte immunoglobulin-like receptor, subfamily A 4 19q13.4  ↓  
AA019615 ubiquitin carboxyl-terminal hydrolase L5 1q32  ↓  
AI809092   ↓  
AA758064    
AI219353 cancer susceptibility candidate 2 10q26.11  ↓  
AI698801     
R12632 hematological and neurological expressed 1 17q25.1   
AA468418     
 histone 1, H2ac 6p21.3  (Barmada et al. 2004) 
H23734 thymosin, beta 4, X-linked  Xq21.3-q22    
H75688 sorting nexin 7 1p21.3    
N63669 triple functional domain (PTPRF interacting)   5p15.1-p14    
AI819016   ↑  
AI831827 ADP-ribosylation factor guanine nucleotide-exchange factor 2  20q13.13    
AI923299 hypothetical LOC158730 Xp21.1 ↑  
AI286257 zinc finger protein 263 16p13.3   
AI863417 runt-related transcription factor 1 21q22.3 ↑  
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Table 2 continued 
 
Accession Gene description Chromosomal 
location 
Expression in 
CD/SpA chronic 
Reference 
AI274438   ↑  
AI289775 weakly similar to 0412263A Ig G2 pFc' PIG Gm   ↑  
AI345173     
AI928384     
AA490519 clone IMAGE:5286005    
AI696951 FLJ21763 fis    
AI339536 IMAGE:5286812, mRNA    
AI245190     
AI261428     
AI809310 hect domain and RCC1 (CHC1)-like domain 1 15q22    
AI831536 interleukin 12 receptor, beta 2 1p31.3-p31.2   
T79944   ↑  
AA480677 IMAGE:4865533  ↑  
AA009461 MUF1 protein 1p34.1  ↑ (Vermeire et al. 2004) 
R61783 synaptogyrin 2 17q25.3 ↑  
AI282992 glutathione peroxidase 2 (gastrointestinal) 14q24.1  ↑  
W65310     
AA588676 PDZ and LIM domain 3 10q22.3-q23.2    
AI811147   ↑  
AI357718     
N58523     
W74496   ↑  
AI352320   ↑  
AI280708 thymidylate kinase family LPS-inducible member  2p25.2    
AI815599 proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 17q11.2    
AI718161     
N98921 tropomyosin 3 1q21.2   (Vermeire et al. 2004) 
AI367201 HSPC135 protein 3q13.2    
AA425545 RP42 homolog 3q26.3   
H44213 hypothetical gene supported by BC031266    
N58936 nuclear receptor coactivator 7 6q22.32    
N90208 hypothetical protein FLJ32440 8q24.13   (Vermeire et al. 2004) 
AA427403 interferon induced transmembrane protein 1 (9-27) 11p15.5   
R25648 phosphatidylinositol 4-kinase type-II beta 4p15.2    
N93265 superoxide dismutase 1, soluble (amyotrophic lateral sclerosis ) 21q22.11    
H99865 nuclear receptor subfamily 2, group F, member 2 15q26   
 
Genes with aberrant expression in both CD and SpA patients with chronic gut inflammation (↓ down-regulated and ↑ up-regulated as compared 
to the control and SpA population (P<0.05). Genetic markers are cited for genes that are located within or near (5 cM) one of the CD loci 
 
Glutathione peroxidase 2 (gastrointestinal glutathione peroxidase, giGSH-Px) is one of the four 
types of selenium-dependent glutathione peroxidases. Its exclusive expression in the 
gastrointestinal tract indicates that it functions as a barrier against the absorption of dietary 
hydroperoxides, and as protection against damage from endogenously formed hydroxyl 
peroxides. Its activity is increased in ulcerative colitis patients in the active and in the remission 
stages (Beno et al. 1997). In CD, plasma levels of giGSH-Px are increased (Tuzun et al. 2002). 
We found that this gene is over-expressed in normal colon tissue in CD and SpA patients with a 
history of chronic gut inflammation, and so it can act as a marker expressed at non-pathological 
sites in the intestine in CD and CD susceptible SpA patients.  
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CONCLUSION 
 
Clinical study of intestinal abnormalities in SpA patients has previously relied on cytokine 
profiles and immunological alterations. In addition to analyzing individual proteins, genome-
wide transcript profiles can be analyzed by microarrays. Global gene expression analysis in non-
inflamed colon tissue was used to find genes that are differentially expressed in both CD patients 
and SpA patients with a history of chronic gut inflammation. Previous studies of gene expression 
in IBD have focused on biopsies of actively inflamed tissues (Lawrance et al. 2001; Dooley et 
al. 2004; Stoll et al. 2004). The use of samples from non-inflamed areas from CD patients offers 
the possibility of identifying early markers for CD, which would permit prediction of the 
evolution to CD in SpA patients. Moreover, changes in the expression of genes that are regulated 
during inflammation would be more prominent than the subtle alterations in non-inflammatory 
genes, although it cannot be ruled out that this procedure will also pick up genes whose 
differential expression is a consequence and not a cause of the disease. Additionally, looking at 
basal gene expression may allow us to take into account genetic influences, since gene 
expression is highly heritable (Morley et al. 2004). Therefore, future studies on markers for CD 
should concentrate primarily on genes that are located near one of the known loci for CD (Table 
2). Genes located within a region linked to CD or IBD in general (if multipoint linkage was 
performed), or within five centimorgan of the markers that are linked to CD or IBD (in case of 
two point linkage) should be considered first. Using a model for early CD when identifying CD 
susceptibility genes can circumvent the heterogeneity of the disease, because probably only a 
very small number of CD genes will be implicated in SpA.  
Array analysis is a rapid procedure for studying the expression of many genes in no more than 
several samples. Because the number of samples is limited, and the number of genes explored is 
usually large, false-positive results will obviously arise. Nevertheless, array analysis enables us 
to explore gene expression with different computational tools. To confirm the importance of a 
set of genes associated with a phenotype, complementary techniques such as quantitative PCR 
(qPCR) are mandatory. Thus, arrays are not simply a way to find single differentially regulated 
genes; they can be used to compare global gene expression in distinct groups.  
We show that SpA patients have an aberrant gene expression profile in comparison to healthy 
controls, indicating that alteration of gene expression in the colon of SpA patients is a 
biologically relevant concept. We identified a set of genes that are differentially expressed in 
both CD and SpA patients who are at higher risk of developing CD. Based on the expression of 
these 95 genes, SpA patients with subclinical chronic gut inflammation cluster with CD, 
Altered gut transcriptome in spondyloarthropathy 
 
 
139 
confirming the clinical association between the two inflammatory disorders. We also suggest a 
number of candidate genes for mutation screening. We are currently verifying a selection of 
genes by qPCR, and exploring the involvement of genes that are differentially expressed in both 
CD and SpA patients with a history of chronic gut inflammation, in order to find early (genetic) 
markers for CD in SpA patients.  
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INTRODUCTION 
 
Microarrays are the ideal tool to study many thousands of genes at once. However, since their 
widespread use, little has been accomplished, except for simply identifying differentially 
expressed genes. Usually, the processing and interpretation of the huge amount of data is 
difficult. Another application based on microarrays is the extraction of new classification 
algorithms. However, this demands a lot of samples, and is thus not cost-effective. Additionally, 
microarrays are used for the identification of pathways. However, many genes will be missed, 
because not all expression changes will occur at one specific time-point. Together with the 
statistical set backs, these are the reasons why studies on microarrays are increasingly criticized. 
They seem to be merely applicable as an initial screen for differentially expressed genes, and 
absolutely require additional verification. Moreover, it was recently postulated that the use of 
microarrays to study transcription profiling in the future might become less important because “it 
focuses on an intermediate” (Hoheisel 2006). Indeed, RNA might be too far removed from the 
actual cellular effectors to be used for diagnostic purposes, unless regulatory RNAs, such as 
microRNAs are targeted (He et al. 2004). We believe, however, that the RNA expression of 
genes is crucial in the development of diseases, and is probably a major determinant for common 
phenotypic characteristics, such as height or intelligence. Therefore, transmitted gene expression 
patterns associated with complex genetic diseases should provide useful information, but up to 
now, this has been underestimated in genetic studies. Here, we consider the use of microarrays in 
the identification of susceptibility genes, and we propose a novel method based on the 
integration of microarray analysis in family pedigrees. 
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NATURAL VARIATION AND SUSCEPTIBILITY 
 
Natural genetic variation at the DNA level greatly influences the basal expression of genes or 
their targets. Analysis of microarrays to investigate the genetic circuitry that regulates expression 
has first been used in yeast (DeRisi et al. 1997). It is a favourable organism to study gene 
expression, since the genes are easy to recognize, and the cis regulatory elements are compact 
and close to the transcription units. Certain yeast mutants have been characterized by their 
expression pattern and sets of genes could be grouped and rationalized by identification of 
upstream regulatory sequences. In mice, differential gene expression induced by single-gene 
effects in complex tissues has been studied (Callow et al. 2000; Aronow et al. 2001). In contrast 
to the exploration of functional consequences of a defined genetic difference, these approaches 
have also been used in combination with traditional quantitative trait locus (QTL) mapping 
techniques. Indeed, Karp and co-workers have successfully identified complement factor 5 (C5) 
as a susceptibility gene in a murine model for allergic asthma (Karp et al. 2000). C5 appeared to 
be the only gene that was differentially expressed between susceptible and non-susceptible 
backcross mice as well as located near one of the previously identified QTL intervals. Similarly, 
Aitman and colleagues have combined a congenic strain strategy with micorarray expression 
analysis in the spontaneously hypertensive rat, a model for human insulin-resistance type 2 
diabetes (Aitman et al. 1999). Hence, CD36 was pursued as a candidate for the observed QTL at 
chromosome 4, and sequencing revealed multiple variants caused by unequal genomic 
recombination of a duplicated ancestral section.  
In humans, little has been studied on gene expression and susceptibility. However, remarkable 
support comes from the study of allele specific variation in gene expression (Lo et al. 2003). 
Among 602 heterozygous genes that contained transcribed single nucleotide polymorphisms, 
54% displayed at least a twofold preferential expression of one allele. This allelic variation was 
shown to be transmitted by mendelian inheritance (Yan et al. 2002). Furthermore, the variance in 
expression level is highest among unrelated individuals, and smallest between members of 
monozygotic twin pairs, suggesting that germ-line differences contribute to variation in gene 
expression (Cheung et al. 2003; Correa et al. 2004). Four studies illustrated that basal gene 
expression levels are highly heritable (Watts et al. 2002; Cheung et al. 2003; Correa et al. 2004; 
Pastinen et al. 2004). Watts and co-workers have defined a unique expression phenotype to 
carriers of a recessive disease called ataxia telangiectasia. Although many studies have addressed 
the inheritance of single-gene mutations, so far the genome-wide inheritable expression in 
human disease has not been studied (Cheung et al. 2002). Moreover, Morley and colleagues 
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have shown that these quantitative traits allow the genetic mapping of determinants that 
contribute to variation in human gene expression (Morley et al. 2004). Taken together, these 
results demonstrate the feasibility and utility of exploring genome-wide gene expression in the 
study of susceptibility to human diseases. 
 
Polymorphisms and gene expression 
How can polymorphisms affect gene expression? First of all, mutations in coding sequences 
often result in an altered half-life of the RNA. Secondly, polymorphisms in untranslated regions, 
or introns can have modest or substantial influences on gene expression. Not only transcription 
factor binding sites or enhancer sites can be changed, but also the stability of the RNA is 
depending on seemingly “junk” sequences. Next to changes in cis acting elements, 
polymorphisms in trans acting factors could influence the expression of downstream genes. 
The small variations in DNA sequences between individuals have been suggested as being 
responsible for inter-individual phenotypic variation. That is why common traits or phenotypic 
characteristics are supposed to result from natural variation. In fact, all forms of life, including 
life-threatening diseases and normal phenotypes, probably share the same basic idea: it is merely 
the impact of the polymorphism that determines the functional consequence (Figure 1). If the 
impact is low, such as small phenotypic changes, the polymorphism will not be eradicated by 
natural selection. On the other hand, if the polymorphism is causing a severe dysfunction of a 
protein, it will be selected out. That is probably one of the reasons why some relatively harmless 
traits such as allergies are common. 
 
Epigenetics and gene expression 
Unfortunately, the classical genetic ideas are complicated by new and slowly accepted 
mechanisms. The concept of the all-determining DNA sequence is not complete. It appears that 
the environment not only affects your own life, but also the life of your progeny. It is becoming 
widely accepted that genes have some sort of “memory”. The way this memory works is 
explained by epigenetic mechanisms (literally: on top of genetics), acting by switching on and of 
the expression of genes. This also gives a new dimension as to what “environmental factors” are 
in genetics. Are they the factors that the person goes through at birth, during adolescence or 
perhaps that his ancestors were confronted with? Epigenetic effects can act on larger regions, 
influencing a number of genes within the same chromosomal region. Moreover, these effects are 
not fixed over time within the same individual. Today, two basic epigenetic mechanisms are 
known: DNA methylation and histone modifications. These modifications act on the expression 
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of genes by interfering with chromatin packaging or the physical binding of trans factors to the 
DNA strand. Furthermore, at least for methylation, evidence exists that it is genetically 
transmitted. 
 
 
Figure 1 Natural genetic variation determines every-day life: from life-threatening diseases to the way we look. 
 
FAMILY-BASED EXPRESSION PROFILING IN CROHN’S DISEASE 
 
As stated above, susceptibility to CD most likely results from several variations in DNA 
sequence. Some of them will alter the gene product, but they may also have profound as well as 
subtle consequences on gene expression. On top, inherited epigenetic mechanisms will 
contribute to differential expression. Instead of analyzing gene expression in randomly selected 
CD patients, we suggest using multiple affected families to screen for sets of genes that are 
differentially expressed, e.g. in blood, between affected and non-affected family members 
(Figure 2). This way, the problem of genetic heterogeneity between random CD patients is 
dramatically reduced. Specific sets of genes can be identified that are transmitted only to patients 
with CD, and are thus ideal candidates to associate to disease. In combination with linkage data 
of the families, we would gain substantial evidence for an actual expression signature for CD, in 
which genes will have to be characterized. In the next section we briefly describe the 
experimental set-up of such a study. 
 
 
epigenetic effects 
frequency of trait 
number of polymorphisms 
impact of polymorphisms 
“every-day“ phenotypes or 
quantitative traits (intelligence, 
height) 
 
less common traits (cystic 
fibrosis, mongolism) or 
rare phenotypes (albinism) 
 
common traits (allergies, 
hypertension) 
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Figure 2 Simplified and theoretic example of 
a family pedigree used to study the 
transmission of expression signatures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Design and methodologies 
Gathering of appropriate families/patients and blood sampling. Patients and relatives will be 
asked to participate in the study. Families will be evaluated based on the magnitude, number of 
affected individuals, and genetic information. Patients within these families will be selected only 
after diagnosis is well defined, and non-affected patients should have reached a certain age, to 
reduce false negatives. 
Collected fresh whole blood will be immediately treated with the RiboPure-Blood Kit (Ambion). 
This way, samples are safe to transport at ambient temperature. The majority of RNA will 
originate from white blood cells (WBC). The RiboPure-Blood Kit was designed to minimize 
contamination with heme, protein and genomic DNA during RNA extraction of whole blood. 
Therefore, there is no need to select for WBC before extraction, reducing experimental 
heterogeneity. It has been reported that some features of variation in expression in blood samples 
are associated with cellular composition, gender, age and time of the day, so care must be taken 
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in this regard (Whitney et al. 2003). To rule out such random effects, sampling will be done at 
two time points per individual, and expression profiling will be carried out in duplicate. In 
addition, variations observed among patients are likely to be significantly greater than the 
background variation in normal gene expression.  
 
RNA extraction and microarray screening. Total RNA will be isolated within 1 day, and stored 
until it can be processed for RNA amplification and hybridization. We choose to perform a 
genome-wide screen and use the Affymetrix platform (Human Genome U133 Plus 2.0 Set, 
containing 47,000 transcripts including 38,500 well-characterized genes). These chips contain 
oligonucleotide probes, designed to maximize sensitivity, specificity, and reproducibility, 
allowing consistent discrimination between specific and background signals, and between 
closely related target sequences.  
 
Data analysis. The raw expression data will be imported in a highly developed software program 
called GeneMaths
® 
XT (Applied Maths, BVBA).  
In first instance we will concentrate on those genes that are annotated and modulated between 
affected and non-affected individuals, base on a simple P-value cut-off. Differentially regulated 
genes will belong to one of the following main categories: 
 
• false positives (due to limited statistical power) 
• secondary to disease (this should be minimized, since we are not looking at the 
site of pathology, and genes should be at their steady-state level. In addition 
samples are analyzed at two time-points per individual) 
• genetic variation in trans-acting genes 
• genetic variation in cis-acting elements 
 
An example of the concept and analysis of cis and trans regulators of expression in human 
genetics has been anticipated (Morley et al. 2004). Genes that are located within regions with 
most significant evidence of linkage are potentially those that are regulated in cis. Based on the 
information of the genes we will have to decide on which genes to focus.  
Genes that are not located within these regions can still be regulated in trans. Extra evidence will 
have to be gathered to decide if and which genes might be interesting to pursue. For example, 
unsupervised clustering can reveal genes that are commonly regulated. Promoter analysis will be 
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conducted to search for common binding factors. Evidently, transcription factors that are located 
within a locus are considered as candidate genes. 
In a more elaborate search for regulators, the expression phenotype can be analyzed genetically 
as a quantitative trait in order to identify the determinants of the variation in gene expression. 
The differentially expressed genes with the most evidence of linkage will be used to carry out 
genome-wide linkage analysis in CEPH families (Centre d'etude du polymorphisme humain) 
(Morley et al. 2004). These are large three-generation families, many of which have been 
genotyped. Immortalized lymphocytes are available from all the members of the pedigree. 
Consequently, loci can be attributed to specific expression phenotypes, and be evaluated by 
comparing to known CD loci. 
 
Genetic screening. Genes that meet the criteria as discussed above, will be screened for 
mutations/polymorphisms in matching patients. For this, sequence analysis of exonic sequences 
and ~1000 nucleotides upstream of the start codon will be performed. Polymorphisms are then 
evaluated in an independent CD and control population to assess the population risk. 
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  Summary and discussion 
 
The objective of this project was to use gene expression analysis in the search of genetic 
susceptibility genes for Crohn’s disease (CD). Crohn’s disease is a debilitating disease with 
substantial impact on the patients’ quality of life. For some reason, the intestine becomes 
chronically inflamed, extending deep into the layers of the intestinal wall. The patient 
experiences periods of clinical relapses and remission. In general, the complete gastrointestinal 
tract can be affected, however, the inflammation is usually confined to the small bowel (ileum) 
or the large bowel (colon). In fact, the location of disease is one of the most accepted phenotypic 
classifications for CD, because it stays particularly stable throughout disease duration. 
Moreover, concordance rates for disease location in affected siblings are high.  
The principle treatment for CD is the lifetime controlling of gut inflammation, often 
resulting in surgical resection of parts of the intestine. However, because of substantial side 
effects and uncontrollable relapses, conventional treatment remains far from satisfactory for 
patients and physicians. A more rational approach for developing therapies should evolve from a 
good knowledge of the pathogenesis: when and why is inflammation initiated, how does it result 
in a chronic state and why is the patient not able to control the inflammation? A very important 
question is which genetic or environmental factors are common in most CD patients. It is 
generally accepted that good hygiene standards contributes significantly to the development of 
CD. This so-called hygiene-hypothesis is based on the reality that today, people encounter too 
little infections, resulting in a less trained immune system. Indeed, in developing countries, 
infectious diseases are fairly common, yet CD does practically not exist. Nevertheless, it is still a 
guess whether CD arises from the loss of tolerance to commensal bacteria or whether it is 
infection-triggered. In any case, the role of intestinal flora in genetically predisposed people is 
undisputable. Today, most studies are directed at this hypothesis.  
In 2001, two independent research groups mapped the first susceptibility gene for CD, 
CARD15.  This gene is located at the IBD1 locus (16q12), a locus that was identified in almost 
every genome screen. The CARD15 protein is a cytosolic sensor for bacterial components. Up to 
one-third of CD patients have a probable loss-of-function mutation in this gene. The discovery of 
CARD15 and CD-associated mutations was a major advance in unravelling some of the 
characteristics of CD pathogenesis. Firstly, it explains a great deal about the involvement of 
bacteria in the disease. For example, it was shown that epithelial cells overexpressing a mutated 
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CARD15 protein were not able to respond to infection with Salmonella. Secondly, these 
mutations are associated with ileal involvement. Interestingly, CARD15 is expressed in the 
paneth cells, which are specialized cells that secrete anti-bacterial molecules into the lumen of 
the gut. These paneth cells are normally restricted to the ileum, which fits with the phenotype of 
ileal affection in CD.   
However, maybe CARD15 should not be considered as being mutated in the strict 
meaning of the word (see also Intermezzo). In up to 20% of healthy persons, these mutations are 
also present. A gene like CARD15 is most likely not a causative gene for CD, but rather a 
disease-modifying gene. Therefore, we better consider them as polymorphisms. An interesting 
hypothesis stated by Hugot and co-workers fits well within this concept. They speculated that 
these polymorphisms, which arose quite recently, were somehow beneficial during the outbreak 
of the plague in Europe. Later, the number of CD patients increased, partly because of increased 
hygiene standards. Because CARD15 is predominantly expressed in the ileum, patients carrying 
the “altered” CARD15 protein show more inflammation of the ileum. 
The example of CARD15 and the implications it had on research is substantial: a pubmed 
search on CARD15 gives 501 hits since 2001. Thus, the search for new functionally relevant 
proteins in the form of susceptibility genes is essential for a thorough understanding of mucosal 
biology in general and pathogenesis of CD in particular. The classical genetic linkage studies on 
CD have been crucial in the identification of CARD15. Therefore, we reviewed all the data of 
genetic linkage and gene association studies in Chapter 1. As for most complex genetic traits, 
many so-called chromosomal disease loci have been identified. Unfortunately, the exact genes 
within these loci that are associated with CD are not known. In contrast to simple mendelian 
traits, finding a master gene for the causation of CD is not plausible. In reality, the combination 
of many subtle polymorphisms with environmental risk factors and epigenetic mechanisms will 
most likely be responsible for disease onset.  Another method for finding susceptibility genes is 
the candidate gene approach. Here, a gene is chosen based on a known property. Subsequently it 
is screened for mutations in several CD patients, and frequencies are compared in a larger case-
control study. Though many genes have been screened in this manner, the reproducibility of 
association studies is disappointing. Mainly, this is the result of statistic setbacks and population 
biases. We gave an overview of all genes that were tested in such association studies. Two main 
conclusions can be drawn from this review. Firstly, patient and control cohorts should be large 
and thoroughly chosen. Often, populations are too small, and control cohorts are not age and sex 
matched. Good collaboration and communication of research labs with clinicians and hospitals is 
crucial.   For   most  small  laboratories,   unfortunately,  the  use  of  undersized  populations  for  
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epigenetic effects 
frequency of trait 
number of polymorphisms 
impact of polymorphisms 
“every-day“ phenotypes or 
quantitative traits (intelligence, 
height) 
 
less common traits (cystic 
fibrosis, mongolism) or 
rare phenotypes (albinism) 
 
penetrance problems: are they the result of 
additional polymorphisms in protecting or 
sensitizing genes? 
common traits (allergies, 
hypertension) 
Intermezzo: Natural genetic variation determines every-day life: from life-threatening diseases to the way 
we look. 
Any two humans are approximately 99.9% identical in their DNA sequences. However, the 0.1% variation, 
that is one dissimilarity per 1,000 bases on average, contributes to difference in the risk of developing 
certain diseases, and responses to drugs, infectious agents, toxins and other environmental factors. Finding 
the genetic variants that influence disease risk and drug response is necessary to understand how genetic 
and environmental factors interact to influence health. In fact, the foundation of all forms of life, including 
life-threatening diseases and normal phenotypes, probably share the same basic idea: it is merely the 
functional impact of the polymorphism that determines its frequency. If the impact is low, such as small 
phenotypic changes, the polymorphism will not be eradicated by natural selection. On the other hand, if the 
polymorphism is causing a severe dysfunction of a protein, it will be selected out. That is probably one of 
the reasons why some relatively harmless traits such as allergies are so common. Incomplete disease 
penetrance is a term that is used to describe individuals with a specific genotype who do not manifest that 
genotype at the phenotype level. In reality, this might reflect the absence or presence of polymorphisms in 
other sensitizing or protecting genes respectively. In addition, epigenetic mechanisms complicate this 
generalized mechanism. They influence the expression of genes, and represent thus another level of 
determining penetrance. Probably, but this has not been proven, they will not be important in simple 
mendelian traits. Moreover, epigenetic influences also give a new dimension as to what “environmental 
factors” are in genetics. Are they the factors that the person goes through at birth, during adolescence or 
perhaps that his ancestors were confronted with?  
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association studies is the only means of competing with the  more organized labs. Nevertheless, 
even small scale pooling of cohorts can improve the outcome of genetic screenings. In 1997, a 
group of scientists and clinicians founded the IBD International Genetic Consortium (IBDIGC), 
now a group of twelve research groups involved in studying genes that are implicated in IBD. 
They collaboratively study large numbers of well-documented families for linkage. The 
formation of large international consortia offers research groups both large and small to 
participate equally in CD gene identification. The second conclusion is that more standardized 
methodologies for the screening of genes are required. In addition, we should evolve from single 
polymorphism association studies to the association of so-called haplotype structures. These 
haplotype blocks are the minimal genomic fragments that are genetically transmitted. A single 
polymorphism within a gene might not necessarily influence its function or transcription. Yet 
this defect could be caused by a nearby polymorphism within the same haplotype block. For 
instance, the CARD15 gene contains, next to the CD-associated mutations, many other 
polymorphisms dispersed all over the gene. Because not all linkage observed at 16q12 can be 
explained by the three CD-associated polymorphisms, the question arises whether the actual 
disease causing mutation is located near the CARD15 gene. In Chapter 2, we conducted a search 
for polymorphisms in the CARD15 promoter region, because the expression of CARD15 is up-
regulated during inflammation. We found a common polymorphism, c.-59G>A, located within a 
DNA stretch that potentially binds the E2F transcription factor. Using an in vitro reporter 
system, we showed that the promoter is less responsive to tumor necrosis factor alpha induction 
in the presence of the c.-59A allele. This functional defect prompted us to study this 
polymorphism in more detail. It appears that the -59A allele is always linked to the three other 
CD-associated mutations. This allele occurs isolated, but it is always present whenever one of 
the three CD-associated mutations occurs. Therefore, we decided to study the haplotype 
structure surrounding CARD15, which is currently ongoing. 
The selection for a gene to study in a candidate gene approach might require some 
adjustment. The choice of a gene is very subjective, and virtually every gene can theoretically fit 
somewhere within the complexity of CD pathogenesis. We used a complementary and 
hypothesis-independent approach to identify more reliable candidate genes for CD in Chapter 3. 
A gene expression survey on unaffected colon biopsies from CD patients and healthy controls 
was used to identify genes that are differentially expressed in CD. We then focused on those 
genes that are located within an arbitrary region of 5 centimorgan from a marker that showed 
highest linkage to CD in at least two independent studies and in a study performed on a Flemish 
cohort. Eighteen genes were selected in this way. These genes can individually serve as new 
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focus genes, also for other researchers within the field. We focused on two genes within this list 
that belong to a cluster of highly related genes called metallothioneins (MT). These genes are 
located in tandem within the IBD1 locus. Moreover, its role in host protection against various 
forms of stress and inflammation made them ideal candidate genes to pursue. We showed that 
their expression is significantly down-regulated in colon, ileum and blood of CD patients that 
have colonic disease. In addition, a reduced protein expression in this type of patients was shown 
by immunohistochemistry. Remarkably, we showed a correlation between RNA and protein 
levels, even though biopsies used for RNA extraction and for staining were not taken at the same 
moment. This further supports the idea that the altered MT expression is genetically determined. 
We found no coding or promoter mutations in one of the MT genes, MT1M. Therefore, we 
screened a well-characterized MT transcription factor, MRE-binding transcription factor 1, 
MTF1, for mutations. Two missense mutations were found in 6 out of 95 patients. Their 
functional relevance still needs to be determined. A frequent polymorphism in the splice site 
junctions at the boundary of exon 8 was found, however, we could not detect any splice variants. 
In our study, we focused on a polymorphism in the first intron, IVS-128A>T, which is a 
potential binding site for the GATA4 transcription factor. Although we showed that the 
frequency of this polymorphism was not different in CD patients as compared to healthy 
controls, it was significantly associated with disease location. The apparent resemblance to the 
association of CARD15 with disease location encouraged us to study the combined risk for 
developing ileal disease. The odds for developing ileal disease was 4 in CARD15 mutant 
patients, and 2.4 in patients that carry the IVS-128T allele. Moreover, we showed a gene-gene 
interaction of CARD15 and MTF1 as shown by a higher combined risk. Theoretically, this means 
that when CD patients are genotyped for CARD15 and MTF1, ileal involvement (or alternatively, 
pure colonic disease) during disease progression can be predicted with substantial precision. 
Moreover, this is to our knowledge the first report of the use of microarray screening of tissues 
in genetic studies. We described the importance of gene expression profiling for the mapping of 
new susceptibility genes in the Future prospects, and provided a novel method based on 
transmission of expression signatures in family studies. 
The involvement of MTF1 in the genetic down-regulation of MTs in CD patients needs 
to be determined. Interestingly, both CARD15 and MT are highly expressed in the ileum, and 
are involved  in bacterial  detection and  eradication respectively.  Bacterial  load in  the  ileum is  
10
2-3
 per gram faeces, while it reaches 10
9-12
 in the colon. It thus seems likely that the ileum is 
specialized in eliminating bacteria from its environment. CARD15 and MT may belong among 
the players that regulate this elimination. Conversely, the observation that mutant CARD15 and 
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the IVS-128T allele predispose to ileal disease could even so be reversed. Possibly, a CARD15 
mutated protein or the MTF1 protein in IVS-128T allele carriers, protects against an unwanted 
colonic inflammation, which might occur as a result of the high bacterial load at the colonic site. 
Importantly, the next priority is examining MT expression and assessing the risk of MTF1 and 
CARD15 in ulcerative colitis (UC) development, which is another related inflammatory bowel 
disease. Indeed, UC pathology could be considered as the extreme end of the disease location 
phenotype of CD. In UC patients, only the colon is affected but inflammation is disturbing only 
the superficial layers of the bowel wall. Although UC and CD are fundamentally different 
diseases, the concept of disease location might be influenced by the same molecular 
mechanisms. 
We and others have demonstrated that MTs are highly expressed in intestinal epithelial 
cells (IEC).  Over the past decade, many studies have revealed the physical and immunological 
importance of IEC in the gut homeostasis. These cells have developed a variety of mechanisms 
to reduce the risk of infection or damage by toxic compounds or free radicals. The effective 
maintenance of a physical barrier function is dependent on the establishment of well-organised 
intercellular junctions and a constant state of regeneration/renewal of the epithelium. Intestinal 
epithelial cells also participate in the innate immune responsiveness of the intestine by their 
ability to secrete mucus, antimicrobial peptides, cytokines and as well as chemokines. We 
generated an MT-knockdown model of HT29 colonic epithelial cells to study the biological 
consequences of a reduced MT expression in IEC. Initial experiments revealed that in 
comparison to the wild type cell line, these cells produce less IL8 when they were challenged 
invasive E. coli. This might provide a direct pathogenic role, since CD was previously linked to 
immunodeficiency caused by impaired innate immunity. In addition, preliminary data showed 
that these cells do not induce IL8 secretion in response to commensal bacteria (Lactobacillus 
rhamnosus), therefore an infection model for CD may fit best with our hypothesis. Nevertheless, 
a number of other bacterial strains, both commensal and pathogenic, need to be tested in this 
system.  
Metallothioneins have been linked to a number of diseases, including some neurological 
disorders and different types of cancers. However, the regulation of MT isoforms in human cells 
is very complex, and its expression in health and disease is difficult to interpret.  An overview of 
MT involvement in diseases, together with the regulation of MT expression is given in Chapter 
4. For CD, conflicting data on MT expression are found in literature. The same holds true for 
MT expression in many cancers. The main problem in comparing these studies is the use of 
different techniques used for quantification. Since the original cloning of the first MT gene from 
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the renal cortex in 1960, original data on MT quantification in serum or on histological sections 
greatly depend on the antibody used. It is obvious that cross-reactivity between species but also 
between isoforms complicates the interpretation of results. These days, many researchers use the 
same anti-MT antibody, which facilitates comparing results. Recently, more detailed information 
on the expression on the different MT isoforms is gathered because of the emergence of more 
sensitive and specific techniques such as quantitative real-time PCR. In order to learn why MTs 
are not adequately expressed in CD, we made a literature overview of human MT regulation. 
This overview was based on an in silico comparison with murine expression control, because the 
majority of studies on MT were performed in mice. The genes upstream of MT are good 
candidates to study with respect to MT expression in CD. 
 
In the next section, we used gene expression analysis to study the well-defined 
association between CD and another group of chronic inflammatory diseases called 
spondyloarthropathies (SpA).  In addition, the genetic contribution of CD-associated CARD15 
mutations was assessed in these patients. SpA covers a heterogeneous group of arthritic diseases 
sharing clinical and radiological features and presence of the HLA-B27 allele. Previous research 
has indicated that patients with spondyloarthropathy (SpA) form a population with a substantial 
higher risk for the development of CD, which is discussed in Chapter 5. Subclinical 
inflammatory gut lesions are common in SpA, as observed during colonoscopic studies in these 
patients. These gut lesions are either classified as acute or chronic inflammation. The latter form 
resembles closely lesions found in CD patients. Follow-up studies of SpA patients indicated that 
7% develop an inflammatory bowel disease and, of those with chronic inflammatory gut lesions, 
30% develop clinical CD. Several lines of evidence suggest that the gut could have an important 
pathogenic role in SpA. However, the precise relation of the join-gut axis is not completely 
understood. We therefore assessed the contribution of CARD15 mutations in SpA patients, as 
described in Chapter 6. We found that the frequency of CARD15 mutations in SpA patients 
with chronic gut lesions was significantly higher than in the control population, and comparable 
to the frequency in CD patients. Thus, we provided a first line of evidence that gut inflammation 
in SpA patients is genetically determined, and that SpA patients with subclinical chronic gut 
inflammation are a separate group, with a higher risk to develop CD.   
We wondered whether the intestinal gene expression pattern in SpA patients differs from 
that of controls. In Chapter 7 we described alterations in gene expression in unaffected colon 
biopsies of SpA patients as compared to controls. Furthermore, the alterations found in patients 
with a history of chronic gut inflammation are comparable to those found in CD patients, 
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confirming the clinical observations. Hence, SpA serves as a good model to study early CD. 
Furthermore, the SpA model might be used in the selection for potential candidate genes for the 
predisposition of gut inflammation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
159 
Samenvatting en discussie 
 
De opzet van dit project bestond erin genexpressie te bestuderen om genetische 
afwijkingen voor de ziekte van Crohn (ZVC) op te sporen en te karakteriseren. Patiënten met de 
ZVC lijden aan een chronische ontsteking in de darmen. Hierbij is de volledige darmwand, 
zowel de oppervlakkige als de diepere lagen, aangetast. Het ziektebeeld is sterk individueel 
bepaald en kent een grillig verloop: periodes van hevige klachten en kalmere periodes wisselen 
elkaar af. De belangrijkste verschijnselen van de ZVC zijn een rechtstreeks gevolg van de 
ontsteking zelf, zoals pijn in de buik, koorts, krampen, al dan niet bloederige diarree en 
gewichtsverlies. Vooral het uiteinde van de dikke darm (colon) en de dunne darm (ileum), maar 
ook andere delen van het maag-darmstelsel kunnen worden aangetast. Het is zelfs zo dat de 
plaats van ontsteking wordt gebruikt om patiënten met de ZVC te classificeren, omdat deze 
relatief stabiel blijft tijdens het ziekteverloop. Bovendien is er een sterke overeenkomst in de 
plaats van inflammatie tussen verwanten met de ZVC. 
De ZVC kan niet worden genezen, dus is de behandeling erop gericht de ontsteking 
onder controle te houden en complicaties te verminderen. Vaak moeten patiënten na verloop van 
tijd een chirurgische ingreep ondergaan, gaande van het weghalen van een abces tot het 
verwijderen van een deel van de zieke darm of zelfs het volledige colon. Hoewel veel patiënten 
aanvankelijk geholpen zijn met de standaardbehandelingen treden er vaak neveneffecten op, en 
kunnen perioden van herval niet worden gecontroleerd. Een meer rationele aanpak gebaseerd op 
kennis van het ziekteproces is noodzakelijk bij het ontwikkelen van nieuwe behandelingen. 
Hierbij moeten we enkele concepten proberen te begrijpen: wanneer en hoe wordt de ziekte 
geïnitieerd, waarom evolueert een ontsteking tot chronisch lijden, en waarom is de patiënt niet in 
staat de inflammatie onder controle te houden? Belangrijk is ook de vraag welke genetische en 
omgevinsfactoren patiënten gemeenschappelijk hebben. Een algemeen aanvaarde hypothese is 
de zogenaamde hygiëne-hypothese. Ze gaat ervan uit dat we tegenwoordig te weinig 
infectieziekten doormaken, waardoor het afweersysteem onvoldoende geoefend wordt. 
Inderdaad, het is opmerkelijk dat er bijna geen ZVC voorkomt in ontwikkelingslanden, waar er 
echter veel infectiegevaar dreigt. Nochtans weten we nog altijd niet of patiënten die de ziekte 
ontwikkelen een verminderde tolerantie vertonen in de darm, of dat de ziekte een initiële infectie 
vereist. Hoe dan ook, we gaan er van uit dat de darmflora een belangrijke rol speelt in de ZVC, 
maar enkel bij personen met een genetische aanleg de ziekte uitlokt. Dit is dan ook vandaag de 
dag het onderwerp van veel onderzoek in de ZVC. 
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Het eerste gen dat sterk werd geassocieerd met de ZVC werd gekloneerd in 2001. Dit 
gen, CARD15 genaamd, ligt in de IBD1 locus (16q12), een locus die in bijna elke genoomscan 
werd geïdentificeerd. Het CARD15 eiwit herkent bacteriële componenten binnen in de cel, en 
activeert NFκB. Ongeveer een derde van de patiënten met de ZVC dragen een mutatie in dit gen. 
Veel onderzoek was aanvankelijk gebaseerd op de functie van deze mutaties, maar hierover 
bestaat nog geen sluitend antwoord. Er zijn echter sterke aanwijzingen dat het gemuteerde 
CARD15 eiwit zijn functie gedeeltelijk niet meer kan uitoefenen. Over het algemeen was de 
ontdekking van CARD15 van groot belang om enkele aspecten in het ziekteverloop van de ZVC 
te begrijpen. Ten eerste bieden ze een verklaring voor het belang van bacteriën in het 
ziekteproces.  Een mooi voorbeeld hiervan is dat epitheliale cellen die het gemuteerde CARD15 
eiwit overexpresseren niet meer reageren op infectie met Salmonella. Ten tweede, mutaties in 
CARD15 werden gecorreleerd met ileale aantasting van de ZVC, de plaats waar CARD15 sterk 
tot expressie komt. CARD15 wordt er geëxpresseerd in paneth cellen, gespecialiseerde cellen die 
bacteriën in het ileum elimineren. In normale omstandigheden komen deze cellen enkel voor in 
het ileum, wat een directe link vormt tussen de werking van CARD15 en de plaats van 
aantasting.  
Misschien is het belangrijk om de mutaties in CARD15 eerder te beschouwen als 
polymorfismen die een invloed uitoefenen op het ziekteproces (zie ook Intermezzo). Ze komen 
ook voor bij 20% van gezonde personen. Het is geen oorzakelijk gen, maar eerder een gen dat 
een invloed heeft op de manifestatie van de ziekte, in dit geval, ileale aantasting. Deze 
redenering sluit goed aan bij een hypothese die Hugot en medewerkers vooropstelden. Zij 
geloven dat personen die deze polymorfismen in CARD15 droegen, bevoordeeld waren bij het 
uitbreken van de pest in Europa. De oorsprong van deze polymorfismen loopt inderdaad gelijk 
met deze periode. Vanaf dan is de incidentie van de ZVC beginnen stijgen, mede door een 
hogere hygiënestandaard. Personen met mutaties in CARD15 en de ZVC ontwikkelen 
voornamelijk ontsteking in het ileum, waar CARD15 voornamelijk tot expressie komt. 
De impact van CARD15 op het onderzoek naar de ZVC,  maar ook naar aangeboren 
immuniteit is groot: het resultaat voor CARD15 in pubmed geeft 501 hits sinds 2001. Dit 
betekent dat de identificatie van nieuwe eiwitten betrokken bij genetische predispositie, van 
belang is bij de studie van mucosale biologie en van de ZVC in het bijzonder. De klassieke 
genetische linkage studies waren cruciaal bij het kloneren van CARD15. Daarom hebben we een 
overzicht gemaakt van alle linkage en associatie studies bij de ZVC in Chapter 1. Zoals voor de 
meeste complex genetische aandoeningen werden er meerdere chromosomale loci gevonden 
voor de ZVC. De precieze genen binnen die loci  die geassocieerd zijn met ZVC werden echter  
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epigenetische effecten 
frequentie van de aandoening 
aantal polymorfismen 
impact van het polymorfisme 
“alledaagse“ fenotypes of 
quantitatieve fenotypes 
(intelligentie, grootte) 
 
zeldzame ziekten (cystische 
fibrose, mongolisme) of 
fenotypes (albinisme) 
 
penetrantie: is dit het resultaat van 
additionele polymorfismen in modificerende 
genen? 
vaak voorkomende ziekten 
(allergieën, hypertentie) 
Intermezzo: Natuurlijke genetische variatie bepaalt het leven van alledag, gaande van levensbedreigende 
ziekten tot hoe we er uit zien. 
Het genoom van twee individuen is 99.9% identiek. De 0.1% variatie in DNA sequentie is echter bepalend 
voor de individuele gevoeligheid voor bepaalde aandoeningen of de respons op geneesmiddelen, toxische 
stoffen en andere omgevingsfactoren. Indien de genetische varianten voor dergelijke gevoeligheden kunnen 
worden geïdentificeerd, kunnen we beter begrijpen hoe bepaalde ziekten tot stand komen. Als we de lijn 
verder doortrekken kunnen we aannemen dat alle levensvormen, gaande van levensbedreigende ziekten tot 
normale fenotypische karakteristieken, draaien rond hetzelfde basisidee: de functionele consequentie van 
een polymorfisme bepaalt in grote mate hoe vaak het polymorfisme voorkomt. Als de impact klein is, zoals 
bescheiden fenotypische veranderingen, zal het polymorfisme niet verdwijnen door natuurlijke selectie. Als 
de impact van een polymorfisme daarentegen groot is en bijvoorbeeld een ernstige verandering van een 
cruciaal eiwit veroorzaakt, zal het worden uitgeselecteerd. Dit is waarschijnlijk een reden waarom sommige 
relatief onschuldige ziekten zoals allergieën vaak voorkomen. Onvolledige ziekte-penetrantie is een term 
die wordt gebruikt om te beschrijven dat iemand een bepaald genotype draagt, maar het fenotype niet tot 
uiting brengt. Dit kan mogelijk verklaard worden door het voorkomen van variaties in modificerende 
genen. Epigenetische mechanismen compliceren dit algemeen schema. Ze beïnvloeden de expressie van 
genen, en kunnen op die manier dan weer beschouwd worden als bepalend voor penetrantie. Wellicht, maar 
dit werd niet bewezen, spelen epigenetische mechanismen geen of weinig rol bij mendeliaanse ziekten. 
Epigenetische invloeden geven ook een heel nieuwe kijk op wat omgevingsfactoren zijn voor de klassieke 
genetica. Zijn dit factoren die een iemand meemaakt tijdens de geboorte, gedurende adolescentie, of zijn dit 
misschien factoren die zijn voorouders hebben doorgemaakt? 
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nog niet geïdentificeerd. In tegenstelling tot mendeliaanse genetische ziekten verwacht men geen 
geïsoleerd dominant gen dat de oorzaak is bij alle patiënten met de ZVC. Wellicht zal de 
combinatie van vele polymorfismen, omgevingsfactoren en epigenetische mechanismen aan de 
basis liggen van de ZVC. Een veel gebruikte alternatieve manier om genen op te sporen is de 
zogenaamde kandidaatgen benadering. Hierbij wordt er een arbitrair gen gekozen dat mogelijk 
betrokken is in de ziekte, en zoekt men bij een klein aantal patiënten naar mutaties in dat gen. 
Vervolgens wordt de frequentie van eventuele mutaties vergeleken bij een groot aantal patiënten 
en controles. Veel genen en mutaties werden op deze manier geassocieerd met de ZVC, maar de 
reproduceerbaarheid is telkens minimaal. Dit is voornamelijk het gevolg van beperkingen in 
statistische methoden en populatie bias. In Chapter 1 geven we een overzicht van alle genen die 
werden getest op associatie. Hieruit kunnen we twee belangrijke conclusies trekken. Ten eerste 
moet de keuze van de testpopulaties goed overwogen worden, en moet deze voldoende groot 
zijn. Vaak zijn de populaties te klein, en zijn controles niet gelinkt aan leeftijd en geslacht met de 
patiëntenpopulatie. Een goede samenwerking tussen onderzoekslaboratoria, artsen en hospitalen 
is cruciaal. Zelfs het poolen van cohorten op kleine schaal kan grote impact hebben op de 
uitkomst van genetische studies. In 1997 stichtten enkele wetenschappers en artsen het IBD 
International Genetic Consortium (IBDIGC). Vandaag telt die groep twaalf onderzoeksgroepen 
die werken rond genetica van inflammatoire darmaandoeningen. Dit consortium biedt ook kleine 
groepen de mogelijkheid om op gelijke basis deel te nemen aan de identificatie van genen voor 
de ZVC. De tweede conclusie die kan worden getrokken uit de vele associatiestudies is dat er 
meer gestandaardiseerde methodologieën moeten gebruikt worden bij het screenen van genen. 
Daarenboven zouden we moeten evolueren van de analyse van geïsoleerde polymorfismen naar 
zogenaamde haplotype blokken. Deze haplotype structuren zijn de minimale DNA fragmenten 
die worden overgeërfd. Het is best mogelijk dat een geïsoleerd polymorfisme in een gen geen 
effect heeft op zijn expressie of de functie van zijn eiwit, maar dat een mutatie verderop, binnen 
hetzelfde haplotype blok, wel een effect heeft. Een mooi voorbeeld hiervan is dat er binnen het 
CARD15 gen vele polymorfismen werden geïdentificeerd, waarvan er drie werden geassocieerd 
met de ZVC. Men kan zich nu afvragen of een andere mutatie binnen het haplotype blok dat 
CARD15 bevat, verantwoordelijk is voor een gewijzigde functie van CARD15. In Chapter 2 
hebben we gezocht naar polymorfismen in de promoter regio van CARD15, mede omdat de 
expressie van CARD15 opgereguleerd wordt bij inflammatie. We beschrijven een polymorfisme, 
c.-59G>A, in een regio dat mogelijk de E2F transcriptiefactor bindt. In een in vitro 
reportersysteem toonden we aan dat het c.-59A allel minder responsief was op tumor necrosis 
factor alpha inductie. Dit heeft ons ertoe aangezet om dit polymorfisme meer in detail te 
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bestuderen. Dit polymorfisme komt altijd samen voor met de andere mutaties in CARD15, maar 
het kan ook geïsoleerd voorkomen. Daarom zijn we gestart met het karakteriseren van het 
haplotype blok dat CARD15 omvat, om na te gaan of het c.-59G>A polymorfisme deel uitmaakt 
van een haplotype blok dat geassocieerd kan worden met de ZVC. Dit werk is nu gaande. 
Er is nood aan additionele aanwijzingen bij de keuze van genen om te testen in associatie 
studies. Inderdaad, de keuze van een gen is vaak subjectief, en elk gen kan bij wijze van spreken 
functioneel gekoppeld worden aan de ZVC. Daarom gebruikten we in Chapter 3 een alternatieve 
en hypothese-onafhankelijke aanpak om nieuwe en meer betrouwbare kandidaatgenen te 
identificeren voor  de ZVC. In eerste instantie werd een genexpressie-analyse uitgevoerd in 
gezonde colon biopten. Er werden differentiële geëxpresseerde genen geïdentificeerd tussen 
patiënten met de ZVC en gezonde controles. Vervolgens selecteerden we genen die binnen een 
range van 5 centimorgan rond een merker lagen. De merkers die we hiervoor gebruikten lagen in 
een locus die in ten minste twee onafhankelijke studies werd geïdentificeerd, of in loci die 
werden geidentificeerd in een studie uitgevoerd met een vlaamse cohorte. Op deze manier 
selecteerden we 18 genen. Elk van deze genen kunnen dienen als focus genen voor eenieder die 
geïnteresseerd is in genetica van de ZVC. Wij hebben ons toegelegd op het karakteriseren van 
twee genen binnen deze lijst van 18, de metallothioneines (MT). Deze twee genen behoren tot 
een grote genfamilie die allen in tandem gelegen zijn binnen de IBD1 locus. Een tweede reden 
om deze genen te bestuderen is dat ze een belangrijke rol spelen bij de verdediging van het 
organisme tegen verschillende vormen van stress en inflammatie. We toonden aan dat deze 
genen minder tot expressie komen in het colon, ileum en bloed van patiënten met de ZVC met 
colon aantasting. Dit werd bevestigd op eiwitniveau. Een interessante bevinding was dat het 
RNA- en eiwitniveau gecorreleerd waren binnen dezelfde patiënten, hoewel het weefsel voor 
beide technieken niet op dezelfde dag werd genomen. Dit en de algemeen verminderde expressie 
in bloed toonde aan dat er een mogelijk genetisch defect is bij de expressie van MT in patiënten 
met de ZVC die colon aantasting hebben. We vonden geen mutaties in coderende sequenties of 
in de promoter regio van één van de MT genen, MT1M. Omdat de verminderde expressie van 
meerdere MT isovormen werd aangetoond, besloten we om de best gekarakteriseerde 
transcriptiefactor van MT, MRE-binding transcription factor 1 of MTF1, te screenen op 
mutaties.  We vonden twee mutaties die een aminozuurverandering teweeg brachten in 6 van de 
95 patiënten met de ZVC. De functionele relevantie hiervan moet echter nog worden bestudeerd. 
Verder beschreven we een polymorfisme in een splice acceptor positie, maar we hebben geen 
alternatieve splice variant kunnen aantonen. Wij hebben ons toegelegd op een polymorfimse in 
het eerste intron van MTF1, IVS-128A>T, omdat deze regio mogelijk de transcriptiefactor 
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GATA4 kan binden. Er was geen verschil in frequentie van dit polymorfisme in controles en 
patiënten, maar het heeft net zoals CARD15 een grote invloed op de locatie van de ziekte. Het 
risico om ileale aantasting te krijgen is bijzonder hoog als het IVS-128T allel en een van de 
CARD15 mutaties aanwezig zijn: de odds ratio is 4 in patiënten met een CARD15 mutatie, en 2.4 
in  patiënten met het IVS-128T allel. We toonden ook aan dat er een gen-gen interactie is tussen 
CARD15 en MTF1, aangezien er een hoger gecombineerd risico is dan verwacht in 
aanwezigheid van beide factoren. In theorie kan dit betekenen dat we door genotypering van 
patiënten met de ZVC goed kunnen voorspellen of ze in de loop van het ziekteproces ileale 
inflammatie, of zuivere colon aantasting zullen ontwikkelen. Tot slot, deze studie is de eerste 
waar genexpressie wordt gebruikt bij genetische studies. We benadrukken het belang van het 
bestuderen van genexpressie in predispositie voor complexe ziekten in de Future prospects, en 
beschrijven een nieuwe methode om kandidaatgenen te identificeren aan de hand van de 
overerving van expressiepatronen binnen families. 
De manier waarop MTF1 een invloed kan hebben op de expressie van MT in de ZVC 
vereist nadere studie. Zowel CARD15 als MT worden voornamelijk geëxpresseerd in het ileum, 
en zijn betrokken bij respectievelijk de herkenning en eliminatie van bacteriën. Er is een groot 
verschil in aantal en soort bacteriën tussen het ileum en het colon: in het ileum bedraagt het 
aantal bacteriën ongeveer 10
2-3
 per gram faeces, terwijl dat in het colon oploopt tot 10
9-12
. Men 
kan dus stellen dat het ileum een gespecialiseerde omgeving is waar het aantal bacteriën 
gelimiteerd moet worden. CARD15 en MT zouden in dit proces een rol kunnen spelen. De 
observatie dat CARD15 mutaties en het IVS-128T allel geassocieerd zijn met ileale aantasting 
kan ook anders worden geïnterpreteerd: CARD15 mutanten en dragers van het IVS-128T allel 
kunnen beschermd zijn tegen zuivere colon aantasting, omdat de mogelijkheid om een 
inflammatoire respons op te wekken verminderd is. De hoogste prioriteit is nu om de MT 
expressie en het IVS-128A>T polymorfisme in combinatie met CARD15  mutaties te bepalen in 
patiënten met colitis ulcerosa (CU), een andere vorm van inflammatoir darmlijden. Deze ziekte 
kan tot op zekere hoogte beschouwd worden als het extreme uiteinde van een continu 
ziektebeeld van ZVC. Bij patiënten met CU is enkel het colon ontstoken, maar alleen de 
oppervlakkige lagen van de darmwand zijn aangetast. Hoewel CU en de ZVC fundamenteel 
verschillende ziekten zijn, is het niet ondenkbaar dat er gemeenschappelijke erfelijke factoren 
bestaan die een rol spelen bij het tot stand komen van inflammatie op een specifieke plaats in de 
darm. 
We toonden aan dat MTs voornamelijk geëxpresseerd worden in epitheliale cellen, een 
eigenschap die al eerder werd beschreven. De laatste jaren werd het belang van intestinale 
Samenvatting en discussie 
 165 
epitheelcellen in immunologie aangetoond. Deze cellen bevatten een aantal mechanismen om de 
kans op bacteriële infectie of schade door toxische stoffen te reduceren. Ze zijn ook betrokken in 
aangeboren immuniteit: ze produceren anti-bacteriële stoffen en mucus, maar ook cytokines en 
chemokines. We hebben HT29 colon-epitheelcellen gegenereerd die MT verminderd tot 
expressie brengen, d.m.v. small interfering RNA. We toonden aan dat deze cellen een 
verminderde IL8-secretie vertonen in vergelijking met de normale HT29 cellen wanneer ze 
geïnfecteerd werden met invasieve E. coli. Deze observatie is een eerste directe link tussen een 
verlaagde MT expressie en de ZVC: deze wordt immers gekarakteriseerd door 
immunodeficiëntie als gevolg van een gestoorde innate immuniteit. Preliminaire resultaten 
toonden aan dat deze cellen niet reageren op commensale bacteriën (Lactobacillus rhamnosus). 
Dit betekent dat een infectiemodel eerder aanleunt bij onze bevindingen. Om hierover zekerheid 
te krijgen moeten we echter een reeks bacteriestammen testen, zowel pathogene als niet-
pathogene stammen. 
Metallothioneines werden gelinkt aan een aantal ziekten, waaronder enkele 
neurologische aandoeningen en kankers. De expressie van humane MT isovormen is echter zeer 
complex, en de interpretatie van de resultaten is vaak erg moeilijk en onderling niet te 
vergelijken. In Chapter 4 geven we een overzicht van de expressie van MT in verschillende 
ziekten, alsook de regulatie van MT in humane cellen. Er bestaan een aantal tegenstrijdige 
resultaten in verband met MT en de ZVC.  Hetzelfde probleem geldt voor MT en kankers. De 
voornaamste reden hiervoor is dat er verschillende technieken werden gebruikt voor het 
kwantificeren van MT. Sinds het eerste MT gen werd gecloneerd in 1960, verschenen er veel 
studies die MT maten in serum en op histologie aan de hand van antilichamen. Cross-reactiviteit 
tussen species, maar ook tussen verschillende isovormen maakt het moeilijk om deze data te 
vergelijken. Vandaag wordt echter meestal hetzelfde anti-MT antilichaam gebruikt. 
Daarenboven maken meer gespecialiseerde technieken, zoals kwantitatieve PCR, het mogelijk 
om gedetaileerde informatie te krijgen over de expressie van verschillende isovormen. Om een 
breed beeld te krijgen over hoe een verlaagde MT expressie kan verklaard worden in de ZVC 
maakten we een overzicht van de regulatie van MT in humane systemen. Dit overzicht is 
gebaseerd op een in silico vergelijking tussen humane en muis genregulatie, aangezien de 
meerderheid van de studies gebeurd is op muizen. De genen die aan de basis liggen van MT 
regulatie zijn uiteraard kandidaatgenen om te testen in de ZVC. 
 
In het tweede gedeelte van het project hebben we gebruik gemaakt van genexpressie om 
het verband te bestuderen tussen de ZVC en een andere chronisch inflammatoire aandoening, 
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spondyloartropathie (SpA). Daarenboven werden de CARD15  mutaties bestudeerd in deze groep 
van patiënten. SpA is een heterogene groep van verwante aandoeningen gekarakteriseerd door 
specifieke radiologische en klinische aspecten. Ze vertonen ook een sterke associatie met het 
HLA-B27 allel. Er zijn veel aanwijzingen, beschreven in Chapter 5, dat SpA patiënten een 
risicogroep vormen voor het ontwikkelen van de ZVC. Darmlaesies zijn een vaak voorkomend 
fenomeen bij SpA patiënten, zij het in subklinische vorm. Deze laesies kunnen acuut of 
chronisch van aard zijn. De chronische laesies lijken sterk op de laesies die gevonden worden bij 
patiënten met de ZVC. Een studie toonde aan dat 7% van de SpA patiënten de ZVC of CU 
ontwikkelen, en meer specifiek 30% van de SpA patiënten met chronische darminflammatie 
ontwikkelden de ZVC. Een aantal argumenten wijzen op het belang van deze subklinische 
darminflammatie bij het ontstaan van SpA. Hoe dan ook, het precieze verband tussen het 
gewricht en de darm is nog niet volledig begrepen. In Chapter 6 beschrijven we een studie 
waarbij we de ZVC-geassocieerde CARD15 mutaties in SpA patiënten beschouwen. We toonden 
aan dat de frequentie van CARD15 mutaties in SpA patiënten met subklinische chronische 
darminflammatie was verhoogd in vergelijking met controles, en vergelijkbaar met de frequentie 
in patiënten met de ZVC. Met deze studie toonden we aan  dat darminflammatie in SpA mede 
genetisch bepaald is. SpA patiënten met chronische darminflammatie zijn inderdaad te 
beschouwen als een aparte groep die een verhoogd risico vormen voor het ontwikkelen van de 
ZVC, mede door het dragen van CARD15 mutaties. 
We stelden ons de vraag of de darm bij SpA patiënten verschillen vertoont in 
genexpressie in vergelijking met controles. In Chapter 7 beschrijven we afwijkingen in 
genexpressie van normale colon biopten bij SpA patiënten. Deze afwijkingen zijn bij patiënten 
met chronische darminflammatie te vergelijken met afwijkingen in de ZVC, wat de originele 
klinische data bevestigen. SpA kan daarom dienen als een pre-crohn model, ook bij het 
selecteren van kandidaatgenen voor darminflammatie. 
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moet knokken. Je bent dan ook nog eens een mooi mens, verlies de moed niet, het tij zal wel 
keren... Samen met ons Karolien moeten je nog unit 1 recht houden, he! Veel plezier, en als je 
nog eens aan mij denkt, ik ben altijd bereid om gezellig samen te gaan eten... Karolien, onze 
gesprekjes over de zo vaak gelijkaardige “ingebeelde” kwaaltjes en angsten, en natuurlijk over 
de poes zal ik missen. Nog veel succes met je doctoraat, hopelijk gauw jou feestje?  
Ik denk nu ook aan Veerle. Veel geluk met je nieuwe kleine “projectje”, en natuurlijk ook met al 
de rest. Ons Ve, altijd goedlachs en fijn om mee te kletsen. Dat geldt natuurlijk ook voor An, 
altijd in the mood om eens goed te lachen, en altijd bereid om te helpen met een probleem. Klaas 
en Sofie, nog veel geluk samen, en, Sofie, ik hoop dat je snel een fijne job vindt! Ik vergeet nog 
bijna onze Koen! ’T Is ook zo’n stilleke, alhoewel... Stille waters? Veel succes op je nieuwe job, 
en ik hoop dat er gauw een tof vrouwke passeert die je kan thuis houden! 
Dan zijn er nog de twee Tommen.  Tombo, ik hoop dat je de moed vindt om eens eindelijk al je 
data samen te bundelen in een doctoraat, want dat is nu het enige dat telt voor jou. Je hebt zoveel 
in je mars. Ik heb veel aan jou te danken, zeker in het begin van mijn doctoraat. Denk nu eerst 
aan jezelf. Tom is ondertussen vertrokken naar het buitenland. Ik hoop dat alles daar verloopt 
zoals gepland en dat hij daar met zijn vrouwtje een fantastische tijd beleeft. Tom, bedankt voor 
de leuke tijd! Steven, ik ben je inderdaad zeer dankbaar dat je mijn data hebt gered op een kritiek 
moment. Miekje, bedankt voor al die sequenties en hulp. Verder mag ik zeker niet vergeten om 
de GOA te bedanken. Deze maandelijkse vergaderingen waren erg belangrijk in het verloop van 
mijn project. Ook de microarray faciliteit, applied-maths en de genetica faciliteit hebben heel 
wat van het werk lichter gemaakt. Ondertussen beginnen we met the girls van de pathologie wat 
nauwer samen te werken. Ik denk dat we elkaar nog veel gaan nodig hebben, en Anouk: de 
metallothioneines pakken we samen aan he!  
De laatste jaren heb ik vaak de opmerking gekregen dat ik wat meer moet buiten komen. 
Liesbetje, bedankt voor het nalezen van mijn tekstjes, en ik hoop dat we binnenkort elkaar terug 
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wat meer zien! Dat geldt ook voor mijn lieve vriendin Babske. Die sauna-dagen moeten we 
meer doen, of... onze mannen mogen meer verrassingen organiseren! 
Chrisje, ik heb zo de indruk dat je hebt geleerd om te gaan met mijn verschrikkelijke 
gemoedsschommelingen ten tijde van stress. Bedankt daarvoor, en voor de steun en knuffels! 
Terwijl ik mij gedurende de laatste vijf jaar heb afvraagd wanneer ik aan kinderen moet 
beginnen, heeft mijn lieve broer en zijn Anneke er twee op de wereld gezet. Eerst “miniatuur 
Dirk” Milan en twee jaar later “nieuwe man” Patje. Wat een plezier die twee brengen is 
geweldig. Mercikes, Dirk en Anneke, dat jullie er zijn. 
Mijn lieve bomma, die zo trots is op mij, moet ik ook beloven om eens wat meer langs te 
komen. Ik ga daar zeker werk van maken! 
 
En dan, he... papa en mama... Naast het feit dat jullie een fantastische dochter op de wereld 
hebben gezet ☺, is er zoveel om jullie voor te bedanken. Ik denk nog altijd dat ik de beste ouders 
heb die er ooit hebben bestaan. Papa, de cliche dat “mijne papa alles kan” is zo waar. Ik kan 
altijd bij jou terecht, ik kijk echt op naar jou. Mama, ik weet dat je erg fier bent op mij. Bedankt 
voor de steun, liefde en inspiratie... 
 
Juni 2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
